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Zusammenfassung  
In den letzten Jahren sind Pharmazeutika und deren Metabolite mehr und mehr in den 
Fokus der Wissenschaft gerückt. Diese Substanzen sind aufgrund ihrer physiologischen 
und toxikologischen sowie ökotoxikologischen Wirkungen im menschlichen Körper bzw. 
in der Umwelt von besonderem Interesse. Cytochrom-P450-Enzyme (P450s) spielen eine 
Schlüsselrolle bei der Umsetzung und Detoxifizierung bioaktiver Substanzen, darunter 
vieler Pharmazeutika und Drogen. Es handelt sich bei diesen Enzymen in erster Linie um 
Monooxygenasen, die intrazellulär lokalisiert und relativ instabil sind; sie benötigen 
komplexe, teure Kofaktoren und sind nur unter hohem Aufwand zu reinigen, was ihre 
Anwendung in isolierter Form insgesamt erschwert. Die hier durchgeführten 
Untersuchungen zu pilzlichen Peroxygenasen haben gezeigt, dass diese Enzymsubklasse 
(EC 1.11.2.x) ein hohes Oxyfunktionalisierungspotenzial besitzt und eine Vielzahl P450-
typischer Reaktionen zu katalysieren vermag. Peroxygenasen sind extrazelluläre, d.h. 
sekretierte Pilzenzyme, die eine hohe Stabilität aufweisen und lediglich ein Peroxid als 
Kosubstrat benötigen. Die unter Verwendung der unspezifischen/aromatischen 
Peroxygenasen (APOs) von Agrocybe aegerita, Coprinellus radians und Marasmius rotula 
gewonnenen Ergebnisse belegen, dass APOs verschiedene H2O2-abhängige 
Monooxygenierungen von Pharmazeutika und psychoaktiven Substanzen realisieren. Dazu 
gehören i) die Monooxygenierung von Aromaten, ii) die benzylische Hydroxylierung von 
Toluolderivaten, iii) die O-Dealkylierung verschiedener Etherstrukturen einschließlich der 
Spaltung von Benzodioxolen (O-Demethylenierung) und Estern sowie iv) die N-
Dealkylierung von sekundären und tertiären Aminen. Die untersuchten Peroxygenasen 
wiesen teilweise deutliche Unterschiede im Substratspektrum und den präferierten 
Oxidationspositionen auf. Dieser Befund eröffnet die Möglichkeit, zukünftig einen 
„enzymatischen Werkzeugkasten“ auf Basis pilzlicher Peroxygenasen für die 
Oxyfunktionalisierung von pharmazeutisch relevanten Wirkstoffen zu entwickeln. 
Mechanistische Experimente zeigten, dass (1) die Monooxygenierungen stets unter Einbau 
eines aus dem Peroxid stammenden Sauerstoffatoms erfolgen, (2) die Deethylierung von 
Phenacetin-d1 einen Deuteriumisotopeneffekt ähnlich dem der P450s aufweist, (3) die 
katalytischen Effizienzen für die untersuchten Oxidationen im gleichen Bereich wie die der 
P450s liegen (wobei die kcat- und Km-Werte deutlich höher ausfallen), (4) die kinetischen 
Untersuchungen zur Oxidation von Nitro-1,3-Benzodioxol parallele Verläufe der 
ermittelten Ausgleichsgeraden in der doppelt reziproken Darstellung ergaben, was für 
einen “Ping-Pong-Mechanismus“ spricht, (5) sich das Substratspektrum und die 
Aktivitätsmuster der APOs in einem weiten Bereich mit denen der wichtigsten 
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menschlichen P450s decken sowie dass (6) die in Bindungsstudien gewonnenen 
Differenzspektren denen des Phenoltyps der P450s entsprechen. Desweiteren erwiesen sich 
APOs in Langzeitexperimenten über zwei Wochen als stabil und aktiv und sie waren in der 
Lage, Pharmazeutika in umweltrelevanten Konzentrationen (ppb-Bereich) zu oxidieren. 
All die genannten Eigenschaften legen nahe, dass APOs eine interessante Alternative zur 
enzymatischen Umsetzung von Pharmazeutika sowie zur Herstellung von humanen 
Pharmazeutika-Metaboliten darstellen, die z.B. Einsatz in der medizinisch-
pharmakologischen Forschung oder im Umweltbereich (Entfernung von Pharmazeutika 
aus Umweltmedien) finden könnten. 
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Summary 
Over the recent years, increasing scientific attention has been paid to pharmaceuticals, 
other drugs and their metabolites. These substances are of particular interest because of 
their physiological, toxicological and ecotoxicological effects in the human body and 
respectively in the environment. Cytochrome P450 enzymes (P450s) play a key role in the 
conversion and detoxification of bioactive compounds including many pharmaceuticals 
and drugs. Most of these enzymes belong to the monooxygenases; they are intracellular 
and rather unstable biocatalysts that are difficult to purify and require expensive, complex 
cofactors, which alltogether hampers their use in isolated form. The investigations carried 
out here with fungal peroxygenases have shown that this enzyme sub-subclass (EC 
1.11.2.x) has a promising potential for oxyfunctionalizations and can catalyze a variety of 
reactions typical for P450s. Peroxygenases are extracellular, i.e. secreted fungal enzymes 
with high stability, which merely need peroxide for function. Results obtained with the 
unspecific/aromatic peroxygenases (APOs) of Agrocybe aegerita, Coprinellus radians and 
Marasmius rotula have demonstrated that APOs catalyze numerous H2O2-dependent 
monooxygenations of pharmaceuticals and psychoactive drugs. Among them are i) the 
monooxygenation of aromatic compounds, ii) the benzylic hydroxylation of toluene 
derivatives, iii) the O-dealkylation of different ether structures including the scission of 
benzodioxoles (O-demethylenation) and esters as well as iv) the N-dealkylation of 
secondary and tertiary amines. The peroxygenases studied considerably differ in their 
substrate spectrum and the preferred positions of oxidation. This finding opens the 
possibility to develop in the future an “enzymatic toolbox“ on the basis of fungal 
peroxygenases for the oxyfunctionalization of pharmaceutically relevant compounds. 
Mechanistic studies showed that (1) the monooxygenations always proceed via 
incorporation of one oxygen atom from the peroxide, (2) the demethylation of phenacetin-
d1 established a deuterium isotope effect similar to P450s, (3) the catalytic efficiencies for 
the studied oxidations are in the same range as those of P450s (though the kcat- and Km-
values are noticeably higher), (4) the kinetic studies with nitro-1,3-benzodioxole gave 
parallel double reciprocal plots suggestive of a “ping pong” mechanism, (5) the substrate 
spectrum and the activity pattern of APOs follows in a wide range those of the human key 
P450s as well as that (6) the difference spectra obtained in bindings studies are of the 
phenol type of P450s. Furthermore, APOs were found to be stable and active in long term 
experiments over two weeks and they oxidized pharmaceuticals at low, environmentally 
relevant concentration (ppb range). All the above properties strongly indicate that APOs 
respresent an interesting alternative for the enzymatic conversion of pharmaceuticals as 
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well as for the preparation of human drug metabolites, for example, in medicinal and 
pharmacological research or the bioremediation sector (removal of pharmaceuticals from 
environmental media). 
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Streszczenie  
W ostatnich latach, w świecie nauki, coraz więcej uwagi poświęca się lekom i ich 
metabolitom. Substancje te cieszą się szczególnym zainteresowaniem z powodu ich 
fizjologicznego oraz toksykologicznego działania w ludzkim organiźmie, a także na 
środowisko naturalne. Cytochromy P450 (P450s) odgrywają kluczową rolę w konwersji i 
detoksyfikacji bioaktywnych substancji, między innymi wielu leków i substancji 
psychoaktywnych. W pierwszym rzędzie należą do tej grupy enzymów monooksygenazy, 
które są wewnątrzkomórkowe i relatywnie niestabilne. Potrzebują kompleksowych, 
drogich kofaktorów i ich oczyszczanie wymaga dużego nakładu pracy, co utrudnia ich 
zastosowanie w wyizolowanej formie. Przeprowadzone badania z grzybowymi 
peroksygenazami pokazały, że ta podklasa enzymów (EC 1.11.2.x) posiada wysoki 
potencjał oxofunkcjonalizacyjny i katalizuje wiele typowych reakcji dla cytochromów 
P450. Peroksygenazy są zewnątrzkomórkowe, to znaczy należą do wydzielanych 
enzymów grzybowych. Charakteryzują się wysoką stabilnością i wymagają jedynie 
obecności nadtlenku wodoru jako kosubstratu. Wyniki otrzymane przy użyciu 
aromatycznych/niespecyficznych peroksygenaz (APOs) z Agrocybe aegerita, Coprinellus 
radians i Marasmius rotula pokazują, że APOs katalizują wiele rożnych, zależnych od 
H2O2, monooksygenacji leków i substancji psychoaktywnych. Do tego należą i) 
monooksygenacja aromatów, ii) hydroksylacja grupy benzylowej pochodnych fenolu, iii) 
O-dealkilacja różnych struktur eterycznych włączając rozszczepianie benzodioksoli (O-
demetylenowanie) oraz estrów, jak rownież iv) N-dealkilacja. Badane peroksygenazy 
wykazują częściowo znaczne różnice w spektrum substratów i preferowanej pozycji 
oksydacji. Powyższe wyniki otwierają możliwość opracowania w przyszłości tak zwanej 
„enzymatycznej skrzynki narzędziowej“ na bazie grzybowych peroksygenaz do 
oxofunkcjonalizowania farmaceutycznie istotnych substancji czynnych. Mechanistyczne 
eksperymenty pokazały, że (1) monooksygenacje nastepują przez wbudowanie atomu tlenu 
pochodzącego z nadtlenku wodoru, (2) demetylowanie fenacetyny-d1 wykazuje podobny 
efekt izotopowy deuteru jak cytochromy P450, (3) wydajność katalityczna dla badanych 
oksydacji znajduje się w podobnym zakresie jak dla P450s, przy czym wartości kcat i Km są 
znacznie wyższe, (4) kinetyczne badania w zakresie oksydacji nitro-1,3-benzodioxolu 
wykazały równoległe przebiegi prostych w podwójnym wykresie Lineweavera-Burka, co 
odpowiada tak zwanemu mechanizmowi “Ping-Pong“, (5) spektrum substratów i rodzaj 
aktywności w przypadku APOs pokrywa się w dużym zakresie z najważniejszmi ludzkimi 
P450s, oraz że (6) badania w zakresie wiązań wykazały spektra różnicowe w dużym 
stopniu przypominające spektra fenolowe cytochromów P450. Ponadto w eksperymentach 
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długoterminowych (dwa tygodnie) grzybowe peroksygenazy okazały się być stabilne 
i aktywne. Były również w stanie oksydować leki, w koncentracjach wystepujących 
w środowisku naturalnym (stężenie w zakresie ppb).Wszystkie wymienione wyżej 
właściwości wskazują na to, że grzybowe peroksygenazy stanowią interesującą 
alternatywę do enzymatycznej konwersji leków, a także do produkcji ludzkich 
metabolitów. Mogą być na przykład stosowane w badaniach medyczno-farmakologicznych 
oraz w obrębie ochrony środowiska (usuwanie leków ze środowiska). 
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1 Introduction 
1.1  Physiological and environmental aspects of pharmaceuticals 
1.1.1 Pharmaceuticals 
On 31 March 2004, the European Parliament and the Council of the European Union 
defined a medicinal product: "(a) Any substance or combination of substances presented as 
having properties for treating or preventing disease in human beings; or (b) Any substance 
or combination of substances which may be used in or administered to human beings either 
with a view to restoring, correcting or modifying physiological functions by exerting a 
pharmacological, immunological or metabolic action, or to making a medical diagnosis 
"(Parliment and Council 2004). Pharmaceuticals from a wide spectrum of therapeutic 
classes are used worldwide in human and animal medicine. Pharmaceuticals include more 
then 4,000 molecules with different physico-chemical and biological properties and 
distinct modes of biochemical action (Beausse 2004, Mompelat et al. 2009, Whitacre et al. 
2010). Pharmaceuticals can be classified by chemical properties, mode or route of 
administration, biological system affected or therapeutic effects. An elaborate and widely 
used classification system is the Anatomical Therapeutic Chemical Classification System 
(ATC system) (Fricke et al. 2012, WHO Collaborating Centre for Drug Statistics 
Methodology 2012). Important classes of pharmaceuticals include: 
⎯ Analgesics (painkillers), 
⎯ Antibiotics (inhibiting microbial growth), 
⎯ Antihypertensives/α-/β-blockers (α-/β-adrenoreceptor antagonists; used to treat 
hypertension = high blood pressure), 
⎯ Antiepileptic drugs (enhance the effect of the neurotransmitter γ-aminobutyric 
acid), 
⎯ Nonsteroidal anti-inflammatory drugs, NSAIDs (with analgesic and antipyretic 
(fever-reducing) effects; in higher doses with anti-inflammatory effects), 
⎯ Antitussives (cough medicines), 
⎯ Bronchodilators/antiasthmatic drugs (β2-agonists, anticholinergics, and 
theophylline), 
⎯ Psychoactive drugs (antidepressants, stimulants, antipsychotics, mood stabilizers, 
anxiolytics, depressants, hallucinogens), 
⎯ Chemotherapeutic agents (anticancers), and 
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⎯ Hormones (contraceptives, anabolics). 
The World Health Organization keeps a list of essential medicines. Essential medicines are 
defined as: "those drugs that satisfy the health care needs of the majority of the population; 
they should therefore be available at all times in adequate amounts and in appropriate 
dosage forms, at a price the community can afford." (World Health Organization 2012). 
The core list presents a number of minimum medicine needs for a basic health-care system, 
listing the most efficacious, safe and cost-effective medicines for priority conditions. 
Priority conditions are selected on the basis of current and estimated future public health 
relevance, and potential for safe and cost-effective treatment. The complementary list 
presents essential medicines for priority diseases, for which specialized diagnostic or 
monitoring facilities, and/or specialist medical care, and/or specialist training are needed. 
In case of doubt, medicines may also be listed as complementary on the basis of consistent 
higher costs or less attractive cost-effectiveness in a variety of settings (World Health 
Organization 2011). As on 17 June 2011, the BfArM (Bundesamt für Arzneimittel und 
Medizinprodukte; the Federal Institute for Drugs and Medical Devices) reported marketing 
authorizations or registrations for 60,237 pharmaceutical drugs in all indications. The 
"Rote Liste®" for 2011, the comprehensive drug registry for Germany, includes only 8,280 
preparations, with a total of 33,737 prices (pharmaceuticals are almost always marketed at 
different prices for different package sizes). This difference between nearly 60,000 
authorized pharmaceuticals on the one hand and only roughly 10,000 drug entries in the  
"Rote Liste®" can be explained by the different tallying methods and the only partial 
listing of self-medication drugs in the "Rote Liste®" (German Association for 
Pharmaceutical Industry 2011). 
1.1.2 Pharmacokinetics and Metabolism 
Pharmacokinetics, "the movement of drugs" is the study of a drug and/or its metabolite 
kinetics in the body. The human body is a very complex system and a drug undergoes 
many steps as it is being absorbed (A), distributed through the body (D), metabolized (M), 
and/or excreted (E) (figure 1). When the studies are focused solely on one specific 
pharmacokinetic aspect (A,D,M or E) by in vitro, in situ, in vivo or in silico techniques 
they are usually referred to as ADME studies, whereas the term pharmacokinetics is 
normally reserved for in vivo studies where all four aspects are considered (Ruiz-Garcia et 
al. 2008). Biotransformation/metabolism is an integral component of the processes that 
govern the pharmacokinetic profile of therapeutically used drugs. Biotransformation 
generally converts nonpolar, lipophilic pharmacologically active drug molecules into polar, 
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inactive or nontoxic metabolites that are readily eliminated by kidneys or other organs. The 
liver is the major site of drug metabolism, with intestinal drug extraction playing a 
secondary yet potentially important role in the presystemic elimination of orally 
administered agents. Traditionally, biotransformation pathways are classified into two 
groups: 
⎯ Phase I reactions that involve (oxy)functionalization of drug substrates to yield 
more polar derivatives such as alcohols, phenols or carboxylic acids, and 
⎯ Phase II reactions involving bimolecular conjugation with endogenous hydrophilic 
moieties to yield products such as glucuronides and sulfates that are readily 
excreted by kidneys (Venkatakrishnan et al. 2001). 
 
 
 
Figure 1 Processes involved in the determination of pharmacokinetic parameters. Adapted from 
Gibson and Skett (Gibson and Skett 2008). 
 
Cytochrome P450s (P450s) are the enzymes principally responsible for Phase I oxidations 
in animals. Because the chemicals that must be metabolized are structurally very diverse, 
animals express multiple P450s that have evolved via gene duplications and conversions, 
thus giving rise to genes encoding new P450 forms that metabolize not only xenobiotics, 
but also endogenous substances. One consequence of human P450 gene evolution is the 
polymorphism of drug metabolism, leading to marked differences in the response of 
individuals to the toxic and carcinogenic effects of drugs and other environmental 
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chemicals. Differences in P450 expression between human individuals, which are 
correlated with ethnicity in some cases, may reflect the presence or absence of a particular 
P450 gene, but may also involve transcriptional regulation. These differences may be 
clinically manifested in quantitative differences in the metabolism of certain drugs, 
resulting in "poor" or "extensive" metabolizers (Souček and Gut 1992). P450-mediated 
drug metabolism can also lead to altered drug efficacies through inactivation of an active 
drug or activation of a prodrug (Ding and Kaminsky 2003). Three P450 gene families 
(CYP1, CYP2, and CYP3) and to some degree a fourth one (CYP4) are currently thought 
to be responsible for the majority of hepatic drug metabolism in humans (Wrighton and 
Stevens 1992).   
 
Figure 2 A summary of major human P450s involved in drug metabolism, including major 
substrates. The circle sizes approximate relative levels of expression in human liver. The overlap of 
the circles conveys the point that an overlap of catalytic action is often observed (Gibson and Skett 
2008, Guengerich and Montellano 2005).  
 
All three members of the CYP1 family (CYP1A2, CYP1B1, CYP1A1) are upregulated by 
halogenated and polycyclic aromatic hydrocarbons, such as those found in cigarette smoke 
and charred food (e.g. benzo(a)pyrene). CYP1A2 is responsible for melatonin oxidation 
and uroporphyrin formation from uroporphyrinogen: it metabolizes about 24 drugs and all 
three members are metabolically active and detoxify many environmental carcinogens 
(Nelson and Nebert 2011). CYP2 is the largest P450 family in mammals with 13 
subfamilies and 16 genes in humans. CYP2C8, -9, -18, and -19 together metabolize more 
than 50 drugs, as well as arachidonic acid and steroids. CYP2D6 metabolizes more than 70 
drugs. CYP2A6, -A13, -B6, -E1 and -F1 are also major contributors to drug metabolism 
(Guengerich et al. 1998, Meyer and Zanger 1997, Nelson and Nebert 2011). P450 
subfamily 3A is the most abundantly expressed P450 gene in the human liver and 
gastrointestinal tract and known to metabolize more than 120 commonly used 
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pharmaceutical agents (Nelson and Nebert 2011). The human fetus is capable of 
metabolizing a large number of compounds, and its major P450 is a member of the 3A 
subfamily, specifically 3A7. This single P450 comprises 30 to 50% of the total fetal P450s. 
However, 3A7 has not been detected in the liver of adults (Wrighton and Stevens 1992). 
The CYP4 family metabolizes some drugs, but is involved mainly in the metabolism of 
fatty acids (Nelson and Nebert 2011).  
1.1.3 Pharmaceutical drugs development and studies 
In the course of modern drug development, there are four areas in which issues pertaining 
to drug metabolites need to be addressed, namely (i) drug metabolites as components of 
(plasma) drug assays, (ii) drug metabolites in bioavailability studies, (iii) drug metabolites 
in bioequivalence studies, and (iv) drug metabolites in safety testing (Baillie et al. 2002). 
Pharmaceutical companies and regulatory agencies are becoming increasingly interested in 
the role of metabolites as potential mediators of the toxicity of new drug products (Baillie 
et al. 2002). In 2005, the U.S. Food and Drug Administration issued a draft guidance 
document "Safety testing of drug metabolites" which was followed in 2008 by the final 
version (Baillie 2009, Center for Drug Evaluation and Research (HFD-130) and Food and 
Drug Administration 2008). Drugs entering the body undergo biotransformation via Phase 
I and Phase II metabolism. Based on the nature of the chemical reactions involved, 
metabolites formed from Phase I reactions can be chemically more reactive or even 
represent the actually bioactive form of the drug. An active metabolite may bind to the 
therapeutic target receptors or other receptors, interact with other targets (e.g. enzymes, 
proteins), and cause unintended effects (Center for Drug Evaluation and Research (HFD-
130) and Food and Drug Administration 2008). It is recommended that - while there is a 
necessity to maintain a flexible, case-by-case evaluation of the need to perform additional 
safety studies on human drug metabolites - those metabolites present at disproportionately 
higher levels in human plasma than in any of the animal test species should be considered 
for safety assessment (Baillie 2009).  
By the early 1990s, much of the interest in P450 research had shifted to the human P450 
enzymes because of the availability of systems for handling them. In particular, studies in 
the areas of drug metabolism and chemical toxicology/ carcinogenesis were facilitated by 
the knowledge that a relatively small number of the P450s account for a large fraction of 
the metabolism of the drugs. In the pharmaceutical industry, the roles of the major hepatic 
P450s are extensively studied to develop predictions about bioavailability, drug-drug 
interactions, and toxicity (Guengerich and Montellano 2005). The metabolism of foreign 
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compounds by P450s generally leads to products that are less toxic and more easily 
excreted. However, in some cases oxidative metabolism produces substances that are 
reactive toxins and mutagens (Williams et al. 2000). Toxic compounds may be detoxified 
following P450-catalyzed biotransformation while inert xenobiotics, including drugs, may 
be activated and thus become toxicants. Most xenobiotic compounds require metabolic 
activation by P450s to form ultimate carcinogens or toxicants. Most hepatic P450s are also 
present in extrahepatic tissues, and often at higher levels. Furthermore, some P450s are 
expressed preferentially in extrahepatic tissues, which may lead to unique extrahepatic 
metabolites and tissue-specific consequences in cellular toxicology and organ pathology. 
Risk assessment of potential human toxicants is currently based primarily on data obtained 
from animal bioassays and the knowledge of mechanism of toxicity derived from animal 
experiments (Ding and Kaminsky 2003). Metabolic studies using biological models are 
important for determining the significance of specific enzymes or pathways for toxicity 
(Ding and Kaminsky 2003). 
Pharmaceutical products (PPs) and by-products (BPs) are spread into 24 therapeutic 
classes, among which four are dominant in terms of references. About 40% of studies 
concern non-steroidal anti-inflammatory drugs (NSAIDs), the three others being 
anticonvulsants, antibiotics, and lipid regulators. NSAIDs are essentially represented by 
ibuprofen and diclofenac. The most studied lipid regulator is gemfibrozil. Carbamazepine 
is the most tested anticonvulsant (Mompelat et al. 2009). 
1.1.4 Environmental aspects 
In the European Union today, about 3,000 different substances are being used in medicines 
such as painkillers, antibiotics, contraceptives, β-blockers, lipid regulators, tranquilizers, 
and impotence drugs (Ternes et al. 2004, Wiegel et al. 2004). In Germany, in the year 
2000, about 7,000 t of synthetic medicines for human consumption were sold. (report from 
the Federal Environmental Authority; Umweltbundesamt). The figure for veterinary drugs 
was 2,320 t in 2002 (Wiegel et al. 2004). Table 1 shows some examples of pharmaceutical 
drugs chosen as environmentally relevant together with their annual consumption and 
quantities remaining as unconverted substances. Human-use medicines are designed to 
have a biological effect and to be bioavailable. However, it is only in recent years that 
there has been increasing concern over the trace amounts of pharmaceuticals that are 
appearing in the environment and the effects they may cause (Daughton and Ternes 1999, 
Whitacre et al. 2010).   
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Table 1 Consumption of pharmaceutical drugs in Germany in 2001 and percentages remaining 
unconverted (Sachverständigen Rat für Umweltfragen 2007). 
 Pharmaceutical class/drug Consumption per year 
(kg) 
Unconverted substrate
(% of dose) 
Analgesics   
Metamizole 64,400 0 
Phenazone 24,850 5 
Propyphenazone 24,180 2 
Codeine 9,700 70 
Morphine 880 10 
NSAIDs (see 1.1)   
Ibuprofen 344,880 1 
Diclofenac 85,800 70 
Indometacin 3,700 30 
Ketoprofen 1,613 10 
Piroxicam 724 5 
Meclofenamic acid not determined not determined 
Antitussives/cough medicines   
Ambroxol 14,470 6 
Codeine 9,700 70 
Dihydrocodeine 1,245 40 
Hydrocodone 8 40 
Bronchodilators/antiasthmatic 
drugs 
  
Salbutamol 414 80 
Terbutaline 118 60 
Fenoterol 72 50 
Clenbuterol 1 90 
Antibiotics   
Sulfamethoxazole 53,600 33 
Doxycycline 24,180 2 
Ciprofloxacin 17,973 45 
Clindamycin 16,100 30 
Trimethoprim 11,426 80 
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Roxithromycin 9,550 60 
Clarithromycin 7,159 35 
Norfloxacin 4,724 70 
Ofloxacin 2,280 95 
Oxytetracycline 2,020 not determined 
Tetracycline 1,530 not determined 
Spiramycin 300 25 
Chloramphenicol 202 10 
Chlortetracycline 99 not determined 
Antihypertensives/α/β-blockers   
Metoprolol 93,000 10 
Sotalol 26,600 90 
Atenolol 13,500 90 
Propranolol 3,900 5 
Bisoprolol 2,914 50 
Antiepileptics   
Carbamazepine 87,600 30 
Psychoactive drugs   
Diazepam 1,107 30 
Chemotherapy agents   
Cyclophosphamide 385 7 
Ifosfamide 170 50 
Hormones/contraceptives   
17α-Ethinylestradiol 50 85 
Data origin: SRU/Stellungnahme Nr.12-2007; Huschek and Krengel 2003 
 
The occurrence of anthropogenic organic contaminants in aquatic ecosystems has drawn 
the attention of both the public and scientists in recent years, a fact confirmed by the 
numerous studies published in this field. With respect to pharmaceuticals, many 
investigations have focused on high consumption substances currently being introduced 
into the environment (Hass et al. 2012). Accurate assessment of drugs impact on the 
environment is difficult, since there is a multitude of input sources in the environment with 
no evident quantitative data available concerning the relative distribution of 
pharmaceuticals from all emission sources (shown in figure 3). 
INTRODUCTION 
 
 
9 
 
Figure 3 Origin and routes of pharmaceutical products (adapted from Petrović et al. (Petrović et al. 
2003) and from Mompelat et al. (Mompelat et al. 2009). DWT: drinking water treatments; WWTP: 
waste water treatment plant. 
 
However, humans and animals account for the main contamination source of potable water 
resources (Mompelat et al. 2009). Once ingested and metabolized, pharmaceuticals (native 
and/or metabolites) are excreted via urine and feces, or unused or expired drugs are 
improperly disposed of in toilets, and travel in urban wastewater to the wastewater 
treatment plant (WWTP) or, for countryside households, they are directly released into 
septic tanks (Carrara et al. 2008, Mompelat et al. 2009). To a minor but relevant extent, 
hospital wastewater also contributes to the total loads. Pharmaceuticals can also enter 
agricultural land when digested sludge is applied as fertilizer. Veterinary pharmaceuticals 
are excreted directly into the environment, and thus contaminate soil while the resulting 
runoff gets into rivers. Therefore, the efficiency with which WWTPs can remove 
pharmaceuticals is crucial (Ternes et al. 2004). 
In recent decades, more than 100 different drugs have been detected in aquatic 
environments at concentrations from ng L-1 to µg L-1 (Daughton and Ternes 1999). Recent 
studies have demonstrated that, despite relatively low concentrations of pharmaceuticals in 
the environment (typically at sub-parts-per-billion level; < ppb), pharmaceuticals are of 
ecological concern due to their potential long-term adverse effects on humans and wildlife 
(Ankley et al. 2007, Celiz et al. 2009). In most of the investigations reported to date, the 
efficiency of drugs removal during water treatment is determined by measuring the 
disappearance of the parent compound, but not the formation of by-products. Similarly, 
INTRODUCTION 
 
 
10 
there is a lack of available information on the environmental fate and occurrence of 
excreted human and animal drug metabolites. The European Medicines Agency has set 
guidelines for reporting concentrations of drugs and their metabolites. A systematic 
approach has been developed to predict the total risk associated with pharmaceuticals 
entering the environment. The guidelines say that any metabolite formed at a concentration 
greater than 10 percent of the parent compound needs further investigation (Boxall et al. 
2004, Celiz et al. 2009). 
Ecotoxicity studies in the laboratory have demonstrated effects of pharmaceuticals on end 
points such as reproduction, growth, behavior and feeding for fish and invertebrates 
(Martinović et al. 2007, Quinn et al. 2008, Whitacre et al. 2010). Drugs have already been 
detected in fish tissues (Brooks et al. 2005). In the terrestrial environment, the catastrophic 
decline of Indian vulture populations was found to be the result of exposure to the human 
anti-inflammatory drug diclofenac (Oaks et al. 2004, Whitacre et al. 2010). In the river 
Elbe, in 1998, diclofenac, ibuprofen and carbamazepine were found as well as various 
antibiotics and lipid regulators in a concentration range from <20 to 140 ng L-1. Wide scale 
sampling in Saxony during 2002 showed the ubiquitous occurrence of carbamazepine in 
surface waters. In 2000 (limited to sales from pharmacy outlets), 590 t acetylsalicylic acid, 
326 t acetylcysteine, 240 t paracetamol, 44 t diclofenac, 31 t ibuprofen and 9.1 t ambroxol 
were sold (Wiegel et al. 2004). In the same year, in the Saale river near Halle, 120 ng L-1 
of metoprolol and in the river Ilm, 140 ng L-1 were detected. In the Elbe river, the 
concentration of metoprolol was below the detection limit. A maximum of 300 ng L-1 
carbamazepine was found in the section of the river Elbe in Saxony (Wiegel et al. 2004). 
Carbamazepine was detected at concentrations up to 1,075 ng L-1 in surface water samples 
in Berlin (Heberer 2002). In Cologne and surroundings, in surface water samples, 
diclofenac was detected in the range from 10 to 15 µg L-1 (Jux et al. 2002). In 2007, 
analysis of samples from a few WWTPs in Spain showed the following mean 
concentrations: 44 ng L-1 of propranolol, 61 ng L-1 of metoprolol, 136 ng L-1 of 
carbamazepine, 247 ng L-1 of omeprazole, 553 ng L-1 of ketoprofen, 826 ng L-1 of 
diclofenac, 1,840 ng L-1 of naproxen, and 2,567 ng L-1 of ibuprofen (Martinez Bueno et al. 
2007). 
1.2 Cytochrome P450 enzymes 
Cytochromes P450 (P450s) represent one of the largest and oldest superfamilies of enzyme 
proteins. Genes encoding for these enzymes are present in the genomes of all biological 
kingdoms (Hannemann et al. 2007, Werck-Reichhart and Feyereisen 2000). The 
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terminology P450 is uncommon for enzymes because it is not based on function, but 
originally describes the spectral properties of this b-type heme containing red pigments, 
which display a typical absorption band around 450 nm in their reduced carbon-monoxide 
bound form (Omura and Sato 1964). All P450s contain a cysteine-ligated heme (iron 
protoporphyrine IX) that can bind dioxygen (O2) in the active site (Dawson and Sono 
1987). 
The official nomenclature in enzymology, which has been in use since the early 1960s, 
follows the EC1 classification system that is strictly based on the reaction catalyzed. 
Enzymes catalyzing a particular reaction get so-called EC-numbers that comprise four 
digits (Nomenclature Committee of the International Union of Biochemistry and Molecular 
Biology (NC-IUBMB) 2012). 
Most P450s belong to the main class of oxidoreductases (EC 1.x), more precisely to those 
oxidoreductases acting on paired donors, with incorporation or reduction of molecular 
oxygen (EC 1.14.x). There are some exceptions, where P450s are found, for example, in 
the main class of isomerases and lyases (intramolecular oxidoreductases, EC 5.3.x and 
carbon-oxygen lyases, EC 4.2.x) (Degtyarenko 2004). Members of the P450 enzyme 
family are involved in the biotransformation of drugs, the bioconversion of xenobiotics, the 
metabolism of chemical carcinogens, the biosynthesis of physiologically important 
compounds (such as steroids, fatty acids, eicosanoids, fat-soluble vitamins, and bile acids), 
the conversion of alkanes, terpenes, and aromatic compounds as well as in the degradation 
of herbicides and insecticides (Bernhardt 2006). The reactions catalyzed can be extremely 
diverse and include e.g. hydroxylations, N-, O- and S-dealkylations, sulphoxidations, 
epoxidations, deaminations, desulphurations, dehalogenations, peroxidations, N-oxide 
reductions, dehydrations and isomerizations(Bernhardt 2006, Guengerich 2001, Mansuy 
1998). Many P450s convert a broad range of substrates and catalyze multiple reactions. 
For example, unspecific monooxygenases (EC 1.14.14.1) act on xenobiotics, steroids, fatty 
acids, vitamins and prostaglandins and they catalyze amongst others hydroxylations, 
epoxidations, N-oxidations, sulfooxidations, N-, S- and O-dealkylations, desulfations, 
deaminations, and the reduction of azo-, nitro- and N-oxide groups. 
Since many of the individual P450s catalyze multiple reactions, the usual method of 
naming enzymes is inadequate for this group of proteins, so a systematic nomenclature has 
been developed on the basis of structural and sequence homology (Nelson et al., Nelson et 
                                                 
1 EC - Enzyme Commission: Nomenclature Committee of the International Union of Biochemistry and 
Molecular Biology (NC-IUBMB), in consultation with the IUPAC-IUBMB Joint Commission on 
Biochemical Nomenclature (JCBN), http://www.chem.qmul.ac.uk/iubmb/enzyme/ 
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al. 1996). P450 genes are identified by the abbreviation CYP followed by a number 
denoting the family; members of a family show more than 40% sequence identity. 
Following is a letter designating a subfamily whose members share more than 55% 
sequence identity. Finally, the second number indicates the individual gene within the 
subfamily (e.g. CYP2A1) (Hannemann et al. 2007). At present, there is a total of over 
1,000 P450 families and over 2,500 subfamilies (Nelson 2011). Altogether, more than 
12,000 P450 genes have been reported across all kingdoms of life. Mammals have usually 
between 50 and 100 encoded P450 enzymes. There are even more CYP genes found in 
plant genomes than in animal genomes, because plants are sessile and carry out their 
biochemistry de novo from carbon dioxide, ammonia, water and minerals.  
Table 2 Named cytochrome P450s in March 2010, adapted from Nelson et al., 2011 (Nelson 2011) 
Kingdom/ organisms P450 number CYP familiesa Sequenced 
genomesb 
CYPs/genome 
Animals (Metazoa) 4088    
Insects 2137 67 11 37-178c 
Vertebrates 1461 18 8 57-102d 
Invertebrates (without 
insects) 
490 71 4 76-89e 
Plants (Plantae) 4267 126 14 10-332f 
Fungi (Eumycota) 2784 399 53 1-153g 
Protists 247 62 22 1-55h 
Eubacteria 1042 333 212 1-52i 
Archaea 26 13 17 1-4 
Viruses (Mimivirus) 2 2 1 2 
Total 12,456    
a includes all named CYP families; not 
just those from sequenced genomes. 
b only genomes included in the 
nomenclature in 2010 
 
c Aedes aegypti 
d Mouse (Mus 
musculus) 
e Tetranychus 
urticae 
 
f Rice (Oryza 
sativa) 
g Aspergillus 
oryzae 
 
h Dictyostelium 
discoideum 
i Frankia sp.  
 
 
Angiosperm plants may have between 250 (Arabidopsis spp.) and over 400 P450s (potato, 
Solanum tuberosum) that are involved in stress responses, reaction to wounding, seedling 
development, taste, colour and aroma of fruits and flowers, structural support (lignin), 
water barriers (cutins and suberins), hormone signaling and synthesis of allelochemicals 
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for defence against predators (Nelson and Nebert 2011). Fungi can also possess numerous 
P450s; thus in the genome of the basidiomycetous white-rot fungus Phanerochaete 
chrysosporium, more than 150 P450 genes (most of them monooxygenases) were found 
(Subramanian et al. 2010), and 153 genes are present in the ascomycetous mold 
Aspergillus oryzae (Nelson 2011). Table 2 gives an overview of the number and 
distribution of P450s in different groups of organisms.  
1.2.1 Classification of electron transport systems of P450s 
After the discovery of cytochrome P450s, two main classes reflecting the redox partners 
involved were described: the adrenal mitochondrial P450 systems obtaining electrons from 
NAD(P)H via adrenodoxin reductase and adrenodoxin (Hannemann et al. 2007, Omura et 
al. 1966), and the liver microsomal P450s obtaining electrons from NAD(P)H via a flavin-
containing (FAD, FMN) P450 reductase (Hannemann et al. 2007, Lu and Coon 1968). It 
was not until the 1980s, when CYP102 (P450BM3) was discovered, that an example came 
to light showing an unusual property, the fusion of the P450 and reductase components 
into one polypeptide chain (Narhi and Fulco 1987). Since then, several more of such 
“unusual” electron transfer chains have been described for different P450s (table 3). Class 
II cytochrome P450s are the most common type found in all eukaryotic organisms (Črešnar 
and Petrič). 
Table 3: Classes of P450 systems grouped according to the topology of protein components 
involved in the electron transfer towards the actual P450 component, including schematic 
organization of the proteins (Hannemann et al. 2007). Protein components contain the following 
redox centers: Fdx (iron-sulfur-cluster); FdR, Ferredoxin reductase (FAD); CPR, cytochrome P450 
reductase (FAD, FMN); Fldx, Flavodoxin (FMN); OFOR, 2-oxoacid: ferredoxin oxidoreductase 
(thiamin pyrophosphate, [4Fe-4S] cluster); PFOR, phthalate-family oxygenase reductase (FMN, 
[2Fe-2S] cluster). 
Class/ source Electron transport 
chain  
Scheme Localization/ 
remarks 
Class I 
Bacterial 
 
 
 
Mitochondrial 
 
NAD(P)H►[FdR] ►[Fdx] 
►[P450] 
 
 
 
 
NADPH►[FdR] ►[Fdx] 
►[P450] 
 
 
 
 
 
Cytosolic, soluble 
P450s; inner 
mitochondrial 
membrane; FdR-
membrane 
associated; Fdx- 
mitochondrial 
matrix, soluble 
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Class II 
Bacterial, 
fungal, 
Microsomal A 
Microsomal B, 
fungal 
Microsomal C 
 
 
NADPH►[CPR] ►[P450] 
NADPH►[CPR] ►[P450] 
NADPH►[CPR] ►[cytb5] 
► [P450] 
NADPH►[cytb5Red] ► 
[cytb5] ► [P450] 
 
 
 
 
 
Cytosolic, soluble 
Membrane 
anchored, 
endoplasmatic 
reticulum 
(A,B,C) 
Class III 
Bacterial 
 
NAD(P)H►[FdR] ►[Fldx] 
►[P450] 
 
 
 
Cytosolic, 
soluble, 
Citrobacter 
braakii 
 
Class IV 
Bacterial 
 
 
 
 
Pyruvate, CoA►[OFOR] 
►[Fdx] ►[P450] 
 
Cytosolic, 
soluble, 
Sulfolobus 
tokadaii 
Class V 
Bacterial 
 
 
 
 
NADPH►[FdR] ►[Fdx-
P450] 
 
 
Cytosolic, 
soluble, 
Methylococcus 
capsulatus 
Class VI 
Bacterial 
 
 
 
 
NAD(P)H►[FdR] ►[Fldx-
P450] 
 
 
Cytosolic soluble, 
Rhodococcus 
rhodochrous 
strain 11Y 
Class VII 
Bacterial 
 
NADPH►[PFOR-P450] 
 
 
Cytosolic, 
soluble, 
Rhodococcus sp 
strain NCIMB 
9784, 
Burkholderia sp., 
Ralstonia 
metallidurans 
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Class VIII 
Bacterial, 
fungal 
 
 
NADPH►[CPR-P450] 
 
 
Cytosolic, 
soluble, Bacillus 
megaterium, 
Fusarium 
oxysporum 
Class IX 
Only NADH 
dependent, 
fungal 
 
NADH►[P450] 
 
 
Cytosolic, 
soluble, Fusarium 
oxysporum 
Class X 
Independent in 
plants/ 
mammals 
 
[P450] 
 
 
 
Membrane bound, 
ER, example: 
Thromboxane 
synthase  
1.2.2 Bacterial P450s 
Bacterial P450s form a large proportion of the superfamily. They are soluble enzymes 
whereas their eukaryotic counterparts are usually membrane-bound. This fact simplifies 
the overexpression and purification of bacterial enzymes (Munro and Lindsay 1996). Most 
eubacterial species contain at least one P450 enzyme while some archaea seemingly do not 
possess any P450 enzyme. It is possible that P450s may have evolved during the advent of 
atmospheric oxygen in the atmosphere (about 1.5 to 1 billion years ago), where their 
original role was in the detoxification of molecular oxygen (O2) in anaerobic bacteria 
(Lewis and Wiseman 2005, Wickramasinghe and Villee 1975). 
A bacterial P450 was first found in nitrogen-fixing Rhizobium bacteroides (Appleby 1967). 
In contrast to the microsomal and mitochondrial P450s reported before, the Rhizobium 
P450 was soluble (i.e. dissolved in the cytosol); however, the function was not elucidated. 
Then P450s in Pseudomonas putida and Coryebacterium sp. were reported (Cardini and 
Jurtshuk 1968, Katagiri et al. 1968) . P450cam (CYP101) from Pseudomonas was found to 
catalyze the NADH-dependent oxidation of camphor and required soluble NADH, 
putidaredoxin and NADH-putidaredoxin reductase for the reaction. Corynebacterium P450 
catalyzes the NADH-dependent terminal oxidation of n-octane to 1-octanol. More soluble 
P450s were found in various prokaryotic organisms in the following years (Omura 2005). 
The first self-sufficient P450-reductase fusion enzyme was found in Bacillus megaterium 
and named P450 BM-3 (CYP102A2). Similar P450-reductase fusion proteins were later 
found in other bacterial species (Narhi and Fulco 1987, Omura 2005). P450 eryF from 
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Saccharopolyspora erythrea is the only bacterial P450 to which a biosynthetic function has 
been assigned. The bacterium produces erythromycin A, and P450 eryF catalyzes the 
hydroxylation of 6-deoxyerythronolide B to generate erythronolide B, which is a precursor 
of this macrolide antibiotic (Munro and Lindsay 1996). Among the P450s characterized 
from bacteria of the order Actinomycetales (Rhodococcus spp. strains) are enzymes 
catalyzing alkane hydroxylation, pentachlorophenol dehalogenation and alkoxyphenol O-
dealkylation (Karlson et al. 1993, Munro and Lindsay 1996). The most known function of 
bacterial P450s is the oxidation of recalcitrant organic compounds so that the hosts can 
utilize them as sole carbon source for growth. This is also the generally recognized 
difference between prokaryotic and eukaryotic P450s (involvement in carbon metabolism 
vs. detoxification/biosynthesis) (Fulco 1991). However, the role of bacterial P450s in the 
utilization of unusual organic compounds is non-essential for the viability of the 
organisms. The ability of bacterial P450s to metabolize compounds such as terpenes and 
alkanes has attracted interest, not only regarding the decomposition of organic wastes and 
pollutants, but also for biotransformations in the synthesis of pharmaceuticals and fine 
chemicals (Munro and Lindsay 1996). Aside from the inherent interest in the physiological 
roles and biotechnological potential of bacterial P450s, these enzymes have become 
attractive and productive targets for spectroscopic and structural analyses (Munro and 
Lindsay 1996). 
1.2.3 Plant P450s 
Plants utilize a diverse array of P450s in their biosynthetic and detoxification pathways. 
Biosynthetic P450s play paramount roles in the synthesis of lignin intermediates, sterols, 
terpenes, flavonoids/isoflavonoids, furanocoumarins, cyanogenic glycosides, lipids, plant 
growth regulators (phytohormones) such as gibberellins, jasminoic acid, and 
brassinosteroids, and a variety of other secondary plant metabolites (Chapple 1998, 
Nielsen et al. 2005, Schuler 1996a). 
Many scientific studies have shown the important role of P450s in the biosynthesis and 
degradation of compounds important in plant insect interactions (Schuler 1996b), and the 
importance of plant P450s in the metabolism of herbicides (Frear 1995). Plant P450 
monooxygenases are membrane-bound heme proteins which consist of a protoporphyrin 
IX and an apoprotein that confers the substrate specificity. Plant P450s have been shown to 
carry out hydroxylations, epoxidations, heteroatom dealkylations and oxygenations 
(Bolwell et al. 1994). Cinnamic acid 4-hydroxylase from Helianthus tuberosus (Jerusalem 
artichoke) was the first plant P450 to be functionally characterized. This enzyme catalyzes 
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an essential step in the phenylpropanoid pathway and is considered to be ubiquitous in 
plants (Nielsen et al. 2005). Like vertebrates and fungi, certain plants produce 
polyhydroxylated steroidal hormones, called brassinosteroids, to regulate and control tissue 
morphology. They are nonessential phytohormones with impacts on morphological 
characteristics, for example, leaf shape and dwarfism (Clouse and Sasse 1998, Nielsen et 
al. 2005).  
1.2.4 Fungal P450s 
Cytochrome P450 monooxygenases of fungi are involved in many essential cellular 
processes and play diverse roles. They catalyze the conversion of hydrophobic 
intermediates of primary and secondary metabolic pathways, detoxify natural toxins and 
environmental pollutants and allow fungi to grow under different conditions. Fungal P450s 
represent three electron transport systems, Class II, Class VIII and Class IX (table 1; 
1.2.1). Class II P450s are involved in metabolite synthesis as well as in detoxification 
and/or degradation of xenobiotic compounds. Class VIII is represented by P450foxy (from 
Fusarium oxysporum). This enzyme is responsible for the hydroxylation of fatty acids. 
P450s belonging to Class IX of electron transfer systems are involved in the process of 
fungal denitrification (Črešnar and Petrič, Shoun et al.). The key enzyme, nitric oxide 
reductase (EC 1.7.1.14), is also designated as P450nor and shows structural similarity to 
"classic" P450 monooxygenases. But on the other hand, P450nor functionally differs from 
the rest of P450s as it catalyzes the reduction of two molecules of nitric oxide (NO) to 
nitrous oxide (N2O) whereby the electrons are directly transferred from NAD(P)H to the 
enzyme without the need of any additional redox partner. P450nor is the only eukaryotic 
P450 that is soluble, i.e. not membrane-associated (Črešnar and Petrič, Shoun et al.). 
Another fungal P450 family (CYP53) uses e.g. benzoic acid as substrate to produce 4-
hydroxybenzoic acid or catalyzes the demethylation of 3-methoxybenzoic to 3- 
hydroxybenzoic acid, and has thus an essential role in the detoxification of aromatic 
compounds (Lah et al.). One well-studied class of bioconversions carried out by fungal 
P450 enzymes is the (stereo)-specific hydroxylation of pharmaceutically interesting 
steroids, especially progesterone (Mahato and Majumdar 1993, van den Brink et al. 1998). 
Another P450-catalyzed process is the 14α-demethylation of lanosterol in yeasts and of 
eburicol in filamentous fungi. Ergosterol (the product of this reaction), has a similar 
structure as mammalian cholesterol and performs an important role in membrane 
stability/fluidity and in completion of the cell cycle (van den Brink et al. 1998). 
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The evolutionarily conserved (CYP51) and fungi-specific (CYP61 and CYP 56) P450s are 
essential for primary metabolism, enabling these microorganisms to preserve cell wall 
integrity and to form the spore outer wall, respectively, regardless of the fungus’ 
morphology or ecological niche. Furthermore, several other fungal P450s with other 
activities and functions have been characterized. They were found to catalyze e.g. the 
detoxification of xenobiotic compounds, the initial step in n-alkane assimilation, fatty acid 
hydroxylation, nitrite reduction and mycotoxin production (Črešnar and Petrič). A well-
studied P450-catalyzed reaction in fungi is the alkane assimilation/degradation by some 
Candida species (Scheller et al. 1996, van den Brink et al. 1998). Table 4 below lists 
selected fungal P450s and their functions (those known so far). 
 Table 4 Compilation of most known fungal P450s and their functions. 
Fungus 
(fungal group) 
P450 /known 
information 
Catalyzed 
reaction 
Known 
substrate(s) 
Ref. 
Aspergillus 
parasiticus 
(ascomycete) 
CYP64 family oxygenation O-methyl-
sterigmatocystin, 
dihydrosterigmato-
cystin 
(Yu et al. 1998) 
Candida albicans 
(ascomycetous 
yeast) 
P45014αdm (CYP51 
family) 
O-demethylation steroids (Joseph-Horne 
and Hollomon 
1997) 
Candida maltosa 
(ascomycetous 
yeast) 
CYP52 family oxygenation/ 
hydroxylation 
n-alkane (Ohkuma et al. 
1998) 
Cunninghamella 
bainieri 
(zygomycete) 
P450 hydroxylation 
N-demethylation 
hydrocarbons 
codeine 
(Ferris et al. 
1976, Gibson et 
al. 1984) 
Curvularia lunata 
(ascomycete) 
P450lun 11β-hydroxylation steroids (Suzuki et al. 
1993) 
Fusarium 
oxysporum 
(ascomycete) 
P450foxy (CYP505) hydroxylation fatty acids (Nakayama et 
al. 1996) 
Fusarium 
sporotrichioides 
(ascomycete) 
CYP65A1 hydroxylation mycotoxin 
biosynthesis 
(Alexander et al. 
1998) 
Giberella fujikuroi 
(ascomycete) 
CYP68 family hydroxylation kaurenoic acid 
(giberellin 
biosynthesis) 
(Malonek et al. 
2005, Tudzynski 
et al. 2001) 
Nectria 
haematococca 
(ascomycete) 
CYP57 family O-demethylation pisatin (Desjardins and 
VanEtten 1986, 
Maloney and 
VanEtten 1994) 
Penicillium paxilli 
(ascomycete) 
P450paxP, 
P450paxQ 
oxygenation paspalin (paxilline 
biosynthesis) 
(Saikia et al. 
2007) 
Phanerochaete 
chrysosporium 
(basidiomycete) 
 
149 P450s estimated,  
12 families, 
23 subfamilies. 
 
Functions like plant 
CYP73 and CYP98 
 
 
 
 
hydroxylation 
 
 
 
 
cinnamic acid 
(Doddapaneni et 
al. 2005, 
Matsuzaki and 
Wariishi 2004, 
Syed and Yadav 
2012) 
 Functions like bacterial 
CYP102 (P450BM3). 
Seven sequences in the 
hydroxylation cumene (Matsuzaki and 
Wariishi 2004) 
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same phylogenic cluster 
as CYP102  
 Functions like yeast 
CYP52, seven sequences 
were categorized into the 
CYP52 family 
hydroxylation 1,12-dodecanediol (Matsuzaki and 
Wariishi 2004) 
 Functions like bacterial 
CYP105A1 and 
CYP105B1, mammalian 
CYP2B, plant CYP76B1 
and fungal 
CYP510A1,but similarity 
above 35% only with 
CYP510A1 
deethylation 4-ethoxybenzoic 
acid and 7-
ethoxycoumarin 
(Matsuzaki and 
Wariishi 2004) 
 Functions like 
mammalian CYP2A, but 
no sequence similarity 
above 35% 
Hydroxylation 
7-position, by 
P.chrysosporium 
Four different 
positions 
coumarin (Matsuzaki and 
Wariishi 2004) 
 Functions like fungal 
CYP53, one sequence of 
P450 from 
P.chrysosporium fell into 
the CYP53 familiy 
hydroxylation 
4-position, by 
P.chrysosporium  
three different 
positions 
benzoic acid (Matsuzaki and 
Wariishi 2004) 
 Functions like bacterial 
CYP101(P450cam), no 
similarity above 35% 
Hydroxylation 
5- and 6- position, 
by 
P.chrysosporium  
three different 
positions 
camphor (Matsuzaki and 
Wariishi 2004) 
 Functions like bacterial 
CYP176A1(P450cin) and 
mammalian CYP3A, but 
no sequential similarity 
above 35% 
hydroxylation 1,8-cineol (Matsuzaki and 
Wariishi 2004) 
 PcCYP65a2, and 
PcCYP11a3 clones, 
functions like human and 
rat CYP1A2 
hydroxylation mono- and 
dichloro-p-dioxins 
(Kasai et al.) 
 CYP5136A3 hydroxylation alkylphenols, PAH (Syed et al. 
2011) 
 P450dNIR , P450nor denitrification nitrite (Shoun et al., 
Shoun and 
Tanimoto 1991) 
 CYP53 (cloned 
PcCYP1f) 
hydroxylation benzoate (Matsuzaki and 
Wariishi 2005) 
Pleurotus ostreatus 
(basidiomycete) 
P450 hydroxylation pyrene, 
anthracene, 
fluorene, 
dibenzothiophene 
(Bezalel et al. 
1996) 
Pleurotus 
pulmonarius 
(basidiomycete) 
P450 hydroxylation benzo[a]pyrene (Masaphy et al. 
1995, Maspahy 
et al. 1999) 
Rhisopus nigricans 
(zygomycete) 
P45011α 
 
hydroxylation steroids (Bossche and 
Koymans 1998, 
Breskvar et al. 
1995) 
Saccharomyces 
cerevisiae 
(ascomycetous 
yeast). Only three 
P450 sequences: 
CYP61  desaturation steroids (Kelly et al. 
2005, Nelson 
2009) 
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CYP51F1,CYP56A1 
and CYP61A1 
Trametes (Coriolus) 
versicolor 
(basidiomycete) 
Cloned gene, similarity 
with CYP512A1, but less 
then 40% identity with 
any P450 
sulfur-oxidizing 
reactions 
DBT derivatives (Ichinose et al. 
2002) 
Trichosporon 
moniliiforme 
and T.cutaneum 
(basidiomycetous 
yeast) 
P450 decarboxylation salicylate, phenol (Stundl et al. 
2000) 
Yarrowia lipolytica 
(ascomycetous 
yeast) 
CYP52 family oxygenation/ 
hydroxylation 
n-alkane (Iida et al. 2000) 
 
1.2.5 Animal P450s 
1.2.5.1 Insect P450s 
In insects, the number of cytochrome P450s in sequenced genomes ranges from 37 in the 
body louse, Pediculus humanus (Lee et al. 2010, Sztal et al. 2012), up to 160 (178, 
corrected in 2011 (Nelson 2011)) in the dengue mosquito, Aedes aegypti (Strode et al. 
2008, Sztal et al. 2012). There are four large clades of insect P450 genes that existed 
before the divergence of the class of Insecta and that are also present in vertebrates: the 
CYP2 clade, the CYP3 clade, the CYP4 clade and the mitochondrial P450 clade. 
Mitochondrial P450s are not found in plants or fungi, but seem to be restricted to animals 
(Feyereisen 2006). P450s from each of these clades have been linked to insecticide 
resistance or to the metabolism of natural products and xenobiotics. In particular, insects 
appear to maintain a repertoire of mitochondrial P450 paralogues devoted to the response 
to environmental stress (Feyereisen 2006). The metabolism of xenobiotics, insecticides in 
particular, to less toxic metabolites is probably the best-known feature of P450s 
(Feyereisen 1999). Cytochrome P450 monooxygenases are involved in many cases of 
resistance of insects to insecticides. Resistance has been proposed to be associated with 
increase in monooxygenase activities and the cytochrome P450 content (Bergé et al. 1998). 
Insect P450s can metabolize a wide range of plant allelochemicals, including 
furanocoumarins, terpenoids, indoles, glucosinolates, flavonoids, cardenolides, 
phenylpropenes, ketohydrocarbons, alkaloids, lignans, pyrethrins, and the isoflavonoid 
rotenone (Li et al. 2007). However, there is an increasing number of studies indicating that 
P450s have a much broader role in insects than just detoxification. For example, 
biosynthesis of juvenile and molting hormones are processes in which the role of insect 
P450s has been well documented (Scott 2008). 
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1.2.5.2 Mammalian/ Human P450s 
There are eight P450 families in mammalians, which are involved in the metabolism of 
pharmaceuticals and drugs, products of incomplete combustion (e.g. polycyclic aromatic 
hydrocarbons, PAHs) as well as of plant ingredients (e.g. phenolics, phytoalexins). It has 
been proposed that four of these P450 gene families (I, II, III, and IV) evolved and 
diverged in animals due to their exposure to plant ingredients and decayed plant products 
during the last one billion years. The overlapping substrate specificities of these P450 
enzymes are remarkable (Nebert and Gonzalez 1987). There are at least 43 gene families 
recognized in animals. In humans, 57 P450s were identified and this number seems to be 
complete because of our excellent knowledge of the human genome (Guengerich and 
Montellano 2005, Nelson 2009). 
Most eukaryotic P450s are intrinsic membrane proteins that are expressed in the 
endoplasmic reticula of plant, fungal, and animal cells. Animal cells also express P450s 
that are located in the inner membrane of mitochondria. The human enzymes contribute to 
the synthesis of steroid hormones, prostacyclin, thromboxane, cholesterol, and bile acids, 
as well as to the degradation of endogenous compounds, such as fatty acids, retinoic acid, 
and steroids, and exogenous compounds that include drugs and carcinogens (Williams et 
al. 2000). In humans, of the P450s with known catalytic activities, 14 are involved in 
steroidogenesis, 4 are involved in certains aspects of vitamin metabolism, 5 are involved in 
the metabolism of eicosanoids, 4 have fatty acids as substrates, and 15 catalyze the 
transformation of xenobiotics. Many of the xenobiotic-converting P450s can also oxidize 
steroids and fatty acids. Most of the steroid-oxidizing enzymes are constitutive and their 
levels are relatively invariable, in contrast to the xenobiotic-metabolizing P450s, the levels 
of which can vary considerably (Guengerich and Montellano 2005). 
The organ that expresses the highest levels of P450s is the liver, which plays the dominant 
role in the first-pass clearance of ingested xenobiotic compounds and controls the systemic 
level of drugs and other chemicals. Extrahepatic tissues, especially those that are the 
portals of entry for xenobiotic compounds, such as the respiratory and the gastrointestinal 
tracts, also express P450s. In these tissues, 450 enzymes not only contribute to the first-
pass clearance, but may also influence the tissue burden of xenobiotic compounds or 
bioavailability of therapeutic agents (Ding and Kaminsky 2003). 
1.2.6 Engineered P450s 
The catalytic versatility, substrate diversity, and sheer number of P450s have led to 
considerable interest over the last 25 years in the engineering of P450 enzymes for a 
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variety of purposes (Gillam 2008). Mammalian P450 enzymes, as membrane-bound two-
enzyme systems, are notoriously difficult to express and hard to maintain in an active form. 
Parallel heterologous expression in addition must provide exact ratios of components to 
ensure catalytic activity (Vail et al. 2005). P450s can be engineered using rational and 
evolutionary approaches. Rational approaches are characterized by the deliberate mutation 
of one or more amino acids based on mechanistic or structural information and are 
appropriate for altering P450 selectivities (Jung et al., Urlacher and Girhard). By directed 
evolution, mutations are introduced in a random or semi-random manner, for example by 
site-saturation mutagenesis at residues thought to be important for the desired property, 
and the resulting mutant P450s are screened for enhancement of that property or set of 
properties. A recent area of interest is the design and development of novel P450s as 
biocatalysts of reactions of commercial interest, such as in pharmaceutical or fine chemical 
synthesis (Gillam 2008). 
For example, over the past decade, P450 BM3 was engineered for the oxidation of alkanes, 
terpenes, heteroaromatics, alkaloids, steroids and other chemical substances, which are 
either hydroxylated, epoxidized or demethylated (Jung et al., Urlacher and Girhard). P450 
BM3 from Bacillus megaterium (discovered in the 1980s (Warman et al. 2005)) possesses 
favorable properties that makes it an attractive target for engieneering (Munro et al. 2002). 
It is a soluble bacterial, highly active enzyme, which is naturally fused to its reductase and 
routinely expressed in E. coli. The hydroxylation of arachidonic acid catalyzed by P450 
BM3 is the most rapid P450-catalyzed hydroxylation known so far (kcat = 17,000 min-1) 
(Jung et al., Warman et al. 2005). 
In the 1990s the technique of DNA shuffling (Crameri et al. 1998, Stemmer 1994), 
involving homology-dependent recombination of fragments of orthologous P450 genes in a 
primerless PCR reassembly, was applied for P450-engineering with great success (Gillam 
2008). A novel approach for DNA recombination (the so-called SCHEMA algorithm) was 
used to obtain chimeras based on P450 BM3 and its homologs CYP102A2 and CYP102A3 
from Bacillus subtilis. A survey of the activities of new chimeras demonstrated that this 
approach created completely new functions absent in the wild-type enzymes, including the 
ability to oxidize drugs (Urlacher and Girhard).  
1.2.7 Catalyzed reactions 
P450 enzymes play two main roles in living organisms. Some cytochrome P450s catalyze 
oxidation steps involved in the biosynthesis or biodegradation of endogenous compounds 
like steroids, fatty acids or prostaglandins. The second group is responsible for oxidative 
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biotransformation of exogenous substances from the environment, facilitating their 
elimination from living organisms (Mansuy 1998). Cytochrome P450s catalyze more than 
20 different reaction types (Sono et al. 1996). Some of the "atypical" reactions are 
oxidations involving C-C or C=N bond cleavage, reductions, dehydrations, 
dehydrogenations or isomerizations. The classical reactions performed by P450s involve 
the transfer of one oxygen atom from dioxygen (O2) to the substrate.  
 
++ ++−→+++− )()( 22 PNADOHOHRHHPNADOHR  
 
 
1.2.8 The most important P450 reactions are summarized in Table 5. 
Reaction mechanism of P450s 
 
The catalytic cycle of P450 has been studied over decades. The active center for catalysis 
is the iron(III)-protoporphyrin IX (heme) with the thiolate of the conserved cysteine 
residue as fifth ligand (Werck-Reichhart and Feyereisen 2000) (Figure 4). Four pyrrole 
rings are bonded by methine bridges (-CH2=), giving a planar and highly conjugated 
porphyrin system (Nagababu and Rifkind 2004). Six 
heteroatoms coordinate the heme iron octahedrally. The 
four porphyrin nitrogens are the equatorial ligands. The 
remaining two axial ligands are located below (fifth 
coordination site, proximal) and above (sixth coordination 
site, distal) the plane of the heme (Cirino and Arnold 
2003). 
 
Figure 4 Iron (III) protoporphyrin-IX linked with a proximal cysteine ligand. Modified according to 
Meunier et al. (Meunier et al. 2004). 
 
The P450 reaction cycle has been proposed by several authors(Guengerich 2001, Munro et 
al. 2007, Ogliaro et al. 2002) and can be summarized as follows (Figure 5). It is initiated 
by the binding of a substrate, usually with concomitant displacement of the distal water 
ligand [(a), H2O…heme(FeIII)] (Ortiz de Montellano et al. 2005, Sligar and Gunsalus 
1976). The substrate binds to the species (a) near the distal region of the heme, which 
causes a dehydration of the active site resulting in a five-coordinated heme iron within the 
enzyme-substrate complex [(b), R-H…heme(FeIII)]. 
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Table 5 Oxidative and non-oxidative reactions catalyzed by P450 enzymes(Guengerich 2001, Isin and Guengerich 2007, Mansuy 1998, Sono et al. 1996) 
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The latter accepts a first electron that is derived from NAD(P)H and supplied via 
flavin/ferredoxin or diflavin reductases to form the ferrous state of the enzyme [(c), (R-
H)…heme(FeII)] (Groves 2006, Ullrich and Hofrichter 2007). The ferrous complex is 
reactive enough to add dioxygen (O2) resulting in the formation of a ferrous dioxy-
complex [(d), R-H…heme(FeII)-O2], which then accepts the second electron (Groves 2006, 
Ullrich and Hofrichter 2007). This results in formation of a ferric peroxy ion [(e), (R-
H)…heme(FeIII-O2-)], which is protonated to form the hydroperoxy complex (also referred 
as Compound 0, [(f), (R-H)…heme(FeIII-O-OH)]. Compound 0 undergoes heterolytic 
cleavage between the oxygen atoms giving rise to the putative oxo-ferryl state [(g), (R-
H)…heme(FeIV=O)•+], referred to as Compound I (Rittle and Green 2010). 
 
Figure 5 The catalytic cycle of cytochrome P450s monooxygenases, including the peroxide “shunt” 
pathway. RH is the substrate and ROH the product of the reaction. The rhombus symbolizes the 
heme. Modified according to Ullrich and Hofrichter (Ullrich and Hofrichter 2007) and Werck-
Reichhart and Feyereisen (Werck-Reichhart and Feyereisen 2000). (a) native (hydro)ferric enzyme 
(resting state), (b) ferric heme-substrate complex, (c) ferrous heme-substrate complex, (d) ferrous-
dioxygen complex, (e) ferric peroxy anion complex, (f) ferric hydroperoxy complex (Compound 
0), (g) putative oxy-ferryl radical complex (Compound I), (h) product-ferric enzyme complex.  
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This electron-deficient complex may abstract a hydrogen atom or one electron from the 
substrate to form a sigma complex (g) with the substrate. A subsequent collapse of the 
intermediate or an intermediate pair in step (g) generates the product. (In the case of a 
hydrogen abstraction mechanism, step (g) is referred to as an “oxygen rebound.”) In step 
(h), the product dissociates from the enzyme, and the cycle can restart (Guengerich 2001, 
Isin and Guengerich 2007). The so called “shunt” pathway is a remarkable side reaction of 
many P450s, in the course of which substrate is directly oxidized by hydrogen peroxide (or 
an organic peroxide) to the hydroperoxo-ferryl state (f) (Ullrich and Hofrichter 2007).  
1.3 Peroxygenases 
Since February 2011, a second sub-subclass (EC 1.11.2.x) of peroxidases (EC 1.11.x) has 
been listed in the Enzyme Nomenclature system. The enzymes of this sub-subclass are 
named peroxygenases and catalyze reactions with a peroxide as acceptor, one oxygen atom 
of which is incorporated into the product 
(http://www.chem.qmul.ac.uk/iubmb/enzyme/EC1/11/2/). This means peroxygenases 
catalyze the direct transfer of one oxygen atom from a peroxide to the substrate (→ mono-
peroxygenation). The peroxide (preferably hydrogen peroxide, H2O2) is reduced and the 
substrate is oxidized (Hanano et al. 2006): 
 
OHROHOHRH 222 +→+   
 
On a functional level, peroxygenases can be regarded as hybrids of cytochrome P450 
monooxygenases and "classic" heme peroxidases.  
The sub-subclass of peroxygenases contains four entries: EC 1.11.2.1 (unspecific 
peroxygenase, the key enzyme of this group), EC 1.11.2.2 (myeloperoxidase), EC 1.11.2.3 
(plant seed peroxygenase) and EC 1.11.2.4 (fatty-acid peroxygenase). However, it has to 
be mentioned that in the other sub-subclass (EC 1.11.1: peroxidases) an enzyme is listed - 
chloroperoxidase (CfuCPO, EC 1.11.1.10) - that catalyzes, in addition to halogenation 
reactions, also a number of peroxygenase-type reactions (Allain et al. 1993, Omura 2005). 
CfuCPO, which was already discovered 50 years ago [(Hager et al. 1966), belongs as do 
the P450s to the heme-thiolate proteins and is apparently produced only by the 
ascomycetous sooty mold Caldariomyces fumago (Omura 2005). 
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All unspecific peroxygenases2 characterized so far are also heme-thiolate proteins 
secreted by agaric basidiomycetes (colloquially called mushrooms). They are very stable, 
highly glycosylated proteins that have been shown to [per]oxygenate and oxidize various 
organic substances (for details, see 1.3.1 below). Myeloperoxidase (MPO; until 2011, 
listed under EC 1.11.1.7) contains calcium and a covalently bound heme with histidine as 
proximal ligand (Booth et al. 1989, Davey and Fenna 1996). It is present in 
mammalian/human phagosomes of neutrophils and monocytes (Klebanoff 1999). MPO 
catalyzes the hydrogen peroxide mediated peroxygenation of halide ions (chloride, 
bromide, iodide) and of the pseudohalide thiocyanate, according to the following reaction 
(Harrison and Schultz 1976): 
−−−−
+−
=
+→++
SCNIBrClX
OHHOXOHXOH
,,,
2 2322  
Products of this reaction (hypohalous acids) and their following products are strong 
oxidants and responsible for killing phagocytized bacteria and viruses. MPO differs from 
CPO (EC 1.11.1.10) in its preference for formation of free hypochlorite over the 
chlorination of organic substrates under physiological conditions (pH 5-8). Hypochlorite in 
turn forms a number of antimicrobial products (Cl2, chloramines, hydroxyl radical, and 
singlet oxygen). In the absence of halides, MPO can oxidize phenols and exhibits a 
moderate peroxygenase activity towards styrene (Fiedler et al. 2000, Klebanoff 2005, 
Tuynman et al. 2000). 
Plant seed peroxygenase is a heme protein with a calcium binding motif of the caleosin-
type. Enzymes of this type include membrane-bound proteins found in seeds of different 
plants. It catalyzes the direct transfer of one oxygen atom from an organic hydroperoxide  
(R-OOH), which is reduced to the corresponding alcohol, to a substrate that will be 
oxidized. Reactions catalyzed include hydroxylation, epoxidation and sulfoxidation. 
Preferred substrate and co-substrate are unsaturated fatty acids and fatty acid 
hydroperoxides, respectively. Plant seed peroxygenase is thought to be involved in the 
synthesis of cutin (Hanano et al. 2006, Lequeu et al. 2003). 
Fatty acid peroxygenase is a bacterial, cytosolic heme-thiolate protein with sequence 
homology to P450 monooxygenases. Unlike the latter, it needs neither NAD(P)H, 
                                                 
2 In earlier publications, unspecific peroxygenase was also referred to as haloperoxidase, haloperoxidase-
peroxygenase, mushroom/fungal peroxygenase, AaP (Agrocybe aegerita peroxidase/peroxygenase), CrP 
(Coprinellus radians peroxygenase) or APO (aromatic peroxygenase). In February 2011, these enzymes were 
classified as unspecific peroxygenase in the Enzyme Nomenclature system (EC 1.11.2.1; systematic name: 
substrate:hydrogen peroxide oxidoreductase, RH-hydroxylating or -epoxidizing; for more details see 
following web page: http://www.chem.qmul.ac.uk/iubmb/enzyme/EC1/11/2/1.html). 
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dioxygen nor specific reductases for function. Enzymes of this type are produced by 
eubacteria (e.g. Sphingomonas paucimobilis, P450SPα and Bacillus subtilis, P450BSβ) and 
catalyze the hydroxylation of long chain fatty acids (e.g. myristic acid) using hydrogen 
peroxide as oxidant/electron acceptor to produce hydroxylated fatty acids (Imai et al. 2000, 
Lee et al. 2003, Shoji et al. 2010). 
Caldariomyces fumago chloroperoxidase (CfuCPO) catalyzes the unspecific chlorination, 
bromination, and iodation of a variety of electrophilic organic substances via hypohalous 
acids as actual halogenating agent. In the absence of halide, CfuCPO mimics 
peroxygenases and P450s by catalyzing allylic and benzylic hydroxylations, alcohol 
oxidations, heteroatom dealkylations, and oxo transfer to alkenes, alkynes, alkyl- and 
arylamines, and sulfides; however, CfuCPO does not peroxygenate aromatic rings or 
alkanes (Hofrichter and Ullrich 2006, Hofrichter et al. 2010, Hrycay and Bandiera 2012). 
1.3.1 Fungal unspecific peroxygenases 
Like CfuCPO, fungal peroxygenases are functional hybrids of P450 monooxygenases and 
heme-peroxidases, but with a more pronounced oxygen transfer activity. Agrocybe 
aegerita aromatic peroxygenase (AaeAPO) was the first enzyme of this type discovered 
in 2004 and is, for the time being, the best-characterized aromatic/unspecific 
peroxygenase. At first, this enzyme was reported to oxidize aryl alcohols to the 
corresponding aldehydes and hence to the corresponding benzoic acids. AaeAPO was 
found to catalyze also the conversion of typical peroxidase substrates, such as ABTS (2,2’-
azinobis-(3-ethylbenzothiazoline-6-sulfonate) or DMP (2,6-dimethoxyphenol);  
furthermore, it brominates MCD (monochlordimedon) and phenol (Ullrich et al. 2004). 
Later it turned out that the enzyme epoxidizes/hydroxylates toluene and naphthalene over a 
wide pH range (3-10) with an optimum around pH 7 (Kluge et al. 2007, Ullrich and 
Hofrichter 2005). Further studies showed that AaeAPO has a very broad reaction spectrum 
that includes, for example, sulfoxidations (e.g. of dibenzothiophene, thioanisole), N-
oxidations (e.g. of pyridine), the O-dealkylation of diverse ethers (e.g. of tetrahydrofuran, 
diethyl ether, alkyl aryl ethers), the O-demethylenation of benzodioxoles, N-dealkylations 
(e.g. of secondary and tertiary amines), the epoxidation/hydroxylation of polycyclic 
aromatic hydrocarbons (PAHs), aliphatic hydroxylations (e.g. of n-alkanes) and the 
epoxidation of alkenes (Aranda et al. 2009a, Aranda et al. 2009b, Kinne et al. 2009a, 
Kinne et al. 2009b, Kinne et al. 2008, Kinne et al. 2010, Kluge et al. 2007, Kluge et al. 
2012, Peter et al. 2011, Poraj-Kobielska et al. 2011b, Ullrich 2008, Ullrich et al. 2008, 
Ullrich and Hofrichter 2007). In the course of several studies, numerous basidiomycetes 
have been screened for peroxygenase acitivity. As an outcome, the second true 
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peroxygenase was discovered in 2006 in the inky caps Coprinopsis verticillata (CveAPO) 
and Coprinellus radians (CraAPO) (Anh 2008). The latter enzyme was characterized in 
2007 and shown to oxidize veratryl and benzyl alcohol as well as ABTS, DMP and 
guaiacol into the corresponding aldehydes/benzoic acids and quinones, respectively. 
CraAPO is able to brominate phenol and to regioselectively epoxidize/hydroxylate 
naphthalene to form preferably 1-naphthol (Anh et al. 2007). Further studies demonstrated 
that CraAPO catalyzes the sulfoxidation and hydroxylation of dibenzothiophene, the 
[per]oxygenation of various PAHs, as well as the O- and N-dealkylation of many 
pharmaceuticals (Aranda et al. 2009a, Aranda et al. 2009b, Poraj-Kobielska et al. 2011b). 
An additional interesting peroxygenase was found in the pinwheel mushroom, Marasmius 
rotula. This enzyme (MroAPO), which is smaller than the other peroxygenases (32 kDa 
instead of 40-45 kDa), can oxidize all typical peroxidase and peroxygenase substrates such 
as ABTS, DMP, veratryl and benzyl alcohols, naphthalene, and pyridine. Furthermore, it 
hydroxylates and O-/N- dealkylates many pharmaceuticals including steroids that are not 
converted by the other peroxygenases (Gröbe et al. 2012, Yarman et al. 2012) (Poraj-
Kobielska, 2012 unpublished results). 
The full-length sequences of the peroxygenases of A. aegerita, C. radians and M. rotula 
have recently been obtained. The sequences of AaeAPO, CraAPO and MroAPO do not 
show any homology to classic heme peroxidases (such as lignin, manganese or horseradish 
peroxidase) or to cytochrome P450 monooxygenases, and display less than 30% sequence 
homology to CfuCPO (Pecyna et al. 2009). The CraAPO sequence shows 59% identity and 
69% similarity to AaeAPO, and 27% identity and 42% similarity to CfuCPO. The sequence 
of MroAPO differs considerably from those of the other known fungal peroxygenases, 
showing only 33% identity and 49% similarity to AaeAPO, 29% identity and 43% 
similarity to CfuCPO, and 31% identity and 45% similarity to CraAPO (Pecyna 2012). 
Last but not least it should be mentioned that hundreds of peroxygenase-like sequences 
from all classes of true fungi (Eumycota: Basidio-, Asco-, Glomero-, Zygo-, 
Chytridiomycota) as well as from Oomycota (e.g. Phytophtora spp.) can be found in 
genetic data banks (Hofrichter et al. 2010, Pecyna et al. 2009). The significance of these 
putative peroxygenases remains to be investigated. 
1.4 Aims and objectives 
In recent years, increasing scientific attention has been given to pharmaceuticals and their 
metabolites. Both their effects on the human body and the environment are the subject of 
physiological, toxicological and ecotoxicological research approaches, dealing in particular 
with the fate of drugs. To bring more light into this field, it is important to know the 
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properties of drug metabolites and their effects on living organisms. On the other hand, 
there is a need to remove such substances from the environment in order to reduce their 
risk potential. In many organisms, cytochrome P450 enzymes play a key role in the 
conversion and detoxification of bioactive compounds including pharmaceuticals. 
However, P450s are intracellular biocatalysts and consequently relatively unstable. They 
need expensive cofactors and are difficult to purify, which hampers their broad use in an 
isolated form. For a few years it has been known that fungal peroxygenases can catalyze 
similar reactions to those catalyzed by P450s, and several studies have demonstrated their 
great biotechnological potential for oxyfunctionalizations. The peroxygenases are 
extracellular - i.e. they are actively secreted by the fungus - and highly stable, and they do 
not need cofactors other than hydrogen peroxide. Peroxygenases catalyze a wide variety of 
reactions, including hydroxylations, epoxidations, and dealkylations. These catalytic 
properties suggest that they may also be an interesting alternative for the enzymatic 
conversion of pharmaceuticals both in terms of metabolite preparation and drug removal. 
Accordingly, my PhD work has addressed the following questions: 
1. Are fungal peroxygenases (APOs) capable of oxygenating complex 
pharmaceuticals? If so, what are the limitations in terms of substrate structure and 
size?  
2. What are the products of these conversions? 
3. Are these products similar to human drug metabolites formed by P450s? 
4. Are illicit drugs and narcotics subject to peroxygenase attack? 
5. Do peroxygenases of different fungal origin produce different patterns of 
metabolites? 
6. Are peroxygenases able to oxidize pharmaceuticals at low, environmentally 
relevant concentrations? 
7. Can peroxygenases be used in long term experiments over several days/weeks? If 
so, what is their performance under such conditions? 
 
Finally, on the basis of the answers to the questions posed above, this study has aimed to 
develop perspectives for the application of fungal peroxygenases in the pharmaceutical 
industry and the water treatment sector. 
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2 Materials and Methods 
2.1 Chemicals and reactants 
2.1.1 Pharmaceuticals and their metabolites 
Metoprolol, oseltamivir phosphate, 4-hydroxytolbutamide, 4'-hydroxydiclofenac, 5-
hydroxydiclofenac, 3-hydroxyacetaminophen, omeprazole, and sildenafil were obtained 
from Chemos GmbH (Regenstauf, Germany). 3-Hydroxycarbamazepine, 1-
hydroxyibuprofen, 2-hydroxyibuprofen, 1-oxoibuprofen and N-desmethylsildenafil were 
purchased from Toronto Research Chemicals Inc. (Toronto, Canada), and α-
hydroxymetoprolol, glycinexylidide and monoethylglycinexylidide from TLC 
PharmaChem. Inc. (Vaughan, Canada). 17α-Ethinylestradiol, (R)-naproxen, 4-
hydroxypropranolol, 5-hydroxypropranolol, (S)-N-desisopropylpropranolol and O-
desmethylmetoprolol were obtained from Fluka (St. Gallen, Switzerland), from Shanghai 
FWD Chemicals Ltd. (Shanghai, China), Biomol GmbH (Hamburg, Germany), SPIbio, 
Bertin Group (Montigny Le Bretonneux, France), ABX Advanced Biochemical 
Compounds (Radeberg, Germany) and Sandoo Pharmaceuticals & Chemicals Co., Ltd. 
(Zhejiang, China), (S)-mephenytoin, S-desmethyl mephenytoin and 4’-hydroxy 
mephenytoin were purchased from Santa Cruz Biotechnology Inc. (Heidelberg, Germany) 
respectively. H218O2 (90 atom %, 2% wt/vol) was a product of Icon Isotopes (New York, 
USA). All other chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany). 
Phenacetin-d1 (N-(4-[1-2H]ethoxyphenyl)acetamide) was prepared from acetaminophen 
(N-(4-hydroxyphenyl)acetamide) and ethyl iodide-d1 as described previously for 
phenacetin-d3 (Garland et al. 1977). The reaction product of the synthesis (phenacetin-d1) 
was identified by comparison of retention time, UV absorption spectra, and mass spectra 
relative to authentic phenacetin (Nottebaum and McClure 2010); mass spectrum (m/z, %): 
180 (100, - H), 138 (62, - C2H2O), 110 (12, - C4DH6O), 109 (96, - C3DH2O2), 108 (100, - 
C3DH6ON), 80 (16), 43 (18).  
2.1.2 Drugs and their metabolites 
Codeine hydrochloride, dextroamphetamine hydrochloride, (R,S)-Methamphetamine, 3,4-
methylenedioxyamphetamine (tenamphetamine), norcodeine, benzoylecgonine, lysergic 
acid diethylamne, flurazepam, midazolam and Δ9-tetrahydrocannabinol were purchased 
from Lipomed GmbH (Weil am Rhein, Germany). All other drugs and metabolites were 
obtained from Sigma-Aldrich (Schnelldorf, Germany). 
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2.1.3 Steroids and anabolic agents 
Cortisone, pregnenolone and cholesterol were purchased from TCI Deutschland GmbH 
(Eschborn, Germany). Testosteron was obtained from Fisher Scientific GmbH (Schwerte, 
Germany). All other steroids, anabolic steroids and metabolites were obtained from Sigma-
Aldrich (Schnelldorf, Germany). 
2.1.4 Benzodioxole derivatives 
Safrole, sesamol, myristicin, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and 
5-chloro-1,3-benzodioxole were purchased from Sigma-Aldrich (Schnelldorf, Germany). 
5-Nitro-1,3-benzodioxole (3,4-methylenedioxynitrobenzene, MDONB, NBD), 4-Bromo-
1,2-methylenedioxybenzene (3,4-methylenedioxybromobenzene) were obtained from TCI 
Deutschland GmbH (Eschborn, Germany). Pisatin was obtained from Apin Chemicals Ltd. 
(Abington, United Kingdom).  
2.2 Fungal cultivation and purification of peroxygenases 
2.2.1 Agrocybe aegerita and its peroxygenase 
Agrocybe aegerita (Black poplar mushroom) is a typical agaric fungus, whose fruiting 
bodies consist of a stalk and a cap with lamellae (gills) on the underside (Fig. 6; Foto by 
René Ullrich). The fruiting bodies are edible and 
have been cultivated in Mediterranean countries 
for centuries. A. aegerita preferably colonizes 
hardwood (Populus spp., Acer spp.) where it 
causes an atypical white-rot, but also mulch and 
straw-like materials (Stamets 1993). 
The extracellular peroxygenase of A. aegerita 
(AaeAPO; isoform II, 44 kDa) was produced and 
purified as described previously (Ullrich et al. 
2004). Agrocybe aegerita (fungal strain: A1, 
isolated from a straw-pile in Jena/Wöllnitz in 
1970) was cultivated on agar plates and in liquid 
cultures, the culture liquid of which was 
ultrafiltered and concentrated. 
Figure 6 Agrocybe aegerita (Photo by René Ullrich)       
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These crude enzyme preparations were further purified by three steps of ion exchange 
chromatography using the strong cation exchangers SP Sepharose™ FF and Mono S™, 
and the strong anion exchanger Mono Q™. All chromatographic steps were performed 
with an ÄKTA FPLC™ system (Fast Protein Liquid Chromatography, GE Healthcare 
Europe GmbH, Freiburg, Germany). After every exchange step, enzyme-containing 
fractions were collected, ultrafiltered and desalted by a 150-mL or 20-mL stirred cell 
system (10 kDa cut-off modified polyethersulphone membrane, Pall Life Sciences, 
Dreieich, Germany). After the purification, the molecular mass of enzyme isoforms was 
determined by SDS-PAGE (Novex XCell; Invitrogen GmbH, Karlsruhe, Germany) using a 
12% NuPage™ gel. Protein concentration was determined with a low-molecular-mass 
calibration kit served as a protein standard (MBI Fermentas®, St. Leon Roth, Germany). 
The same electrophoresis system was used for analytical isoelectric focusing (IEF). 
Electrophoretically separated protein bands were visualized with the Colloidal Blue 
Staining Kit (Invitrogen). Final enzyme preparations were sterile-filtered, portionized and 
frozen at -80°C.  
2.2.1.1 Fungal cultivation 
Fungal stock cultures (A. aegerita strain A1; DSM 22459) were maintained on 2% malt-
extract agar (MEA) plates and kept in the dark at 4°C (Pecyna et al. 2009). For subsequent 
studies, fungal precultures were prepared by excising one agar plug (∅ 1 cm)  from the 
stock culture, transferring it onto fresh MEA plates and keeping the cultures at 24°C for 2-
3 weeks. Afterwards, 27 500-mL flasks containing 6 g of soybean flour (Hensel, Magstadt, 
Germany) in 200 mL of destilled water, were sterilized and inoculated with the contents of 
one fungal preculture homogenized in 80 mL sterile water (0.05 % v/v). Fungal cultures 
were agitated on a rotary shaker (100 rpm) at 24°C for 2-3 weeks. 
2.2.1.2 Ultrafiltration 
The fungal mycelium was removed by filtration (filter GF6; Schleicher & Schuell, Dassel, 
Germany) and the enzyme-containing liquid was concentrated 60-fold by two steps of 
ultrafiltration using a tangential-flow cassette system (Ultrasette™, cut-off 10 kDa, Pall 
GmbH, Distributor VWR GmbH, Darmstadt, Germany). 
2.2.1.3 SP Sepharose™ FF separation 
The pH of the crude enzyme preparation was adjusted to 4.75 and the proteins were 
separated on the strong cation exchanger SP Sepharose Fast Flow (column XK 26/20, GE 
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HealthCare). Sodium acetate buffer (10 mM, pH 4.75) was used as a mobile phase and 10 
mM sodium acetate buffer containing 2 M sodium chloride (pH 4.75) was used as the 
eluent. The column was operated at a flow rate of 13 mL min-1 and fractions (10 mL) were 
collected. The elution of protein was performed with a linear gradient from 0% to 50% 
eluent in 8 column volumes (modified according to (Ullrich et al. 2004)). 
2.2.1.4 Mono Q™ separation 
The pH of the enzyme preparation was adjusted to 6.0, and the mixture separated by a 
Mono Q 10/100 GL column. Separations were carried out with sodium acetate buffer (10 
mM, pH 6.0) as mobile phase and sodium acetate buffer (10 mM, pH 6.0) containing 
sodium chloride (2 M) as eluent. Fractions (2 mL) were collected at a flow rate of 4 mL 
min-1. The elution of protein was achieved with a linear gradient from 0% to 30% eluent in 
7 column volumes. 
2.2.1.5 Mono S™ separation 
The pH of the enzyme preparation was adjusted to 4.75, and the mixture separated by a 
Mono S 10/100 GL column. Separations were carried out with sodium acetate buffer (10 
mM, pH 4.75) as solvent, and sodium acetate buffer (10 mM, pH 4.75) containing sodium 
chloride (1 M) as eluent. Fractions (2 mL) were collected at a flow rate of 6 mL min-1. The 
elution of protein was performed with a linear gradient from 0% to 50% eluent in 10 
column volumes. 
 
 
Figure 7 Elution profile recorded after ion exchange on the strong cation exchanger Mono S. 
Separation of different AaeAPO isoforms (I, II, III, IV). For all further studies with AaeAPO, the 
isoform II was used. 
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2.2.1.6 Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
(SDS-PAGE) 
Molecular weights of proteins were determined by sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) in a Mini-Cell system (XCell SureLockTM, 
Invitrogen GmbH, Karlsruhe, Germany) with Novex® Pre-Cast gels. The method is 
described in the manufacturer’s instructions. After electrophoresis, the gels were stained 
and protein bands were visualized with Colloidal Blue® (Invitrogen). A low molecular 
weight protein calibration kit (MBI Fermentas, St. Leon Roth, Germany) was used as the 
standard (Ullrich et al. 2004). Figure 8 shows exemplary electrophoretic separations: an 
SDS-PAGE gel and an IEF gel of purified AaeAPO.  
 
 
Figure 8 Separated AaeAPO isoform II visualized with the Colloidal Blue® Staining Kit in an 
SDS-PAGE gel (left) and an IEF gel (right). M: marker, MW: molecular weight, pI: isoelectric 
point. 
2.2.1.7 Isoelectric focusing (IEF) 
 
IEF separation was done in a Mini-Cell system (XCell SureLockTM, Invitrogen GmbH, 
Karlsruhe, Germany) applying pre-cast IEF gels (pH 3-7) with IEF markers pH 3–10 and 
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relevant buffers (Invitrogen GmbH, Karlsruhe, Germany), according to the manufacturer’s 
instructions, and previous studies (Ullrich et al. 2009, Ullrich et al. 2004).  
2.2.1.8 Summarized properties of the AaeAPO preparation 
 
The enzyme preparation was homogeneous by SDS-PAGE, had a molecular mass of 46 
kDa, a pI of 5.1 and exhibited an A418/A280 ratio of 1.75 (1.86 3, 1.68 4 ). The specific 
activity of the AaeAPO preparation was 117 U mg-1(65 U mg-1 3, 85 U mg-1 4) where 1 U 
represents the oxidation of 1 µmol of 3,4-dimethoxybenzyl alcohol (veratryl alcohol) to 
3,4-dimethoxybenzaldehyde (veratraldehyde) in 1 min at 23 °C (Ullrich et al. 2004). 
2.2.2 Coprinellus radians and its peroxygenase 
 
This fungus prefers nitrogen-rich habitats and grows both on dung, straw-like materials 
and wet wood. It is found not only outdoors, but also indoors on wet wood in basements 
and bathrooms (Uljé 2001).  
The strain used here, DSM 888 (ATCC 20014) isolated from horse dung, was purchased 
from the DSMZ, Braunschweig, 
Germany (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen 
GmbH 2012). The unspecific 
peroxygenase of Coprinellus radians 
(CraAPO) was produced and purified as 
described previously (Anh et al. 2007). 
The fungus was cultivated on agar plates 
and transferred to liquid cultures, and 
the culture liquid thus obtained was 
ultrafiltered and concentrated. 
 
Figure 9 Fruiting bodies of Coprinellus radians (Photo by Hung Anh) 
Crude enzyme preparations were further purified by two steps of anion exchange 
chromatography (AEX) using Q Sepharose™ FF and Mono Q™ as separation media 
followed by size exclusion chromatography (SEC, Superdex™ 75). All chromatographic 
steps were performed with an ÄKTA FPLC™ system (Fast Protein Liquid 
Chromatography, GE Healthcare Europe GmbH, Freiburg, Germany). After every 
                                                 
3 second purification 
4 Isoform III that was used in long-time experiments (see 2.8.3) 
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exchange step, enzyme fractions were collected, ultrafiltered and desalted with 150-mL or 
20-mL stirred cell systems (10 kDa cut-off modified polyethersulphone membrane, Pall 
Life Sciences, Dreieich, Germany). After purification, the enzyme was characterized. The 
molecular mass of enzyme isoforms was determined by SDS-PAGE (Novex XCell; 
Invitrogen GmbH, Karlsruhe, Germany) using a 12% NuPage™ gel. Protein concentration 
was determined with a low-molecular-mass calibration kit (MBI Fermentas®, St. Leon 
Roth, Germany). The same electrophoresis system was used for analytical isoelectric 
focusing (IEF). Electrophoretically separated protein bands were visualized with the 
Colloidal Blue Staining Kit (Invitrogen GmbH, Karlsruhe, Germany). The final enzyme 
preparations were sterile-filtered, portionized and frozen at -80°C. 
2.2.2.1 Fungal cultivation 
Fungal stock cultures of C. radians (DSM 888) were cultivated on MEA plates and kept in 
the dark at 4°C. For subsequent studies, fungal precultures were prepared by excising one 
agar plug (∅ 1 cm) from the stock culture, transferring it onto fresh MEA plates and 
keeping the cultures at 24°C for 2-3 weeks. Afterwards, 27 500-mL flasks containing 6 g 
soybean flour and 8 g glucose in 200 mL destilled water, were sterilized and inoculated 
with the contents of a fungal preculture homogenized in 80 mL sterile water (0.05% v/v). 
Fungal cultures were agitated on a rotary shaker (100 rpm) at 24°C for 2-3 weeks. 
2.2.2.2 Ultrafiltration 
The fungal mycelium was removed by filtration (filter GF6; Schleicher & Schuell, Dassel, 
Germany) and the enzyme-containing liquid was concentrated 60-fold by two steps of 
ultrafiltration using a tangential-flow cassette system (Ultrasette™, cut-off 10 kDa, Pall 
GmbH, Distributor VWR GmbH, Darmstadt, Germany). 
2.2.2.3 Q Sepharose™ FF separation 
The pH value of crude enzyme was adjusted to 6.0, and the proteins were separated on the 
strong anion exchanger Q Sepharose Fast Flow (column XK 26/20, GE HealthCare) and 
fractionated. As the mobile phase, 10 mM sodium acetate buffer (pH 6.0) was used and 10 
mM sodium acetate buffer with 2 M sodium chloride (pH 6.0) served as the eluent. The 
fraction size was 8 mL at a flow rate of 13 mL min-1. The elution of protein was achieved 
by a linear gradient from 0% to 50% eluent in 10 column volumes. 
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2.2.2.4 Mono Q™ separation 
The pH value of the enzyme preparation was adjusted to 5.5 and the mixture separated on a 
Mono Q 10/100 GL column and fractionated. Separations were carried out with sodium 
acetate buffer (10 mM, pH 5.5) as solvent, and sodium acetate buffer (10 mM, pH 5.5) 
with sodium chloride (2 M) as eluent. The fraction size was 2 mL at a flow rate of 4 mL 
min-1. The elution of protein was performed with a linear gradient from 0% to 30% eluent 
in 7 column volumes. 
2.2.2.5 Size exclusion chromatography (SEC) using 
Superdex™ 75 
The pH value of the enzyme preparation was adjusted to 6.5, and the mixture separated by 
a HiLoad 26/60 Superdex 75 preparative grade column and fractionated. As the mobile 
phase and eluent, 50 mM sodium acetate buffer (pH 6.5) with 0.1 M sodium chloride (pH 
6.5) was used. The fraction size was 4 mL at a flow rate of 2.5 mL min-1. The elution of 
proteins occurred under isocratic conditions. 
 
 
 
 
 
 
 
 
Figure 10 Elution profile of CraAPO recorded 
after size exclusion chromatography on a 
SuperdexTM 75 column. 
2.2.2.6 Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
(SDS-PAGE) and isoelectric focusing (IEF) 
The methods used were the same as described for AaeAPO (2.2.1.6 and 2.2.1.7). Figure 11 
shows as an example the SDS-PAGE gel of the purified Coprinellus radians peroxygenase 
(CraAPO). 
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Figure 11 Purified CraAPO visualized in an SDS-PAGE gel 
with the Colloidal Blue staining kit. M: Marker, MW: 
Molecular weight. 
 
2.2.2.7 Summarized properties of the CraAPO preparation 
The enzyme preparation was homogeneous by SDS-PAGE, had a molecular mass of 44 
kDa, a pI of 4.2, and exhibited an A419/A280 ratio of 1.04. The specific activity was 25.8 U 
mg-1, where 1 U means the oxidation of 1 µmol of 3,4-dimethoxybenzyl alcohol (veratryl 
alcohol) to 3,4-dimethoxybenzaldehyde (veratraldehyde) in 1 min at 23 °C (Anh et al. 
2007). 
2.2.3 Marasmius rotula and its peroxygenase 
Marasmius rotula (Pinwheel 
mushroom) grows in deciduous 
forests and fruits in groups or 
clusters on dead wood (especially 
beech), woody debris such as 
twigs or sticks, and occasionally 
on rotting leaves. M. rotula 
peroxygenase was a gift from K. 
Scheibner and G. Gröbe (Lausitz 
University of Applied Sciences, 
Senftenberg, Germany). 
Figure 12 Marasmius rotula (Foto by René Ullrich) 
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Cultivation of the fungus as well as enzyme purification and characterization were 
described in (Gröbe et al. 2012). The enzyme had a molecular mass of 32 kDa, a pI 
between 4.97 and 5.27, and a specific activity of 12.8 U mg-1. 
2.3 UV-Vis spectroscopy 
2.3.1 Veratryl alcohol assay for peroxygenases 
 
 
 
 
 
 
 
 
Figure 13 Veratryl 
alcohol assay 
 
The assay was routinely performed in quartz cuvettes with a light path of 10 mm. The 
reaction mixture contained in a total of 1 mL the ingredients given in Table 5. The reaction 
was started by addition of H2O2 and followed at 310 nm and room temperature for at least 
20 seconds. Enzyme activity was calculated using the initial linear increase in absorbance 
and the extinction coefficient for veratryl aldehyde at 310 nm (ε310 = 9,300 M-1 cm-1) (Tien 
and Kirk 1984, Ullrich et al. 2004). Note that the same assay is used to measure the activity 
of lignin peroxidase (LiP, EC 1.11.1.14), except that acidic tartrate buffer (pH 3.0) is used 
for Lignin peroxidase instead of neutral phosphate buffer (Hofrichter et al. 2010). 
Table 5 Composition of veratryl alcohol assay. 
Compound Solution 
concentration (mM) 
Amount (µL) End 
concentration (mM) 
Potassium phosphate 
buffer pH 7 
100 500 50 
Veratryl alcohol 50 100 5 
H2O  290-389  
Sample/ Enzyme 
solution 
 1-100  
H2O2 100 10 1 
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2.3.2 ABTS assay for laccase 
 
 
 
Figure 14 ABTS assay for laccases 
 
The assay was routinely performed in quartz cuvettes with a light path of 10 mm. The 
reaction mixture contained in a total of 1 mL the ingredients listed in Table 6. The reaction 
was started by the addition of the enzyme-containing sample to the mixture and was 
followed at 420 nm and room temperature for over 60 seconds. Enzyme activity was 
calculated using the initial linear increase in absorbance and the extinction coefficient for 
the ABTS cation radical at 420 nm (ε420 = 36,000 M-1 cm-1) (Wolfenden and Willson 
1982). 
Table 6 Composition of the ABTS [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)] assay. 
Compound Solution 
concentration (mM) 
Amount (µL) End 
concentration (mM) 
Sodium citrate buffer 
pH 4.5 
100 500 50 
ABTS 6 50 0.3 
H2O  350-445  
Sample/Enzyme 
solution 
 5-100  
2.3.3 Nitrobenzodioxole assay for peroxygenases 
2.3.3.1 Spectrophotometric activity measurement at neutral pH 
 
 
 
Figure 15 Nitrobenzodioxole assay for peroxygenases 
 
This is a new assay developed in the course of this work (see 3.10) and it has been 
published recently (Poraj-Kobielska et al. 2011a). Peroxygenases of Agrocybe aegerita, 
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Coprinellus radians, Coprinopsis verticillata5, Marasmius rotula as well as recombinant 
peroxygenase of Coprinopsis cinerea6 (0.05-2 Units mL-1; ~0.02-10 µM) were individually 
dissolved together with 5-nitro-1,3-benzodioxole [NBD; 1,2-(methylenedioxy)-4-
nitrobenzene (0.125-0.5 mM)7] in potassium phosphate buffer (50 mM, pH 7.0) containing 
acetonitrile (10% vol/vol) and, if the reaction products were to be quantified by HPLC, 
ascorbic acid8 (4.0 mM). After adding the co-substrate H2O2 (1 mM), the reaction mixture 
immediately changed its color to bright yellow (at pH 7 and 23 °C). 
The assay was routinely performed in quartz cuvettes with a light path of 10 mm. The 
reaction mixture contained in a total of 1 mL the ingredients given in Table 7. The reaction 
was started by the addition of H2O2 and followed at 425 nm and room temperature for 15-
30 seconds. Peroxygenase activity was calculated using the initial linear increase in 
absorbance and the extinction coefficient for 4-nitrocatechol at 425 nm (ε425 = 9,700 M-1 
cm-1). 
Table 7 Composition of the nitrobenzodioxole (NBD) assay. 
Compound Solution 
concentration (mM) 
Amount (µL) End 
concentration (mM) 
Potassium phosphate 
buffer pH 7 
100 500 50 
NBD 50 100 5 
H2O  290-389  
Sample  1-100  
H2O2 100 10 1 
2.3.3.2 Colorimetric detection under alkaline conditions 
The colorimetric detection of 4-nitrocatechol can be performed as an end-point 
determination and requires the adjustment of the assay solution mentioned above, after a 
certain reaction time (5-10 min), to a pH >12, e.g. by addition of 100 µL sodium lye (10 
M). In the presence of 4-nitrocatechol, the assay mixture will immediately change its color 
to red and peroxygenase activity can be calculated by detecting the absorbance at 514 nm 
(ε514 = 11,400 M−1 cm−1). 
                                                 
5 gift of E. Aranda and R. Ullrich (International Graduate School of Zittau) 
6 gift of H. Lund (Novozymes A/S, Copenhagen, Denmark) 
7 NBD is hardly soluble in water and aqueous solvent mixtures at concentrations higher than 0.5 mM. Stock 
solutions can be prepared by using pure acetonitrile as solvent. 
8 Ascorbic acid is added to prevent the further oxidation of the product 4-nitrocatechol, which proceeds via 
the peroxidative activity of A. aegerita peroxygenase (Kinne et al. 2009a, Kinne et al. 2008). The addition of 
the radical scavenger is not necessary for the qualitative colorimetric detection of peroxygenases. 
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2.3.3.3 Tests with environmental samples 
Fresh samples of leaf-litter from a riparian Alnus forest near Zittau (Germany) as well as of 
chopped wheat straw and beech wood were homogenized and 2 g of them extracted in 
potassium phosphate buffer (50 mM, pH 7.0) for 24 h. The crude extracts were centrifuged 
and the supernatants used for the experiment. The peroxygenase activity messurements in 
the extracts showed no positive results. The test was performed analogue to the 
nitrobenzodioxole assay (2.3.3.1) in quartz cuvettes with a light path of 10 mm. The 
reaction mixture contained in a total of 1 mL the ingredients given in Table 8. The reaction 
was started by the addition of H2O2 and followed at 425 nm and room temperature for 15-
30 seconds. Peroxygenase activity was calculated using the initial linear increase in 
absorbance and the extinction coefficient for 4-nitrocatechol at 425 nm (ε425 = 9,700 M-1 
cm-1). 
Table 8 Composition of the nitrobenzodioxole (NBD) assay with environmental samples. 
Compound Solution 
concentration (mM)
Amount (µL) End 
concentration (mM) 
Potassium phosphate 
buffer pH 7 
100 500 50 
NBD 50 100 5 
extract  300  
H2O  70  
AaeAPO  20 7.2 U(VA) mL-1/  13.2 
U (NBD) mL-1 
H2O2 100 10 1 
2.3.4 Determination of protein concentration 
The determination of protein concentration was performed using the Bradford assay. This 
is a colorimetric protein assay based on an absorbance shift of the dye Coomassie Brilliant 
Blue G-250, in which under acidic conditions the red form of the dye is converted into its 
blue form to bind with the protein being assayed. The (bound) form of the dye has an 
absorption maximum historically held to be at 595 nm. The cationic (unbound) forms are 
green or red and absorb at 450 nm. 
For the calibration curve, standard protein (Albumin, Roth Chemie GmbH, Karlsruhe, 
Germany) was prepared in following concentrations: 5, 10, 20, 30, 40, 50, 60, 80, 100 µg 
mL-1. 5 mL of the original dye solution Roti®-Nanoquant (Roth Chemie GmbH, Karlsruhe, 
Germany) was diluted in 20 mL of distilled water. A Greiner 96-well Flat Transparent 
Plate was filled as follows: wells A1, A2, and A3 with 250 µL of water (blank), lines B to 
H (1, 2, and 3) and lines A and B (4, 5, and 6) each with 50 µL of the calibration stock 
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solutions. All calibration wells were filled up with 200 µL of the dye solution. 50 µL of the 
protein samples were pipetted in one of the free wells and filled up with 200 µL of the dye 
solution. The color was visually checked and compared with a calibration row. If the color 
fitted into the calibration row, the sample was pipetted into three following wells (if not, 
the sample was first diluted) and filled up with 200 µL dye solution. The plate was 
measured with a multimode reader Infinite M200, TECAN® (Tecan Group Ltd., 
Männedorf, Germany) with the following method: shaking for 5 seconds at 44.3 rpm, 
measurement at 590 nm, followed by measurement at 450 nm. The results were read as the 
quotient 590/450 as mean concentration in µg mL-1.  
2.3.5 Difference spectra 
Difference spectra were recorded in quartz cuvettes (light path 10 mm) in the scanning 
range from 200 to 800 nm at room temperature using a Cary 50 spectrophotometer 
(Varian, Darmstadt, Germany). The mixture contained 50 mM potassium phosphate buffer 
(pH 7), 40 U mL -1 (13.75 µM) AaeAPO and 0.625 mM to 4.6 mM of the ligand. The 
substrate ligands were phenol (as reference (Kinne 2010)), diclofenac, propranolol and 
dextromethorphan. The instrument baseline was set to zero with the reference cuvette in 
the sample beam. The reference cuvette contained 50 mM potassium buffer (pH 7) and 40 
U mL-1 (13.75 µM) of AaeAPO.  
2.4 Standard reaction conditions for peroxygenase conversions 
Typical reaction mixtures (0.2-1.0 mL) contained purified peroxygenase (1.0-2.0 U mL-1 = 
0.04-0.08 µM), substrate to be oxidized (0.5-2.0 mM), potassium phosphate buffer (50 
mM, pH 7.0), and ascorbic acid (4.0-6.0 mM, to inhibit further oxidation of any phenolic 
products that were released (Kinne et al. 2009a, Kinne et al. 2008). The reactions were 
started by the addition of limiting H2O2 (2.0-4.0 mM) and stirred at room temperature. 
They were stopped by addition of sodium azide (1 mM) or trichloroacetic acid (TCA) (5%) 
after 3 min. In some cases, H2O2 was added continuously with a syringe pump and the 
reactions were stopped after 4-6 h, when chromatographic analyses showed that product 
formation was complete. 
Aliphatic aldehydes were analyzed as their 2,4-dinitrophenylhydrazones after addition of 
0.2 volume of 0.1% 2,4-dinitrophenylhydrazine solution in 0.6 N HCl to each reaction 
mixture. 
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2.5 Product identification 
Reaction products of interest were detected, generally with baseline resolution, by high 
performance liquid chromatography (HPLC) using an Agilent Series 1200 instrument 
equipped with a diode array detector (DAD) and an electrospray ionization mass 
spectrometer (MS) (Agilent Technologies Deutschland GmbH, Böblingen, Germany). 
Formic acid was analyzed by ion exchange chromatography (IC) using a Dionex Series 
ICS 1100 system (Thermo Fisher GmbH, Idstein, Germany).  
2.5.1 HPLC method I 
For the experiments with acetaminophen, acetanilide and diclofenac, a Synergi 4µ Fusion 
reversed-phase column (4.6 mm diameter by 150 mm length, 4 µm particle size, 80Ǻ, 
Phenomenex, Aschaffenburg, Germany) was used. The column was run at 40°C and a flow 
rate of 1 mL min-1 with a mixture of aqueous phosphoric acid solution (15 mM, pH 3) and 
acetonitrile, 95:5, for 5 min, followed by a 20-min linear gradient to 100% acetonitrile. 
2.5.2 UHPLC method  
For the experiments with low concentrated propranolol, a Kinetex 2.6 µ C18 column (2.1 
mm diameter by 150 mm length, 2.6 µm particle size, 100 Ǻ, Phenomenex, Aschaffenburg, 
Germany) was used. The column was eluted at 0.3 mL min-1 and 40°C with aqueous 
0.01% vol/vol ammonium formate (pH 3.5)/acetonitrile, 90:10, followed by a 3-min linear 
gradient to 70% acetonitrile. 
2.5.3 HPLC method for chiral separation 
Chiral separation was done using the HPLC apparatus above, but using a Whelk-O 5/100 
Kromasil column (4.6 mm diameter by 250 mm length, Regis Technologies (Morton 
Grove, USA). The isocratic mobile phase consisted of 80% vol/vol methanol and 20% of 
15 mM phosphate buffer. The columns were operated at 40°C and 1 mL min-1 for 30 min. 
2.5.4 HPLC-MS method I 
Unless otherwise stated, reversed-phase (RP) chromatography of reaction mixtures was 
performed on a Luna C18 column (2 mm diameter by 150 mm length, 5 µm particle size, 
100 Ǻ, Phenomenex, Aschaffenburg, Germany), which was eluted at 0.35 mL min-1 and 
40°C with aqueous 0.01% vol/vol ammonium formate (pH 3.5)/acetonitrile, 95:5 for 5 
min, followed by a 25-min linear gradient to 100% acetonitrile (for mass spectrometer 
parameters see 2.5.7). 
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2.5.5 HPLC-MS method II 
The derivatized products were analyzed using a Luna C18 column. The column was eluted 
with aqueous 0.1% vol/vol ammonium formate (pH 3.5)/acetonitrile, 70:30 for 5 min, 
followed by a 20-min linear gradient to 100% acetonitrile (for mass spectrometer 
parameters see 2.5.7) 
2.5.6 HPLC-MS method III 
For metoprolol, a Gemini-Nx 3µ 110A C18 reversed-phase column (2 mm diameter by 
150 mm length, 3 µm particle size, Phenomenex) was used. The column was eluted at 
45°C and a flow rate of 0.3 mL min-1 with a mixture of aqueous 0.2% vol/vol ammonium 
(pH 10.5) and acetonitrile, 95:5, for 1 min, followed by a 20-min linear gradient to 80% 
acetonitrile, followed by 21-min linear gradient to 100% acetonitrile (for mass 
spectrometer parameters see 2.5.7). 
2.5.7 Mass spectrometry for HPLC-MS methods 
Mass spectrometric determinations were made in the positive or negative ESI mode 
(electrospray ionization) in a mass range from 70 to 500, at a step size of 0.1, a drying gas 
temperature of 350°C, a capillary voltage of 4,000 V for the positive mode and 5,500 V for 
the negative mode. Reaction products were identified relative to authentic standards, based 
on their retention times, UV absorption spectra, and mass spectral [M + H]+ or [M - H]- 
ions.  
2.5.8 IC method for organic acids 
Formic acid was analyzed by ion exchange chromatography (IC) on a Dionex Series ICS 
1100 HPLC system fitted with a IonPac® ICE-AS1 column (4 mm diameter by 250 mm 
length, Dionex, Germany). The column was eluted at 30°C and 1.6 mL min-1 with an 
aqueous perfluorobutyric acid solution (1 mM) for 20 min. The product was identified 
relative to an authentic standard by its retention time. 
2.6 Stoichiometrical analyses 
2.6.1 Sildenafil 
Stoichiometrical experiments on sildenafil N-demethylation were conducted in stirred 
reactions (0.20 mL) that contained 2 U mL-1 (0.144 µM) peroxygenase, potassium 
phosphate buffer (50 mM, pH 7.0) and the substrate (0.25 mM). The reactions were 
initiated by 0.0023-0.037 mM H2O2. The resulting product (N-desmetyl sildenafil) was 
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quantified by HPLC-MS as described above (HPLC-MS method I, 2.5.4) using the 
external standard curve prepared with the authentic standard. 
2.6.2 Safrole 
The stoichiometrical experiment on safrole demethylenation occurred in a stirred reaction 
mixture (0.20 mL) that contained 2 U mL-1 (0.144 µM) of peroxygenase, potassium 
phosphate buffer (50 mM, pH 7.0), acetonitrile (10% vol/vol), ascorbic acid (4.0 mM) and 
the substrate (0.25 mM). The reactions were initiated by 0.0125-0.200 mM H2O2. The 
product (formic acid) was quantified by IC as described above, using an external standard 
curve. The standard curve had linear regression values of R2  >0.99. 
2.7 Enzyme kinetics 
2.7.1 Pharmaceuticals 
The kinetics of propranolol hydroxylation as well as metoprolol and phenacetin O-
dealkylation were analyzed in stirred microscale reactions (0.10 ml, 23°C) that contained 
0.40 µM peroxygenase (AaeAPO), potassium phosphate buffer (50 mM, pH 7.0), ascorbic 
acid (4 mM) and 0.010-5.000 mM substrate. The reactions were initiated with 2.0 mM 
H2O2. Reactions with propranolol or phenacetin were stopped with 0.010 mL of a 50% 
TCA solution after 5 seconds, and reactions with metoprolol were stopped with 0.2 volume 
of 0.1% 2,4-dinitrophenylhydrazine solution in 0.6 N HCl after 10 seconds. The resulting 
products were quantified by HPLC as described above using the external standard curves 
prepared with authentic standards.  
The kinetics of acetanilide hydroxylation were analyzed in stirred reactions (0.5 mL, 23 
°C) that contained 0.18 µM AaeAPO, potassium phosphate buffer (50 mM, pH 7.0), 
ascorbic acid (4 mM) and 0.010-5.000 mM substrate. The reactions were initiated by 2.0 
mM H2O2 and stopped by 0.050 mL of a sodium azide solution (1 mM) after 5 seconds. 
The initial velocity of acetaminophen formation was then determined from the increase in 
absorbance at 290 nm (ε = 1,100 M-1 cm-1) using a Cary 50 UV/visible spectrophotometer. 
The kinetic parameters were determined by nonlinear regression using the Lineweaver-
Burk model in the ANEMONA program (Hernandez and Ruiz 1998). 
2.7.2 Nitrobenzodioxole 
The kinetics of 5-nitrobenzo-1,3-dioxole demethylenation were analyzed in stirred reaction 
mixtures (0.60 mL, 23°C ) that contained 0.036 µM (0.5 U mL-1) of AaeAPO, potassium 
phosphate buffer (50 mM, pH 7.0), and 0.125-1.000 mM of the substrate. The reactions 
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were initiated with 0.063-0.100 mM H2O2, and the initial velocity of 4-nitrocatechol 
formation was measured by the increase in absorbance at 425 nm (ε = 9700 M-1 cm-1) 
using a Cary 50 UV-Vis spectrophotometer. Three kinetic data sets were obtained for each 
pair of substrate concentrations. Kinetic parameters were determined by nonlinear 
regression using the ping-pong model in the ANEMONA program (Hernandez and Ruiz 
1998). 
2.8 Experiments with 18O-isotopes 
2.8.1 Pharmaceuticals 
The reaction mixtures (0.20 mL, stirred at room temperature) contained 2 U mL-1 (0.08 
µM) of AaeAPO, potassium phosphate buffer (50 mM, pH 7.0), and 0.5 mM substrate 
(tolbutamide, acetanilide, or carbamazepine). Reactions with tolbutamide or acetanilide 
were initiated by a single addition of 2.0 mM H218O2 (final concentration). For reactions 
with carbamazepine, the same quantity of H218O2 was added continuously with a syringe 
pump over 6 hours. A portion of each completed reaction was then analyzed by HPLC-MS 
as described above (HPLC-MS method I, 2.5.4). For each m/z value, the average total ion 
count within the metabolite (4-hydroxytolbutamide, acetaminophen, 3-
hydroxycarbamazepine) peak was used after background correction to generate the ion 
count used for mass abundance calculations. 
2.8.2 Nitrobenzodioxole 
The reaction mixtures (0.20 mL, stirred at room temperature) contained 2 U mL-1 (0.144 
µM) of the peroxygenase, potassium phosphate buffer (50 mM, pH 7.0), ascorbic acid (4.0 
mM, to inhibit further oxidation of the phenolic products that were released (Kinne et al. 
2009a, Kinne et al. 2008) and 0.25 mM nitrobenzodioxole. The reaction was initiated with 
2.0 mM H218O2. A portion of the mixture was analyzed by HPLC-MS as described above 
(HPLC-MS method I, 2.5.4). Calculation of 18O-incorporation was performed by dividing 
the sum of the natural species abundance and the isotope abundance with the latter. The 
10% of natural abundance H2O2 in the H218O2 preparation was taken into account in these 
calculations. 
2.9 Deuterium isotope effect experiment 
The reaction mixture (0.2 mL) contained purified AaeAPO (2 U mL-1, 0.08 µM), 
potassium phosphate buffer (50 mM, pH 7.0), phenacetin-d1 and ascorbic acid (4.0 mM). 
The reaction was started by the addition of H2O2 (2.0 mM) and stirred at room 
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temperature. The reaction was stopped by addition of 10% sodium azide (10 mM) after 10 
seconds. The reaction products were analyzed as described above (HPLC-MS method I, 
2.5.4). For each m/z value, the average total ion count within the acetaminophen peak was 
used after background correction to generate the ion count used for mass abundance 
calculations. 
2.10  Experiment with different peroxides and peroxide sources 
The reaction mixture (0.20 mL, stirred at room temperature) contained: 2 U mL-1 (0.144 
µM) of AaeAPO, potassium phosphate buffer (50 mM, pH 7.0), 4 mM ascorbic acid, 0.5 
mM of diclofenac and 2 mM of glucose by test with glucose oxidase. Reactions were 
initiated in three different ways: i) single addition, ii) multiple additions (four times in four 
minutes), and iii) continuous addition with a syringe pump; the following peroxides or 
peroxide-generating systems were tested: 
1. 2 mM of hydrogen peroxide (H2O2), 
2. 2 mM of meta-chloroperoxybenzoic acid (mCPBA), 
3. glucose oxidase in excess (~20 U mL-1, in the presence of 2 mM glucose), 
4. 2 mM of L-cysteine, 
5. 2 mM of tert-butyl hydroperoxide, and 
6. 2 mM of Cu(II) in form of copper(II) perchlorate hexahydrate [Cu(ClO4)2 × 6 
H2O]. 
2.11  In vivo incubation experiment 
Eighteen 500-mL round bottom flasks were filled with the two culture media described in 
Table 9 (nine flasks of each medium, 200 mL). 
Table 9 Composition of culture media 
Culture medium (each 1,800 mL) 
Soybean medium Czapek-Dox medium 
54 g (3%) soybean flour 1.8 g glucose 
1,800 mL distilled water 5.4 g sodium nitrate 
  1.8 g potassium hydrogen 
phosphate 
  0.9 g potassium chloride 
  0.018 g ferrous sulfate heptahydrate 
  0.9 g yeast extract 
  1,800 mL distilled water 
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All eighteen flasks were autoclaved and numbered. Single flasks were prepared as 
described in Table 10. 
Table 10 Preparation of different cultures. a precultures of A. aegerita were prepared on MEA 
plates and homogenized as described under 2.2.1.1; b instead, 9 mL distilled water was 
supplemented; c 70% ethanol was used for the preparation of stock solution; d stock solutions: 100 
mM of the substance in ethanol (70%) 
Czapek-Dox medium Soybean medium 
Flask 
no. 
Agrocybe 
aegerita 
homogenate a 
(9 mL) 
Culture type and 
additional 
substance 
Flask 
no. 
Agrocybe 
aegerita 
homogenatea  
(9 mL) 
Culture type and 
additional 
substance 
1 + control, 1 mL of 
70% ethanol c 
4 + control, 1 mL of 
70% ethanol c 
2 -b control, 1 mL 
propranolold on 
inoculation day 
5 -b 1 ml propranolold 
on inoculation day 
3 -b control, 1 mL 
diclofenacd on 
inoculation day 
6 -b control,1 mL 
diclofenacd on 
inoculation day 
7 + sample, 1 mL 
propranolold on 
inoculation day 
9 + sample, 1 mL 
propranolold on 
inoculation day 
8 + sample, 1 mL 
diclofenacd on 
inoculation day 
10 + sample, 1 mL 
diclofenacd on 
inoculation day 
11 + sample,1 mL 
propranolold one 
week after 
inoculation 
13 + sample, 1 mL 
propranolold one 
week after 
inoculation 
12 + sample, 1 mL 
diclofenacd one 
week after 
inoculation 
14 + sample, 1 mL 
diclofenacd one 
week after 
inoculation 
15 + sample, 1 mL 
propranolold two 
weeks after 
inoculation 
17 + sample,1 mL 
propranolold two 
weeks after 
inoculation 
16 + sample, 1 mL 
diclofenacd two 
weeks after 
inoculation 
18 + sample,1 mL 
diclofenacd two 
weeks after 
inoculation 
 
The culture flasks were incubated over sixteen days and agitated on a rotary shaker (100 
rpm) at 24°C. Sampling (1 L) of liquid from fungal cultures and controls was done in a 
clean bench on the day of substrate addition and the two following days. The cultures 7, 8, 
9, and 10 were sampled one week after inoculation. All samples were centrifuged, 500 µL 
were used for enzyme activity measurements, the rest was filtrated through Acrodisc® LC 
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13 Syringe filters (13 mm with 0,2 µM PVDF membrane; Pall GmbH, Distributor VWR 
GmbH, Darmstadt, Germany) and analyzed by the HPLC-MS method I (2.5.4). 
2.12  Conversion of propranolol at environmentally relevant 
concentration 
Propranolol (1.5 mL; 5 µM = 5,000 nM) was added into 1,440 mL of distilled water. Six 
500-mL Schott® flasks were filled each with 240 mL of this diluted solution, and 9 mL of 
distilled water was added into three control flasks; into the other three flasks, 50 Units of 
AaeAPO dissolved in 9 mL water was added. The six flasks were incubated at 24°C 
overnight under mixing and continuous dosage of hydrogen peroxide (end concentration 2 
mM) with a syringe pump. In the next step, remaining proteins were removed from the 
samples; for this, the content from all six flasks was ultrafiltered through an Amicon Cell® 
(with 10 kDa cut-off membrane). The membrane was conditioned with 5 µM propranolol 
(to prevent/reduce absorption) and the pH was adjusted to 12 with 10 M NaOH in order to 
facilitate subsequent extraction. The ultrafiltered samples were transferred to separation 
funnels, extracted with dichloromethane by vigorous shaking for 5 minutes, and left 
overnight for completion of phase separation. The separated organic phase was removed 
and concentrated in the evaporator workstation TurboVap® (Zymark, USA) to a volume of 
1 mL; then 2 mL of acetonitrile were added and the mixture concentrated again. In the last 
step, 2 mL of water was added and the mixture concentrated again. The aqueous samples 
were analyzed by HPLC as described above (2.5.2 and 2.5.4). 
2.13  Long term experiments 
2.8.2 Preliminary test with Vivaspin® (fed-batch method) 
For this experiment, Vivaspin® 2 Centrifugal Concentrators (2 mL, with 10 kDa cut-off; 
VivaScience Sartorius Group, Distributor VWR GmbH, Darmstadt, Germany) were used. 
Two Vivaspins were filled each with 10 Units of AaeAPO. Two reaction mixtures (10 mL 
each) were prepared, both containing 50 mM potassium phosphate buffer (pH 7), 0.50 mM 
propranolol, and 2 mM of hydrogen peroxide and one of them in addition 4 mM of 
ascorbic acid. Of both mixtures 1 mL was filled in parallel into the Vivaspins that were 
then centrifuged with a table-centrifuge at 10,397 x g (Allegra 64R with Beckmann-Rotor 
C1015; Beckmann-Coulter, Krefeld, Germany). This procedure was repeated eight times 
on the first day and six times afterwards with one-day breaks in between (each with fresh 
mixtures). The Vivaspins with the enzyme were repeatedly filled with fresh potassium 
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phosphate buffer after the first day and samples were stored at 4°C. After every 
centrifugation step, the enzyme activity was measured with the veratryl alcohol assay 
(2.3.1) in the permeate, as were the product (5-hydroxypropranolol) and substrate 
(propranolol) concentrations by HPLC-MS (method I; 2.5.4). 
2.8.3 Long term experiment using a hollow fiber cartridge 
Four 250-mL Schott® flasks were filled with following solutions: (i) 2.5 mM propranolol; 
(ii) 100mM potassium phosphate buffer, pH 7; (iii) 8 mM ascorbic acid; (iv) 6.7 mM 
hydrogen peroxide. The outlet-tubes of the four flasks were connected with a quaternary 
HPLC pump (Hewlett Packard series 1050) and the solutions pumped with a flow rate of 
0.2 ml min-1 (25% of each solution) through a hollow fiber cartridge (UFP-5-C-MM01A, 
GE Healtcare Europe GmbH, Freiburg, Germany). The cartridge was loaded before with 
30 Units (0.354 mg; Aspec=84.8) of AaeAPO. For two hours, from the very beginning, 
samples were collected and the propranol and 5-hydroxypropranolol concentrations 
measured every 15 minutes by HPLC-MS (Method I; 2.5.4). This procedure was repeated 
for fourteen days. Every day fresh solutions (i), (ii), (iii), and (iv) were prepared and 
pumped through the cartridge, but the enzyme in the cartridge was the same throughout the 
whole experiment. 
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3 Results 
Previous studies have shown that fungal peroxygenases catalyze various reactions similar to 
P450 enzymes. Pharmaceuticals and illicit drugs are one important group of P450 substrates. 
Their conversion by P450s usually increases solubility and bioavailability, which is 
prerequisite for their detoxification or further degradation in the environment. On the other 
hand, the drug metabolites formed are of relevance for drug development and toxicological 
studies. In this section, the results of comprehensive tests using peroxygenase and a 
representative number of pharmaceutically active substances are summarized and classified 
according to the reaction type. Most substances were treated with peroxygenases from three 
different fungal species. Thereafter, the results of kinetic experiments, stoichiometrical 
analyses as well as of 18O-labeling and deuterium-effect studies are presented. The next two 
subchapters deal with a new enzymatic assay for the determination of peroxygenase activity 
and experiments with selected steroids, in the course of which some catalytic limitations were 
observed. The last part of the results section describes complementary experiments with 
propranolol at low, environmentally relevant concentrations as well as long-term and in vivo 
studies. Due to space limitations, additional information including exemplary chromatograms 
and mass spectra can be found in the appendix section. 
3.1 Aromatic ring hydroxylation 
3.1.1 Ring hydroxylation of pharmaceuticals 
Figure 16 provides an overwiew of pharmaceuticals converted by AaeAPO and CraAPO. In 
many cases, ring hydroxylation was observed and sometimes the preferred reaction was 
catalyzed by both APOs with high regioselectivity. For example, AaeAPO preferentially 
oxidized propranolol (I) to 5-OH-propranolol (Kinne et al. 2009a), acetanilide (II) to 
acetaminophen (paracetamol), carbamazepine (III) to 3-OH-carbamazepine, and diclofenac 
(IV) to 4’-OH-diclofenac (Kinne et al. 2009a). CraAPO catalyzed the same reactions but with 
lower regioselectivity. Both enzymes also hydroxylated ketoprofen, sulfadiazine and 
chlorpromazine. Tamoxifen (table 15, XXVII) was oxidized by both peroxygenases yielding 
low amounts of 4-OH-tamoxifen along with some other products, which we were unable to 
resolve sufficiently by HPLC to permit quantifications. 
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Figure 16 Structures of pharmaceuticals and their ring-hydroxylated products. Chemical structures in 
brackets refer to structures with uncertain positions of the introduced oxygen. 
 
The observed products were also quantified, inso far as respective analytical standards were 
available. The results of quantifications are summarized in table 11. 
 
 
 
 
 
 
Table 11 Products identified by mass spectrometry after oxidation of selected pharmaceuticals by AaeAPO and CraAPO. The following data are given: 
 m/z values of the major observed diagnostic ion for substrates and products, consumed substrate (SC), yield (Y) and regioselectivity (RS). 
AaeAPO (%) CraAPO (%) Substrate Reaction Product Discussed as HDM in Ref. no. m/z SC Y RS SC Y RS 
I    23   11   
5-OH-Propranolol (Otey et al. 2006) [M+H]+276 21 91 6 53 
4-OH-Propranolol (Otey et al. 2006) [M+H]+276 − 2 13 [M+H]+ 260 
N-desisopropylpropranolol (Otey et al. 2006) [M+H]+218 
 
traces 
 
3 22 
II    89   20   
Acetaminophen (Greenberg and Lester 1946) [M-H] −150 80 90 13 65 [M-H]− 134 
3-OH-Acetaminophen (Greenberg and Lester 1946) [M-H] −166 
 
5 5 
 
1 2 
III    22   15   
3-OH-Carbamazepine (Pearce et al. 2002) [M+H]+253  13 61  6 40 [M+H]+ 237 
di-OH-Carbamazepine (Pearce et al. 2002) [M+H]+269  n.d.  n.d. 
IV    78   15   
[M+H]+ 296 4'-OH-Diclofenac (Bort et al. 1999) [M+H]+312  68 87  5 30 
V    30    5   
OH-Ketoprofen (Alkatheeri et al. 1999, Skordi et al. 2005) [M+H]
+271 n.d. n.d. [M+H]+ 255 
di-OH-Ketoprofen n.a. [M+H]+287 
 
n.d. 
 
n.d. 
VI    94   13   
[M+H]+ 251 OH-Sulfadiazine (Winter and Unadkat 2005) [M+H]+267  n.d.  n.d. 
VII    99   15   
OH-Chlorpromazine (Perry et al. 1964) [M+H]+335 
di-OH-Chlorpromazine n.a. [M+H]+351 
  [M+H]+ 319 
N-desalkyl-OH-Chlorpromazine n.a. [M+H]+250  
n.d 
 
n.d. 
               (n.d.) = not determined due to poor resolution or no standard, (−) = not detected, (n.a.) = not applicable 
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3.1.2 Ring hydroxylation of drugs of abuse 
Figure 17 provides an overview of controlled and illegal drugs that were ring-hydroxylated by 
fungal peroxygenases in the presence of H2O2. The benzodiazepine drugs VIII-X were 
hydroxylated by AaeAPO and CraAPO to the same products, though the yields of products 
were lower in case of CraAPO. MroAPO oxidized only oxazepam (X).  
 
Figure 17 Structures of controlled and illicit drugs and their hypothetical ring-hydroxylated products. 
Chemical structures in brackets are uncertain with respect to the position of the hydroxyl group on the 
aromatic ring where no analytical standard was available. 
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As already mentioned in material and methods section, ascorbic acid was added to the 
reaction mixtures, to prevent the oxidative coupling and polymerization of phenolic products, 
by scavenging the phenoxyl radicals produced via the peroxidative activity of AaeAPO. 
Methamphetamine (XI), amphetamine (XII) and LSD (XIII) were also ring-hydroxylated, but 
the yields were very low (<10 ppm). The amount of substrate converted and the molecular 
mass ions of substrates and products are shown in Table 12. 
Table 12 Mass spectrometric data of selected drugs of abuse and their oxidation products formed by 
AaeAPO, CraAPO and MroAPO. The following data are given: m/z values of substrates and products 
for the major observed diagnostic ion and percentage of consumed substrate (SC). (n.d.) = not 
determined due to poor resolution 
AaeAPO CraAPO MroAPO Substrate 
SC 
(%) 
P 
m/z 
SC 
(%) 
P 
m/z 
SC 
(%) 
P 
m/z 
VIII 
[M + H]+ 285 26 [M + H]
+301 n.d. [M + H]+301 n.d. traces 
IX 
[M + H]+ 301 11 
[M + H]+317 
[M + H]+317 n.d. [M + H]
+317 n.d. traces 
X 
[M + H]+ 287 10 [M + H]
+303 10 [M + H]+303 n.d. [M + H]+303 
XI 
[M + H]+ 150 15 
[M + H]+136 
[M + H]+166 6 
[M + H]+136 
[M + H]+150 41 
[M + H]+136 
 
XII 
[M + H]+ 136 10 [M + H]
+152 5 [M + H]+152 n.d. traces 
XIII 
[M + H]+ 324 8 [M + H]
+340 12 [M + H]+340 8 [M + H]+340 
3.2 Oxidation of alkyl side chains 
Peroxygenases of A. aegerita and C. radians catalyzed the oxidation of alkyl side chains 
(methyl, isobutyl) of several pharmaceuticals into primary and secondary alcohols. Thus, 
ibuprofen (XIV) was predominantly oxidized to 2-hydroxyibuprofen via hydroxylation of the 
tertiary carbon of the isobutyl group, with the CraAPO-catalyzed reaction exhibiting a higher 
yield and regioselectivity. Similarly, tolbutamide (XV) was oxidized at the methyl group to 4-
hydroxytolbutamide. Gemfibrozil (XVI) and omeprazole (XVII) were hydroxylated and 
dihydroxylated at their methyl groups but also at other positions. In some cases, the alcohols 
formed were further oxidized into the corresponding carbonyls (aldehydes, ketones) and 
carboxylic acids. Proposed product structures are given in Figure 18. 
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Figure 18 Structures of pharmaceuticals and their products that were oxidized at alkyl side chains. 
Chemical structures in brackets are hypothetical with regard to the position of the introduced oxygen 
(no analytical standard available). 
 
Figure 19 shows the structures of the APO substrate Δ9-tetrahydrocannabinol (THC, XVIII) 
and its products proposed on the basis of mass spectral and literature data (ElSohly and Feng 
1998). 
 
Figure 19 Structures of Δ9-tetrahydrocannabinol and its proposed products. 
 
 
Table 13 Products identified by mass spectrometry after oxidation of the listed pharmaceuticals by AaeAPO and CraAPO. 
The following data are given: m/z values for the major observed diagnostic ions for substrates and products, consumed substrate (SC), yield (Y) and regioselectivity (RS). 
AaeAPO (%) CraAPO (%) Substrate Reaction Product Discussed as HDM in Ref no. m/z SC Y RS SC Y RS 
XIV    87   98   
2-OH-Ibuprofen (Hamman et al. 1997, Holmes et al. 2007) [M+H]
+ 223 21 24 74 75 
1-OH-Ibuprofen (Holmes et al. 2007) [M+H]+ 223 7 8 − [M+H]
+ 207 
1-oxo-Ibuprofen n.a. [M+H]+ 221
 
traces 
 
− 
XVa    25   20   
[M-H] − 271 4-OH-Tolbutamide (Hansen and Brøsen 1999) [M-H] − 287  15 60  13 62 
 4-keto-Tolbutamide n.a [M-H] − 285  n.q.    n.q. 
XVI    98   96   
 OH-Gemfibrozil (Murai et al. 2004) [M-H] − 265   
di-OH-Gemfibrozil (Murai et al. 2004) [M-H] − 281[M-H] − 249 
 keto-Gemfibrozil n.a. [M-H] − 263
 
 
 
 
 carboxy-Gemfibrozil (Murai et al. 2004) [M-H] − 279  
 
n.q. 
 
 
n.q. 
XVII    98   96   
 OH-Omeprazole (Hoffmann 1986) [M+H]+ 362   
Omeprazole-sulfone (Andersson et al. 1993) [M+H]+ 362
keto-Omeprazole n.a. [M+H]+ 362[M+H]+ 346 
O-desmethyl-OH-Omeprazole n.a. [M+H]+ 348
 
 
 
 
 O-desmethyl-Omeprazole-sulfone n.a. [M+H]+ 348   
 carboxy-Omeprazole (Andersson et al. 1993) [M+H]+ 376  
n.q. 
 
n.q. 
XVIII    99   99   
OH-THC (ElSohly and Feng 1998) [M+H]+ 331[M+H]+ 315 
di-OH-THC (ElSohly and Feng 1998) [M+H]+ 347
 n.q.  n.q. 
          aMass spectral data indicate the formation of corresponding carbonyls as described previously (Kinne et al. 2010); (n.q.) = not quantified, no standard available;   (−) = not 
detected, (n.a.) = not applicable 
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Table 13 summarizes the m/z values of substrates and detected products, the amounts of 
consumed substrate as well as the product yields and regioselectivity of reactions. The 
conversion of all substrates into the products shown in Figures 18 and 19 (XIV-XVIII) 
applies both to AaeAPO and CraAPO (though the product yields were different in some 
cases); the quantitative results are summarized in the Table 13. 
3.1 O-Dealkylation 
1.3.1 O-Dealkylation of pharmaceuticals 
AaeAPO and CraAPO cleaved alkyl aryl ether linkages in various drugs to yield phenolic 
products (Kinne et al. 2009b). Thus, naproxen (XIX) was selectively demethylated to O-
desmethylnaproxen, dextromethorphan (XX) to dextrorphan, and metoprolol (XXII) to O-
desmethylmetoprolol.  
 
 
Figure 20 Structures of O-dealkylated pharmaceuticals and their products. Chemical structures in 
brackets are hypothetical and were deduced from mass spectral and literature data. 
 
 
Table 14 Products identified by mass spectroscopy after oxidation of the listed pharmaceuticals by AaeAPO and CraAPO in the presence of H2O2. The m/z values for the major 
observed diagnostic ion of substrates and products are given in each case along with the percentages of consumed substrate (SC), the yield (Y) and the regioselectivity (RS). 
AaeAPO (%) CraAPO (%) Substrate Reaction Product Discussed as HDM in Ref no. m/z SC Y RS SC Y RS 
XIXa    60   10   
[M-H] − 229 O-Desmethylnaproxen (Segre 1975) [M-H] − 215  57 95  9 85 
XX    17   15   
[M+H]+ 272 Dextrorphan (Jacqz-Aigrain et al. 1993) [M+H]+ 258  16 95  8 53 
XXI    34   16   
Acetaminophen (Brodie and Axelrod 1949) [M+H]+ 152 23 66 13 80 [M+H]+ 136 
3-OH-Acetaminophen (Brodie and Axelrod 1949) [M+H]+ 168
 
2 5 
 
− 
XXII    82   73   
O-Desmethylmetoprolol (Hoffmann et al. 1987) [M+H]+ 254 17 20 4 5 [M+H]+ 268 
α-OH-Metoprolol (Hoffmann et al. 1987) [M+H]+ 284
 
2 2 
 
1 1 
XXIIIb    −                          80  
[M+H]+ 313 Oseltamivir carboxylate (McClellan and Perry 2001) [M+H]+ 285 −  71 88 
 
           aA syringe pump was used for hydrogen peroxide supply; (−) = not detected
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Phenacetin (XXI) was deethylated to acetaminophen. Yields and regioselectivities were 
generally greater with AaeAPO. The above phenolic reaction products all tended to 
undergo further oxidation to quinones and/or coupling products because of the APOs’ 
peroxidase activity that generates phenoxyl radicals from phenols via one-electron 
oxidations (Kinne et al. 2009a, Kinne et al. 2009b, Kinne et al. 2008, Ullrich and 
Hofrichter 2007). Undesired coupling reactions were partially inhibitable by addition of the 
radical scavenger ascorbate to the reactions. DNPH derivatization of the reaction mixtures 
showed that the methyl group was released as formaldehyde in each case. The structures of 
substrates and proposed products are summarized in the figure 20. In case of naproxen 
(XIX) and phenacetin (XXI) O-dealkylation, AaeAPO and CraAPO showed significant 
differences in the amount of converted substrate and the yield of products. 
3.1.2 Ester cleavage 
Ester cleavage by peroxygenase can be regarded as a special case of O-dealkylation. 
CraAPO was capable of catalyzing this reaction. The enzyme selectively cleaved the 
antiviral drug oseltamivir (XXIII) to oseltamivir carboxylate and acetaldehyde in high 
yield. Interestingly, oseltamivir was not converted at all by AaeAPO. 
 
3.2 N-dealkylation 
3.2.1 N-dealkylation of pharmaceuticals 
APOs catalyzed the oxidative N-dealkylation of several drugs that contained secondary or 
tertiary amino groups. For example, AaeAPO regioselectively N-demethylated sildenafil 
(XXIV) at the tertiary N of the piperazine ring to give N-desmethylsildenafil and 
formaldehyde in high yield. In contrast to that, CraAPO was ineffective in catalyzing this 
oxidation (figure 21). Among the other N-dealkylations showed in figure 21 are the 
conversion of lidocaine (XXVI) to monoethylglycinexylidide and glycinexylidide, of 4-
dimethylaminoantipyrine (XXVI) to 4-aminoantipyrine and of tamoxifen (XXVII) to N-
desmethyltamoxifen.
 
 
Table 15 Products identified by mass spectrometry after oxidation of the listed pharmaceuticals by AaeAPO and CraAPO in the presence of H2O2. The m/z value for the major 
observed diagnostic ion of substrates and products, consumed substrate (SC), the yield (Y) and the regioselectivity (RS) are shown in each case. 
AaeAPO (%) CraAPO (%) Substrate Reaction Product Discussed as HDM in Ref no. m/z SC Y RS SC Y RS 
XXIV    82   80   
[M+H]+ 475 N-Desmethylsildenafil (Hyland et al. 2001) [M+H]+ 461  82 99  4 5 
XXV    60   45   
Monoethylglycinexylidide (Orlando et al. 2004) [M+H]+ 207 25 41 32 70 [M+H]+ 235 
Glycinexylidide (Orlando et al. 2004) [M+H]+ 179 
 
18 30 
 
5 11 
XXVI    68   38   
[M+H]+ 232 4-Aminoantipyrine (Banerjee et al. 1967) [M+H]+ 204  16 23  19 48 
          
XXVII    25   20   
[M+H]+ 372 N-Desmethyltamoxifen (Jin et al. 2005) [M+H]+ 358  
 4-OH-Tamoxifen (Jin et al. 2005) [M+H]+ 388  
 Endoxifen (Jin et al. 2005) [M+H]+ 374  
n.d.  n.d. 
 (n.d.) = not determined due to poor resolution 
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Figure 21 Structures of pharmaceuticals that were subject to N-dealkylation. Chemical structures in 
brackets are hypothetical. 
 
Most of the products shown in Figure 21 could be quantified; the data are summarized in 
Table 15.  
3.2.2 N-dealkylation of drugs of abuse 
N-Dealkylation was also observed for controlled and illicit drugs including some narcotics. 
The structures of the tested substrates and proposed products are shown in Figure 22. 
Codeine (XXVIII) and morphine (XXIX) were converted by MroAPO. The major 
metabolite of codeine oxidation was the N-demethylation product norcodeine. Only traces 
of morphine were formed, i.e. O-demethylation was much less pronounced than N-
demethylation; codeine was neither a substrate of AaeAPO nor of CraAPO. Unexpectedly 
morphine was not subject to oxidation by MroAPO under the same conditions. Only in the 
absence of ascorbic acid, a conversion of morphine was observed, which – according to 
mass spectroscopic data - resulted in a dimerization of the molecule. This reaction might 
be based on the formation of phenoxyl radicals and was also observed for AaeAPO and 
CraAPO when ascorbate was omitted. 
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Figure 22 Structures of N-dealkylated controlled pharmaceuticals and illicit drugs and their 
products. Chemical structures in brackets are hypothetical. 
 
The reaction of APO with cocaine (XXX) was performed under slightly acidic conditions 
(pH 5) to prevent the spontaneous hydrolysis of the substrate.  
Table 16 Products identified by mass spectrometry after oxidation of the listed pharmaceuticals by 
AaeAPO, CraAPO and MroAPO in the presence of H2O2. The m/z values of the major observed 
diagnostic ion for substrates and products (P), and the amount of substrate consumed (SC) are 
shown in each case; (n.d.) = not determined due to poor resolution. 
AaeAPO CraAPO MroAPO Substrate 
SC 
(%) 
P 
m/z 
SC 
(%) 
P 
m/z 
SC 
(%) 
P 
m/z 
[M + H]+ 286 XXVIII 
[M + H]+ 300 traces n.d traces n.d. 99 [M + H]+ 286 
XXIX 
[M + H]+ 286 76 
[M + H]+ 569 
[M + H]+ 272 58 
[M + H]+ 569 
[M + H]+ 272 72 
[M + H]+ 569 
[M + H]+ 272 
XXX 
[M + H]+ 304 0 - traces [M + H]
+290 9 [M + H]
+ 290 
[M + H]+ 290 
XXXI 
[M + H]+ 388 42 
[M + H]+ 360 
[M + H]+ 332 30 
[M + H]+ 360 
[M + H]+ 332 99 
[M + H]+ 360 
[M + H]+ 332 
[M + H]+ 374 
RESULTS 
 
 
68 
Benzoylecgonine and norcocaine were found to be the major metabolites formed by 
MroAPO and, in traces, by CraAPO. Flurazepam (XXXI) conversion was catalyzed by all 
tested peroxygenases, and single and double N-dealkylated products were detected as 
products. MroAPO turned out to be the best enzyme with a substrate conversion of almost 
100%. The results of this study are summarized in the Table 16. 
3.3 O-Demethylenation 
AaeAPO was found to oxidize diverse benzodioxoles (XXXII-XXXVIII; table 17). The 
reaction products were catechol derivatives and formic acid, which were identified by LC-
MS and IC, respectively.  
 
Table 17 Structures of benzodioxoles and their products identified by mass spectrometry after 
treatment with AaeAPO in the presence of H2O2. The m/z values of the major observed diagnostic 
ion of the products, consumed substrate (SC), and product yield (Y) are given in each case. 
Substrate Yield (%); mass ion (m/z) 
Name Structure 
SC (%) 
Demethylenated 
product 
formic 
acid 
XXXII 
4-Nitrobenzodioxole 
 O
OO2N
 
96 95 [M-H]- 154 95±5.0 
XXXIII 
4-Bromobenzodioxole 
Br O
O  
99 13 [M-H]- 188 68±2.1 
XXXIV 
4-Chlorobenzodioxole 
Cl O
O  
99 75 [M-H]- 143 94±3.2 
XXXV 
Safrole 
O
O  
78 n.d. [M-H]- 149 75±7.0 
XXXVI 
Myristicin 
O
O
O  
99 n.d. [M-H]- 179 98±1.1 
XXXVII 
MDMA („ecstasy“) O
O
NH
88 n.d. [M+H]+ 182 83 
XXXVIII 
Pisatin 
O
O
OH
O
O
O
 
90 n.d. [M-H]- 301 50 
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Examples of oxidized benzodioxole derivatives are the entactogenic drug ecstasy 
(XXXVII, MDMA, 3,4-methylenedioxymethamphetamine), the phytoalexin pisatin 
(XXXVIII) from Pisum sativum as well as the nutmeg-seed ingredients safrole (XXXV) 
and myristicin (XXXVI). Although no authentic standards of all reaction products were 
available, the m/z values for these metabolites were the same as those expected for the 
respective catechols with an m/z loss of 12 relative to the mass of the substrate (table 17). 
Moreover, we used 18O-labeled H2O2 as co-oxidant and did not find an incorporation of 
18O into the catechol products. Our attempts to detect 18O-labeled formic acid failed. The 
reaction proceeded rapidly with total conversions between 78 and 99% of the substrate and 
product yields up to 98%. For example, when we incubated 250 µM of 4-
nitrobenzodioxole with AaeAPO under standard reaction conditions and non-limiting 
H2O2, the total conversion of the substrate was 240 µM (SC = 96 %) and we obtained 
237.5 µM of 4-nitrocatechol and formaldehyde (Y=95%). Some of the products were 
further oxidized; thus when 4-bromo- and 4-chlorobenzodioxole were converted to 4-
bromo- and 4-nitrocatechol, we noticed the formation of additional ring-hydroxylated 
products indicated by an m/z of +16 in the mass spectrum (Appendix, Figure 8). 
Formaldehyde was only released from pisatin and myrisiticin, and may originate from the 
APO-catalyzed O-demethylation of the respective methoxy groups (Kinne et al. 2009b). 
3.4 Oxidation of steroids 
Initial attempts to convert steroids (17α-ethinyl estradiol and Reichstein’s substance S) 
with AaeAPO and CraAPO did not give positive results (Poraj-Kobielska et al. 2011b). 
Later these experiments were repeated with MroAPO and extended to other steroids. 
MroAPO turned out to oxidize at least some steroids including important hormones, 
anabolics and pharmaceuticals. In default of appropriate metabolite standards, the products 
formed are given by their m/z values in Table 18.  
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Table 18 Conversion of steroids by MroAPO. Chemical structures of the substrates, the m/z values 
for the major observed diagnostic ion of substrates and products, and the percentage of consumed 
substrates are given. 
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3.5 Stoichiometrical analyses 
3.5.1 Sildenafil 
A quantitative analysis of AaeAPO-catalyzed sildenafil oxidation in the presence of 
limiting H2O2 revealed that one equivalent of N-desmethylsildenafil was formed per 
equivalent of co-oxidant supplied (Table 19).  
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Table 19 Stoichiometry of sildenafil (XXIV) oxidation by AaeAPO. The initial sildenafil 
concentration was 250 µM. 
H2O2 added N-desmethylsildenafil 
produced 
Ratio 
N-desmethylsildenafil/H2O2
µM  
 2.3 
 4.6 
 9.2 
18.3 
36.6 
  2.12 
  4.27 
  8.75 
20.49 
32.37 
0.92 
0.93 
0.96 
1.12 
0.88 
 
3.5.2 Safrole 
A quantitative analysis of safrole cleavage in the presence of a limiting amount of the co-
oxidant H2O2 gave an atypical result. Only half an equivalent of N-desmethylsildenafil was 
formed per consumed equivalent of H2O2 (table 20). 
 
Table 20 Stoichiometry of safrole oxidation by A. aegerita peroxygenase. The initial safrole 
concentration was 250 µM. 
 H2O2 added Formic acid produced Formic acid/H2O2 
µM  
 10.5 
 17.5 
 22.0 
43.8 
87.5 
  5.70 
  9.02 
11.53 
21.68 
45.53 
0.54 ± 0.01 
0.52 ± 0.01 
0.52 ± 0.06 
0.54 ± 0.06 
0.52 ± 0.03 
 
3.6 18O-Isotope incorporation 
Using AaeAPO and three pharmaceuticals (acetanilide, carbamazepine, tolbutamide), we 
investigated the source of the oxygen introduced during hydroxylation. When the oxidation of 
acetanilide (II) was conducted with H218O2 in place of H2O2, mass spectral analysis of the 
resulting acetaminophen showed that the principal [M-H]− ion had shifted from its natural 
abundance m/z of 150 to m/z 152. Likewise, the hydroxylation of carbamazepine into 3-
hydroxycarbamazepine under these conditions resulted in a shift of the [M+H]+ ion from its 
natural abundance m/z of 253 to m/z 255. Accordingly, hydrogen peroxide was the source of 
the introduced oxygen in both reactions. 
A mass spectral experiment with tolbutamide and H218O2 as the substrates showed that the 
resulting 4-hydroxytolbutamide exhibited a principal [M-H]− ion with an m/z of 289 rather 
than 287, again showing that the peroxide was the source of transferred oxygen (Figure 23). 
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Figure 23 HPLC elution profiles of the 
conversion of tolbutamide (XV) in the 
presence of ascorbic acid and AaeAPO 
(background profile), control without 
enzyme (front profile). Insets of mass spectra 
show the incorporation of 18O from H218O2 
into the alcohol group of 4-
hydroxytolbutamide (XVa). Upper inset: 
MS of the product obtained with natural 
abundance H2O2. Lower inset: MS of the 
product obtained with 90 atom% H218O2. The 
peak XVb conformed to the mass expected 
for 4-ketotolbutamide, an oxidation product 
of 4-hydroxytolbutamide (see Table 13) 
(Kinne et al. 2010). 
 
 
 
 
3.7 Kinetics experiments 
3.7.1 Michaelis-Menten kinetics 
Using AaeAPO, apparent kinetic constants were determined for some representative 
pharmaceuticals. The apparent Km of the the enzyme for propranolol was 1,340 µM and the 
kcat was 55 s-1. For acetanilide, the constants were 1,310 µM and 1,925 s-1. The apparent Km of 
AaeAPO for phenacetin was 998 µM and the apparent kcat was 33 s-1. For metoprolol, an 
apparent Km of 2,330 µM and a kcat of 96 s-1 were detected. All kinetic constants of AaeAPO 
determined here are summarized in Table 21 and compared with data obtained with other 
substrates of AaeAPO in previous studies. 
Table 21 Apparent kinetic constants of AaeAPO for selected pharmaceuticals in comparison to the 
data for other substrates tested in previous studies (Kluge et al. 2007, Ullrich et al. 2004). 
Substrate Product Km (µM) 
Vmax 
[µM min-1] kcat (s
-1) kcat/Km (M-1s-1) 
ABTS(Ullrich et al. 2004) [ABTS]+· 37  283 7.7 × 106 
Acetanilide Paracetamol 1,310 21077 1925 1.5 × 106 
Naphthalene(Kluge et al. 
2007) 1-Naphthol 320  166 5.2 × 10
5 
4-Nitro-benzodioxole 4-Nitrocatechol 1,190  457 3.8 × 105 
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Propranolol 5-Hydroxy-propranolol 1,340 3781 55 4.1 × 10
4 
Metoprolol Desmethyl-metoprolol 2,330 1047 96 4.1 × 10
4 
Veratryl alcohol (Ullrich et 
al. 2004) Veratraldehyde 2,367  85 3.6 × 10
4 
Phenacetin Paracetamol 999 361 33 3.3 × 104 
3.7.2 Bisubstrate kinetics 
The demethylenation of nitrobenzodioxole was chosen as a model reaction for initial rate 
kinetics experiments at pH 7.0, in the course of which the concentration both of the substrate 
and the co-substrate was varied. In contrast to the determination of the above apparent kinetic 
data, steady state conditions can be assumed under these conditions. The calculation of kinetic 
data was done using a nonlinear regression method and their double reciprocal plots gave 
parallel lines (figure 24), which is consistent with an enzymatic ping-pong mechanism. The 
kinetic parameters were as follows: kcat of 457 s-1 and a Km for H2O2 of 2,160 µM and a Km for 
4-nitrobenzodioxole of 1,190 µM (kcat /Km = 3.8×105 M-1 s-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Double reciprocal plots of the 
kinetic data for nitrobenzodioxole oxidation 
by AaeAPO. The H2O2 concentrations used 
were 62.5 µM (■), 75 µM (●) and 100 µM 
(▲). The kinetic parameters reported in the 
text were calculated by a nonlinear 
regression method (Hernandez and Ruiz 
1998) 
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3.8  Deuterium isotope effect experiments 
Phenacetin (XXI) was found to be deethylated by AaeAPO to give acetaminophen and 
acetaldehyde (table 14, figure 20). Since phenacetin has a symmetrical site at its α-carbon, it is 
a suitable substrate to determine whether a catalyzed etherolytic reaction exhibits an 
intramolecular deuterium isotope effect. HPLC-MS analysis of DNPH-derivatized reaction 
mixtures showed that the AaeAPO-catalyzed cleavage of N-(4-[1-2H]ethoxyphenyl)acetamide 
(phenacetin-d1) resulted in a preponderance of [2H]acetaldehyde 2,4-dinitrophenylhydrazone 
(m/z 224, [M - H]-) over natural abundance acetaldehyde 2,4-dinitrophenylhydrazone (m/z 
223, [M - H]-) (Figure 25). The observed mean intramolecular deuterium isotope effect 
[(kH/kD)obs] from three experiments was 3.1 ± 0.2. 
 
Figure 25 Oxidative cleavage of N-(4-[1-
2H]ethoxyphenyl)acetamide (phenacetin-d1) by 
AaeAPO. The mass spectrum of the reaction mixture 
containing the products acetaldehyde 2,4-
dinitrophenylhydrazone ([M - H]–, 123) and [2H] 
acetaldehyde 2,4-dinitrophenylhydrazone ([M - H]–,    
126) obtained from the oxidation of phenacetin-d1 is 
shown. The mass spectrum is one of three used to 
calculate the observed mean intramolecular isotope 
effect. 
 
 
3.9  Spectrophotometric nitrobenzodioxole assay 
Peroxygenases from A. aegerita, C. radians, Coprinopsis verticillata and M. rotula as well as 
recombinant peroxygenase of Coprinopsis cinerea were dissolved together with 
nitrobenzodioxole (NBD) in potassium phosphate buffer containing acetonitrile (10% vol/vol) 
and, if the reaction products were to be quantified by HPLC, ascorbic acid. After adding the 
co-substrate H2O2, the reaction mixture immediately changed its color to bright yellow (figure 
26, inset A, Figure 27). 
The metabolite causing color change was identified as 4-nitrocatechol by HPLC-MS relative 
to an authentic standard with complete baseline resolution (compare also Table 17). The 
reaction proceeded selectively with almost total conversions up to 99% of NBD. The 
concentration-dependent change of absorbance in the reaction mixture (caused by the 
formation of 4-nitrocatechol) at wavelengths in the visible region and at different stages of the 
reaction (figure 26 A) was used to develop a direct spectrophotometric assay. A 
spectrophotometer was applied to follow this rapid reaction over 15-30 seconds, which 
corresponded with the linear initial slope (Figure 26 B). To prove the applicability of the new 
enzyme assay, we followed the secretion of A. aegerita aromatic peroxygenase (AaeAPO) in 
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liquid cultures spectrophotometrically with the NBD assay and compared the results with the 
classic peroxygenase assay9 (Figure 27).  
 
 
 
Figure 26 Concentration of 4-nitrocatechol in reactions followed by HPLC vs. absorbance at 425 nm 
measured spectrophotometrically. Parallel reactions of the AaeAPO-catalyzed conversion of NBD 
(0.125 mM) were stopped after different times of incubation (1: 5 s; 2: 15 s; 3: 30 s; 4: 60 s; 5: 120 s 6: 
240 s; 7: 360 s) using sodium azide (1 mM). Insets show the time course of 4-nitrocatechol production 
(A) and the spectral changes during the conversion (B). 
 
It was found that the absorbance increase of the reaction mixture at 425 nm measured 
spectrophotometrically correlated well (R2=0.99) with the concentration of produced 4-
nitrocatechol detected by HPLC in the range from 10 to 100 μM (Figure 26). Based on this 
result and additional spectrophotometric measurements with NBD and 4-nitrocatechol 
standards, we calculated a corrected extinction coefficient10 of 9,700 M−1 cm−1 for 4-
nitrocatechol at 425 nm under the reaction conditions used. 
                                                 
9 1 U (unit) of peroxygenase represents the oxidation of 1 µmol of 3,4-dimethoxybenzyl 
alcohol into 3,4-dimethoxybenzaldehyde in 1 min at 23 °C (Ullrich et al. 2004) 
10 The actual extinction coefficient was calculated from calibration curves spectrophotometrically recorded for 4-
nitrocatechol at 425 nm (ε = 9,900 M-1 cm-1) and corrected by subtraction of the extinction coefficient of NBD at 
425 nm (ε = 200 M-1 cm-1). 
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 Figure 27 Parallel measurements of AaeAPO activity during liquid cultivation of the fungus A. 
aegerita (days 9 to 23) in a soybean medium (2% w/vol) using the veratryl alcohol assay (I) (Ullrich et 
al. 2004) and the new NBD assay (II). The inset shows the change of color before (A; pH = 7) and 
after the addition of sodium hydroxide (B; pH >12). 
 
The results show that the measured volume activity of the enzyme in the supernatant of the 
culture liquid correlates well with the color change over a broad activity range. The activity of 
A. aegerita peroxygenase measured with NBD was app. 80% higher than that with veratryl 
alcohol (may be due to a higher turnover number of the enzyme for NBD). After alkalization 
(pH >12) of the yellow reaction mixture with 10% (vol/vol) of 1 M sodium hydroxide, its 
color changed to deep red (Figure 27, inset B). The corresponding UV-Vis spectrum of 4-
nitrocatechol showed an absorption maximum at 514 nm (ε514 = 11,400 M−1 cm−1, Appendix 
Figure 9) (Cooper and Tulane 1936a). To confirm the specificity of the assay, we tested a 
number of secreted oxidoreductases, such as horseradish peroxidase, soybean peroxidase, 
chloroperoxidase from L. fumago and laccase from Trametes versicolor, none of which 
showed any activity towards NBD. On the other hand, the aromatic peroxygenases from C. 
radians, C. verticillata and M. rotula as well as the recombinant enzyme of C. cinerea 
converted NBD into 4-nitrocatechol (Appendix Figure 7). 
To prove the applicability of the NBD assay for environmental samples (at pH 7), we added 
extracts (300 µL) from forest litter, wheat straw and beech wood to the assay mixture (0.7 
mL) that contained a defined amount of AaeAPO (0.067 µM = 0.166 U mL-1) (see Chapter 
2.3.3.3). Relative to the control assay, 87 ± 3% of added enzyme activity was detected in the 
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presence of the forest litter extract as well as 74 ± 5% and 55 ± 8% in the presence of the 
straw and beech wood extracts, respectively. 
3.10  Conversion of a set of human P450 substrates 
A set of twelve common human P450 substrates (pharmaceuticals, xenobiotics, plant 
ingredients), that is routinely used to distinguish between different CYP types (Walsky and 
Obach 2004), was tested with our three model peroxygenases (AaeAPO, CraAPO, MroAPO). 
The results are summarized in Table 22. 
Coumarin (LVII; specific for CYP2A6) and felodipine (LV; CYP3A) were not or hardly 
(<1%) oxidized by any peroxygenase. Bupropion (LIII; CYP2B6), chlorzoxazone (LIV; 
CYP2E1), midazolam (LVI; CYP3A) were hydroxylated (m/z +16) by APOs but due to 
lacking standards, it cannot be said whether the position of the hydroxyl group is the same as 
in the CYP metabolites. Testosterone (XLI; CYP3A) was only hydroxylated by MroAPO, but 
also here, the position of hydroxylation remained unclear. Amodiaquine (LII; CYP2C8) was 
desmethylated by all three APOs and very probably in the same way as by human P450s 
(desethylamodiaquine); although a standard of desethylamodiaquine was not available, the 
characteristic ion mass of the detected product (m/z -28) allows no other interpretation. 
Tolbutamide (XV; CYP2C9) and diclofenac (IV; CYP2C9) were hydroxylated by all APOs to 
form the expected human drug metabolites.  
Dextromethorphan (XX; CYP2D6) and phenacetin (XXI; CYP1A2) were respectively N- and 
O-dealkylated by AaeAPO und CraAPO (but hardly by MroAPO). S-Mephenytoin (LVIII; 
CYP2C19) was hydroxylated by AaeAPO and MroAPO to the human drug metabolite 
(CraAPO was not available at the time of this study). In summary, ten of the twelve tested 
P450 substrates were converted by the APOs, and six of them yielded the same metabolites 
that P450s form. 
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Table 22 Results of the treatment of twelve common substrates of human cytochrome P450s (CYPs) 
by the fungal peroxygenases from A. aegerita, C. radians and M. rotula. P450/CYP products were 
adopted from following references: (Walsky and Obach 2004). 1 (+) P450 metabolites were found, 
(±) indication for the formation of P450 metabolites was found but standard was lacking, (-) no P450 
metabolites were found; #rapid further conversion into the corresponding ketone product. 
Substrate  AaeAPO CraAPO MroAPO 
LII 
Amodiaquine 
Conversion 
(%) 
6 15 16 
P450-
product 
(CYP2C8) 
desethyl-
amodiaquine 
 
desethyl-
amodiaquine 
 
desethyl-
amodiaquine 
 
NCl
NH
N
OH  
APO 
Yield (%) 
+ 
4 
+ 
10 
+ 
11 
LIII 
Bupropion 
Conversion 
(%) 
27 26 18 
P450-
product 
(CYP2B6) 
 
hydroxy-
bupropion 
 
 
hydroxy-
bupropion 
 
 
hydroxy-
bupropion 
 
 
NH
O
Cl
 
APO ±              
(3 hydroxylated 
products) 
±              
 (2 hydroxylated 
products) 
- 
LIV 
Chlorzoxazone 
Conversion 
(%) 
58 38 8 
P450-
product 
(CYP2E1) 
6-hydroxy 
chlorzoxazone 
6-hydroxy 
chlorzoxazone 
6-hydroxy 
chlorzoxazone 
O
N
H
O
Cl
 APO ± 
(1 hydroxylated 
product) 
± 
(1 hydroxylated 
product) 
± 
(1 hydroxylated 
product) 
LV 
Felodipine 
Conversion 
(%) 
<1 <1 <1 
P450-
product 
(CYP3A) 
 
dehydro-
felodipine 
dehydro-
felodipine 
dehydro-
felodipine 
N
H
OO
O O
Cl
Cl
 
APO - - - 
LVI 
Midazolam 
Conversion 
(%) 
2 9 26 
P450-
product 
(CYP3A) 
hydroxy-
midazolam 
hydroxy-
midazolam 
hydroxy-
midazolam N
N
N
Cl
F
 
APO ± 
(1 hydroxylated 
product) 
± 
(2 hydroxylated 
products) 
±  
(3 hydroxylated 
products) 
LVII Conversion 0 0 0 
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Coumarin (%) 
P450-
product 
(CYP2A6) 
7-hydroxy-
coumarin 
7-hydroxy-
coumarin 
7-hydroxy-
coumarin 
O O
 
APO - - - 
LVIII 
S-Mephenytoin 
Conversion 
(%) 
15 no data 11 
P450-
product 
(CYP2C19) 
4-hydroxy-S-
mephenytoin 
 
no data 4-hydroxy-S-
mephenytoin 
 
N
H
N
O
 APO + (traces)  + (traces) 
XXI 
Phenacetin 
Conversion 
(%) 
34 16 traces 
P450-
product 
(CYP1A2) 
acetaminophen acetaminophen acetaminophen 
O
NH
O
 
APO/ 
Yield(%) 
+ 
23 
+ 
13 
- 
0 
IV 
Diclofenac 
Conversion 
(%) 
78 15 68 
P450-
product 
(CYP2C9) 
4’-hydroxy-
diclofenac 
4’-hydroxy-
diclofenac 
4’-hydroxy-
diclofenac 
NH
Cl
Cl OH
O
 
APO/ 
Yield(%) 
+ 
68 
+ 
5 
+ 
4 
XV 
Tolbutamide 
Conversion 
(%) 
25 20 29 
P450-
product 
(CYP2C9) 
4-hydroxy-
tolbutamide 
4-hydroxy-
tolbutamide 
4-hydroxy-
tolbutamide 
S
NH
NH
O
O
O  
APO/ 
yield(%) 
+ 
15# 
+ 
13# 
+ 
<1# 
XX 
Dextromethorphan 
Conversion 
(%) 
17 15 traces 
P450-
product 
(CYP2D6) 
dextrorphan dextrorphan dextrorphan 
O
N H
 
APO/ 
yield(%) 
+ 
16 
 
+ 
8 
+ 
traces 
XLI 
Testosterone 
Conversion 
(%) 
0 0 13 
P450-
product 
(CYP3A) 
6β-hydroxy-
testosterone 
6β-hydroxy-
testosterone 
6β-hydroxy-
testosterone 
O
OH
HH
H
 
APO - - ±(hydroxylated 
product) 
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3.11 Difference spectroscopy 
Heme containing enzymes can be characterized using a number of spectroscopic methods. 
Thus it is known that the addition of various substrates or inhibitors can cause characteristic 
changes in the optical absorption spectrum of P450 enzymes. The spectral changes reflect the 
binding of these compounds near the active site, which causes changes in the heme 
environment and influences the electron density (Lewis 2001).  
Lewis described three characteristic types of substrate binding spectra for P450s, namely type 
I (e.g. with phenol or propranolol), type II (e.g. with cyanide or pyridine), and the reverse type 
I (sometimes referred as modified type II, e.g. with ethanol or caffeine) (Lewis 2001, 
Schenkman et al. 1972, Schenkman et al. 1981).  
 
⎯ Type I is characterized by a decrease in intensity of the Soret absorption peak around 
418 nm, coupled with a concominant increase in the band intensity around 390 nm. 
Consequently, a type I spectrum shows that the binding of substrate within the P450 
heme locus brings about a shift in the iron(III) spin equilibrium from low-spin to high-
spin (Lewis 1996). 
⎯ Type II is typical for compounds acting as P450 inhibitors via ligation of the heme 
iron (Lewis 1996). The UV spectrum is characterized by decrease in absorption around 
390 nm with concominant increase around 430 nm. Consequently, there is a shift in 
spin-state equilibrium from high-spin to low-spin iron.  
⎯ Reverse type I is a "mirror-image" change to type I, where increase of absorption at 
420 nm is coupled with a decrease in the 390 nm peak (Lewis 2001).  
The results in Figure 28 and Table 23 show that the substrates propranolol, diclofenac and 
dextromethorphan (Kinne et al. 2009a, Poraj-Kobielska et al. 2011b) as well as phenol  
(Ullrich et al. 2004) caused a type I spectral change with the formation of maxima between 
385 and 398 nm and minima around 420 nm. 
Table 23 Difference absorption spectra of AaeAPO obtained by the addition of three common 
pharmaceuticals and phenol as a reference. 
Ligand λmax (nm) λmin (nm) Spectral type 
Phenol1 388 421 I 
Dextromethorphan 389 422 I 
Propranolol 386 422 I 
Diclofenac 386 417 I 
1 (Kinne 2010) 
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Figure 28 Difference absorption spectra of AaeAPO obtained by the addition of phenol (A), 
dextromethorphan (B), propranolol (C) und diclofenac (D). 
 
3.12 Different peroxides and peroxide-generating systems 
The conversion of diclofenac into 4'-hydroxydiclofenac by AaeAPO was used to test the 
suitability of different peroxides and peroxide-generation systems. The best result was 
obtained with hydrogen peroxide (H2O2) added in a few small doses, the lowest conversion 
was observed with the system of L-cysteine. The organic peroxides mCPBA and tert-butyl 
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hydroperoxide were less efficient than H2O2 but nevertheless enabled AaeAPO to catalyze the 
substantial oxidation of diclofenac. The results of this study are summarized in Table 24.  
Table 24 Comparison of different peroxides and peroxide-generating systems. The experiments were 
performed with diclofenac (0.5 mM), AaeAPO (2 U mL-1) in the presence of ascorbic acid and 2 
mM of each peroxide. Details are described in Chapter 2.10.  
Peroxide/ 
peroxide generating system 
Yield of 4'-OH-
Diclofenac (%) 
H2O2 (one time addition) 42 
H2O2 (few doses) 45 
H2O2 (syringe pump) 34 
mCPBA 25 
mCPBA (few doses) 32 
mCPBA (syringe pump) 27 
Glucose/glucose oxidase 36 
L-cysteine 6 
tert-butyl hydroperoxide 13 
Copper(II) perchlorate hexahydrate/ascorbic acid 12 
3.13  In vivo experiments 
Growing liquid cultures of A. aegerita were supplemented with propranolol or diclofenac 
(500 µM; 500 ppm); controls lacked either the pharmaceuticals or the fungus. Pictures of the 
cultures are shown in Figure 29. 
   
Figure 29 Liquid cultures of A. aegerita: on day 8 (A): soybean medium, one day after addition of 
diclofenac (left) and control without diclofenac (right); (B): Czapek-Dox medium, one day after 
addition of diclofenac (right) and without diclofenac (left). 
  
Figure 30 summarizes the results of this in vivo experiment, in the course of which both 
propranolol and diclofenac disappeared. This effect was more pronounced in soybean cultures 
that produce much more peroxygenase than Czapek-Dox cultures do (Ullrich et al. 2004), but 
where also adsorption processes may significantly contribute to the substrate removal. 
A B 
 
 
 
Figure 31 HPLC elution profiles of samples from fungal cultures containing diclofenac (IV) or propranolol (I) in soybean medium. (A) Culture of A. aegerita with diclofenac on 
day 14 when the pharmaceutical was added and on day 16, compared to a control without fungus; (B) Fungal culture with propranolol on day 7 (when substrate was added) and 
the day after, compared to a control without fungus. (II) and (III) refer to medium components. The insets show the DAD-spectra of: (I) propranolol with structure; (II) and (III) 
unidentified soybean medium components; (IV) diclofenac with structure. 
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Figure 30 Propranolol and diclofenac concentration in in-vivo experiments with liquid cultures of A. 
aegerita: soybean medium (red), Czapek-Dox (green).   
 
No indications for the formation of the typical peroxygenase metabolites were found. 
However, both substrates disappeared rapidly in the fungal culures, particularly in those 
containing soybean flour (where the enzyme activity was near its maximum around day 14; 
Figure 30). Interestingly the detectable concentration of both substrates in the soybean 
cultures decreased by more than 50% immediately after their addition (also in the controls 
without fungus). This was probably the result of substrate absorption to the soybean particles 
(figure 29 A). Figure 31 shows, as an example, the changes in the HPLC elution profiles 
during the incubation of propranolol and diclofenac with A. aegerita in the soybean medium. 
3.14 Tests with environmentally relevant concentrations of 
propranolol 
The concentration of pharmaceuticals in the environment (e.g. waste water, activated sludge) 
is usually rather low (i.e. between 0.1-1000 ppb). Thus the testing of environmetally relevant 
propranolol concentrations required the optimization of the analytical HPLC method and 
sample preparation (2.5.2 and 2.12.). As a result, it was possible to identify and quantify 
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propranolol in the nM range (MW: 259 g mol-1, 1 nM = 0.259 µg L-1). The outcome of this 
experiment was that about 50% of the substrate propranolol at a concentration as low as 5 nM 
(1.3 ppb) could be removed by AaeAPO (figure 32).   
 
 
 
 
 
 
 
 
 
Figure 32 HPLC elution 
profiles showing the 
disappearance of 
propranolol at an 
environmentally relevant 
concentration (5 nM = 1.3 
ppb = 1.3 µg L-1) after 
treatment with 50 units of 
AaeAPO for 20 hours. 
 
 
3.15  Long-term experiments 
3.15.1 Pre-study with Vivaspin® (fed-batch method) 
A Vivaspin® centrifugal concentrator (molecular mass cut-off 10 kDa) was used to determine 
whether AaeAPO is stable enough to be repeatedly used in enzymatic conversions. Since the 
concentrator holds back proteins, the enzyme, can in principle be used several times (Figure 
33). Experiments with propranolol as the substrate demonstrated that this approach is feasible. 
Surprisingly, the experiment without ascorbic acid gave more 
product (5-OH-propranolol) than the experiment in its presence 
(Figure 34), indicating – despite the reduction of phenoxyl radicals 
that ascorbate provides – a general lowering of the overall 
efficiency of the peroxygenase system by the radical scavenger.  
 
 
 
Figure 33 Vivaspin tubes after treatment of propranolol with A. aegerita 
peroxygenase (A) in the absence of ascorbic acid and (B) in its presence. 
A B 
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In the absence of ascorbic acid, the formation of dark substances was observed in the 
Vivaspins®, which can be attributed to the oxidative coupling of phenoxyl radicals formed 
from 5-OH-propranolol by the peroxidase activity of AaeAPO. The results of this experiment 
are summarized in Figure 34. 
 
Figure 34 Production of 5-OH-propranolol (green columns) and presence of remaining propranolol 
(red columns) in Vivaspin experiments with AaeAPO. Reactions with (left) and without (right) 
ascorbic acid. 
3.15.2 Long-term experiment using a hollow fiber cartridge 
 
Figure 35 Production of 5-OH-propranolol in a long-term experiment using AaeAPO. Daily amount of 
propranolol added (green columns); cumulative amount of formed 5-OH-propranolol (orange 
columns). 
The preliminary experiments with Vivaspin® demonstrated that AaeAPO is highly stable and 
can be used in long-term experiments. For that, the ultrafiltration membrane of a fiber 
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cartridge was loaded with AaeAPO protein and continuously used for propranolol 
hydroxylation over 14 days. Figure 35 illustrates the progress of this experiment. In all, 13.85 
mg of 5-OH-propranolol was produced from 217.56 mg of propranolol using 354 µg enzyme 
over a period of fourteen days. 
3.16  Scope of peroxygenase reactions concerning 
pharmaceuticals and drugs 
 
 
Figure 36 Substrates that were not converted by fungal peroxygenases.  
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In the course of this PhD project, some limitations of fungal peroxygenases concerning the 
substrate spectrum have been ascertained. No conversion was observed for cocaine (XXX), 
codeine (XXVIII), testosterone (XLI), 17α-ethinylestradiol (XLII), Reichstein’s substance S 
(XLIII) and felbamate (LIX) when treated with AaeAPO or CraAPO. Furthermore, AaeAPO 
was not able to convert oseltamivir (XXIII). The experimental results furthermore indicate 
that APOs often fail to discriminate between chiral centers in the pharmaceutical substrates. 
For example, chiral HPLC separation of the two O-desmethylnaproxen entantiomers that 
resulted from naproxen oxidation showed that neither enantiomer predominated in the end-
product mixture. In case of MroAPO, no product formation was observed for temazepam 
(IX), oxazepam (X), diazepam (VIII) and amphetamine (XII). All three enzymes were unable 
to convert felodipine (LV) and coumarine (LVII). The structures of the non-oxidizable 
substrates are given in Figure 36. 
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4 Discussion 
4.1 Preparation of human drug metabolites 
Human drug metabolites (HDMs) are valuable chemicals needed for the development of 
safe and effective pharmaceuticals. They are frequently used as substrates and authentic 
standards in studies of drug bioavailability, pharmacodynamics and pharmacokinetics 
(Baillie et al. 2002, Nelson 1982, Peters et al. 2007). In vivo, the C-H bonds of 
pharmaceuticals are predominantly oxygenated by liver cytochrome P450-
monooxygenases (P450s) to yield more polar HDMs that are excreted directly or as 
conjugates (Gibson and Skett 2001). This directed incorporation of an oxygen atom into a 
complex organic structure is one of the most challenging reactions in synthetic organic 
chemistry (Ullrich and Hofrichter 2007). Thus low yields and the need for laborious 
removal of byproducts have prevented the cost-effective preparation of HDMs by purely 
chemical methods (Kinne et al. 2009a). A preferable route to prepare human drug 
metabolites would be the use of isolated human P450s, but these complex multiprotein 
systems are membrane-bound, poorly stable, cofactor-dependent, and generally exhibit 
low reaction rates (Eiben et al. 2006, Urlacher et al. 2004). More promising results have 
been reported for human cell cultures (Acikgöz et al. 2009), microbial whole-cell systems 
that heterologouly express human P450s (Peters et al. 2007) and laboratory-evolved 
bacterial P450s (Damsten et al. 2008, Sawayama et al. 2009). The latter are capable of 
catalyzing the H2O2-dependent hydroxylation of pharmaceuticals via the ”peroxide shunt” 
pathway (Otey et al. 2006). Recent studies, however, have demonstrated that this approach 
needs further optimization, in particular regarding turnover numbers and peroxide stability 
(Sawayama et al. 2009). Alternatively, modified hemoproteins such as microperoxidases 
might be used to catalyze hydroxylations by a P450-like oxygen transfer mechanism, but 
so far these catalysts have not reached the necessary performance and selectivity (Caputi et 
al. 2005, Dallacosta et al. 2003, Dorovska-Taran et al. 1998, Osman et al. 1996, Prieto et 
al. 2006, Veeger 2002). 
A few years ago, a new heme-thiolate enzyme was discovered in the wood- and litter-
dwelling black poplar mushroom, Agrocybe aegerita. This enzyme turned out to be a true 
peroxygenase (aromatic/unspecific peroxygenase, APO; EC 1.11.2.1), efficiently 
transferring oxygen from peroxides to various organic substrates including aromatic, 
heterocyclic and aliphatic compounds (Hofrichter et al. 2010, Ullrich and Hofrichter 2005, 
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Ullrich et al. 2004). In the following years, a few similar enzymes have been found in 
cultures of other agaric basidiomycetes such as Coprinellus radians, Coprinopsis 
verticilata (Anh et al. 2007) and Marasmius rotula (Gröbe et al. 2012) These stable, 
secreted enzymes are promising oxidoreductases for biotechnological applications 
including the synthesis of human drug metabolites. Depending on the particular substrate 
and the reaction conditions, APOs catalyze in addition to peroxygenations, also one-
electron oxidations (e.g. of phenols) and unspecific halogenations (bromination), and for 
all these reactions, they need merely a peroxide as co-substrate to function. 
Previous studies with diverse organic compounds showed that APOs catalyze several types 
of oxyfunctionalization such as epoxidation, aromatic and benzylic hydroxylation, ether 
cleavage (O-dealkylation), N-dealkylation, sulfoxidation and N-oxidation (Aranda et al. 
2009a, Aranda et al. 2009b, Hofrichter et al. 2010, Kinne et al. 2009a, Kinne et al. 2009b, 
Kinne et al. 2008, Kinne et al. 2010). All these reactions are also typical of P450s and part 
of drug transformations in the human liver (Guengerich 1987, Ortiz de Montellano 2005). 
Promising results were achieved in the prestudies with the pharmaceuticals propranolol 
and diclofenac, which were converted regioselectively into the respective hydroxylated 
human drug metabolites (Kinne et al. 2009a). All of this background has contributed to the 
here developed approach: namely that aromatic peroxygenases (APOs) from the 
basidiomycetes A.aegerita (AaeAPO), C. radians (CraAPO) and M. rotula (MroAPO) can 
be used as an "artificial liver" to produce diverse HDMs.  
To this end, a representative selection of widely used pharmaceuticals and illicit drugs was 
tested with the above mentioned peroxygenases. In the first phase of this study, only 
AaeAPO and CraAPO were available, later also MroAPO was included in the in vitro 
experiments. The results have shown that all fungal peroxygenases (APOs) tested 
catalyzed the hydroxylation or dealkylation of diverse pharmaceuticals and drugs of abuse, 
in most cases with high regioselectivity. Moreover, MroAPO was also found to catalyze 
the conversion of some steroids that were not accessible to the other APOs. The findings 
of this study confirm previous work, which suggested that extracellular APOs share 
functional characteristics with intracellular P450s but utilize the peroxide-dependent shunt 
pathway with much higher efficiency (Guengerich 2001, Hofrichter and Ullrich 2010, 
Ortiz de Montellano and de Voss 2005, Shoji et al. 2007). These peroxygenations are 
thought to be initiated when the enzyme heme is oxidized by H2O2 to give an iron species 
(oxo-ferryl iron, compound I) that carries one of the peroxide oxygens, which 
subsequently oxidizes a C-H bond in the substrate (Rittle and Green 2010). 
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Figure 37 Molecular structures of pharmaceuticals and drugs converted by AaeAPO. The substrates 
are divided into three different groups according to the relative effectiveness of their oxidation. 
Arrows indicate the points of enzymatic attack. SC – substrate conversion 
 
Figures 37-39 give an overview of pharmaceutically relevant peroxygenase substrates 
classified by the effectiveness of their conversion. What at first glance (Figure 37) attracts 
the attention is the better (60-100%) conversion by AaeAPO  of relatively small aromatic 
substances or less complex molecules. However, more complex structures with exposed 
aromatic rings, with secondary or tertiary amino groups or methoxy groups were 
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nevertheless oxidized by the enzyme to extents ranging from 20 to 59%. Amphetamines 
were only hydroxylated at the aromatic ring and after long reaction times, and even then 
the conversion rate was relatively low (below 15%). CraAPO has a similar substrate 
spectrum as AaeAPO but the conversion rates were considerably lower in most cases 
(Figure 38). On the other hand, compared to AaeAPO, an overview of the MroAPO 
substrates suggests a preferance for more complex non-aromatic structures by the enzyme 
as found, for example, with steroids or codeine. The latter substrates were hardly or not at 
all oxidized by AaeAPO and CraAPO, which indicates considerable differences in the 
heme channels and/or the active sites of the enzymes. 
Furthermore, most of the observed oxidations matched those catalyzed by human liver 
P450s, e.g. propranolol (I) to 5-hydroxypropranolol (CYP2D6) (Masubuchi et al. 1994), 
tolbutamide (XV) to 4-hydroxytolbutamide (CYP2C9) (Miners and Birkett 1996), 
naproxen (XIX) to O-desmethylnaproxen (CYP1A2) (Miners et al. 1996), acetanilide (II) 
to acetaminophen (CYP1A2) (Liu et al. 1991, Miners et al. 1996) and sildenafil (XXIV) to 
N-desmethylsildenafil (CYP3A4) (Ku et al. 2008). Particularly interesting results will be 
discussed in detail in the next part of this chapter. 
Evidently, APOs have some advantages over P450s - including currently developed, 
laboratory-evolved P450s - where reaction yields are concerned (Kinne et al. 2009a). For 
example, the transformation of diclofenac (IV) to 4-hydroxydiclofenac by mutants of 
P450cam (CYP101A1) resulted in total conversions between 15 and 44% and yields around 
10% (Weis et al. 2009). By contrast, the wild-type AaeAPO used here gave a total 
conversion of 78% and a yield of 68% for the same reaction. For the metabolism of 
propranolol (II) in humans, CYP2D6 and CYP1A2 are responsible, forming three major 
products: 5-hydroxypropranolol, 4’-hydroxypropranolol and desisopropylpropranolol 
(Masubuchi et al. 1994). Positive results concerning the production of propranolol 
metabolites were reported for laboratory-evolved bacterial P450s that use the shunt 
pathway to hydroxylate the pharmaceutical. Thus, an engineered mutant D6H10 from 
P450 BM3 (Bacillus megaterium, expressed in E.coli) was optimized for the synthesis of 
propranolol metabolites, especially the 5-hydroxylated product. The optimization resulted 
in a yield of 0.5% of 5- hydroxypropranolol (6.5 mg L-1) when 5 mM (1,295 mg L-1) 
propranolol was converted (Otey et al. 2006). Analogous experiments with AaeAPO gave 
yields up to 13.6% (176 mg L-1), with regioselectivity higher than 90%. Interestingly, 
CraAPO produced the other human P450 metabolites of propranolol, too. The analysis 
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showed the formation of the following metabolites in the stated yields: 6% of 5-
hydroxypropranolol, 2% of 4’-hydroxypropranolol and 3% of desisopropylpropranolol. 
The conversion of ibuprofen (XIV) is another example for the formation of different 
metabolite ratios by different peroxygenases. In humans, more than 70% of ibuprofen is 
hydroxylated. The formation of metabolites is dependent on the P450 system and 
comprises 2-hydroxy-, 3-hydroxy-, and 1-hydroxyibuprofen (Hamman et al. 1997, Holmes 
et al. 2007). AaeAPO converted ibuprofen to 2-hydroxyibuprofen and 1-hydroxyibuprofen 
with yields of 21% and 7%, respectively. The reaction with CraAPO showed high 
regioselectivity and gave only 2-hydroxyibuprofen with a yield of 72%. 
Not only hydroxylations but also N-dealkylations were differently catalyzed by different 
peroxygenases. For example, the oxidation of lidocaine (XXV) catalyzed by AaeAPO gave 
25% of monoethylglycinexylidide and 18% of glycinexylidide (ratio 1.4:1), whereas 
CraAPO formed 32% of monoethylglycinexylidide (with a regioselectivity of 70%) but 
only 5% of glycinexylidide (ratio 6.4:1). Both substances are major human metabolites 
when lidocaine is used as local anesthetic (Orlando et al. 2004, Tam et al. 1990). 
The different specificities of fungal peroxygenases are an interesting aspect, suggesting 
that a set of them might be used as a "biocatalytic toolbox". Depending on what 
reaction/metabolite is needed, the appropriate enzyme could be chosen and applied under 
appropriate conditions. This interesting approach will be clarified by the following 
examples. 
The regioselective O-dealkylation of the anti-inflamatory drug naproxen (XIX) leads to the 
formation of 6-desmethylnaproxen as the only metabolite in the human liver (Segre 1975). 
In catalyzing this reaction, AaeAPO (yield of 57 %) was more effective than CraAPO (9% 
yield). On the other hand, CraAPO was the only peroxygenase to catalyze the unusual 
cleavage of an ester bond in the antiviral substance oseltamivir, which led to the formation 
of the human metabolite oseltamivir carboxylate (yield 71%; formed in humans by hepatic 
carboxylesterases; (Lindegardh et al. 2006, McClellan and Perry 2001), which is the 
bioactive form of the drug (McClellan and Perry 2001). Sildenafil (XXIV) is an inhibitor 
of the human cGMP-specific phosphodiesterase type 5 and widely used as an anti-
impotence drug (Ballard et al. 1998, Boolell et al. 1996). The compound was N-
dealkylated by all tested peroxygenases at the piperazine ring to form N-
desmethylsildenafil, the major metabolite circulating and operating in vivo. (Walker 1999). 
The conversion rates were quite high in all cases (>80 %), but the yields of N-
desmethylsildenafil differed noticeably with only 4% for CraAPO and almost 90% for 
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AaeAPO and MroAPO. Other pathways of the metabolism of sildenafil lead in humans to 
the formation of piperazine-N,N-deethylation and aliphatic hydroxylation products 
(Muirhead et al. 2002, Walker 1999).  
The benzodiazepine compounds diazepam (VIII), temazepam (IX) and oxazepam (X) 
used as psychoactive drugs in the treatment of mental deseases were efficiently 
hydroxylated (m/z +16) by AaeAPO. 
 
Figure 38 Molecular structures of pharmaceuticals and drugs converted by CraAPO. The 
substrates are divided into three different groups according to the relative effectiveness of their 
oxidation. Arrows indicate the points of enzymatic attack. SC – substrate conversion 
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The reaction of diazepam with human P450s gives also a hydroxylated derivative as the 
major metabolite (temazepam, hydroxylated at the heterocyclic 7-ring) and N-
demethylated diazepam (N-desmethyldiazepam) as a second metabolite (Andersson et al. 
1994). However, since the hydroxylated product of the AaeAPO reaction did not have the 
same retention time as temazepam, and taking into account the preference of AaeAPO for 
aromatic substrates (Aranda et al. 2009a, Aranda et al. 2009b), the hydroxylation of one of 
the carbons of the phenyl moiety would be a plausible explanation (most probably in para-
postion). Temazepam and oxazepam were seemingly hydroxylated by AaeAPO in a 
similar way, and in the case of the latter compound, also a double hydroxylated product 
was detected (m/z +32). By contrast, P450s preferably N-demethylate temazepam to form 
oxazepam (Schwarz 1979), which in turn is almost exclusively conjugated with glucuronic 
acid to improve excretion (Kellermann and Luyten-Kellermann 1979).  
The antitussive morphine-derivative codeine (XXVIII), which was not a substrate of 
AaeAPO or CraAPO, was rapidly converted by MroAPO into the N-dealkylated product 
norcodeine and traces of the O-dealkylation product morphine (XXIX). Unexpectedly, no 
product was found when morphine was treated with MroAPO under standard conditions; 
only in the absence of ascorbic acid, a reaction was observed leading to the formation of a 
coupling product (dimer, m/z 569) that was later also observed for AaeAPO and CraAPO. 
This fact indicates that peroxygenases attack the phenolic group of morphine via one-
electron oxidation resulting in the formation of a phenoxyl radical that in turn can dimerize 
(Figure 22, Figure 50). Since the morphine molecule and its coupling product are relatively 
bulky, the oxidation may occur at the enzyme surface rather than in the heme channel. 
P450s (e.g. human CYP2D6) preferably O-demethylate codeine to form morphine in Phase 
I metabolism, and this product is in turn conjugated with glucuronic acids and excreted 
(Kilpatrick and Smith 2005, Williams et al. 2002). Tests with human plasma samples 
showed that codeine is primarily conjugated at the 6-position. The P450-catalyzed 
demethylation clearance rates of codeine and norcodeine were found to be similar in 
magnitude but about four times lower compared to 6-glucuronidation. Since the partial 
clearance to norcodeine was normal in poor human metabolisers, it would be reasonable to 
infer that the two demethylation processes (N-demethylation to norcodeine, O-
demethylation to morphine) are mediated by different cytochrome P-450 isoenzymes 
(Chen et al. 1991). In contrast to morphine, the psychoactive, illicit drug 
tetrahydrocannabinol (THC, XVIII) was efficiently converted by AaeAPO and CraAPO 
(conversion rate almost 100%) resulting in the formation of two hydroxylated products, the 
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major of which is probably 11-hydroxy-THC; proposed structures are shown in the results 
section (Figure 19). 
 
Figure 39 Molecular structures of pharmaceuticals and drugs converted by MroAPO. The 
substrates are divided into three different groups according to the relative effectiveness of their 
oxidation. Arrows indicate the points of enzymatic attack. SC – substrate conversion. 
 
In other experiments where side chains were attacked the best results were noted for 
MroAPO but in the case of THC, no positive result was observed. In the human liver, THC 
is metabolized mainly to 11-hydroxy-THC, which is further oxidized to the corresponding 
carboxylic acid (11-nor-9-carboxy-THC); both reactions are thought to be catalyzed by 
P450s (CYP2C9, CYP2C19, CYP3A4) (Bland et al. 2005, Lemberger 1973, Watanabe et 
al. 2007). 
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None of the steroids tested were attacked by CraAPO and AaeAPO; however, MroAPO 
again was able to convert these bulky molecules. According to the effectiveness of the 
conversion, two groups of steroid substrates can be distinguished. Substrates of the first 
group were converted by more than 95% (e.g. Reichstein's substance S, cortisone, 
prednisone, medrol), while those of the second group were oxidized with lower rates (2-
70% conversion; e.g. progesterone, testosterone, nandrolone, pregnenolone). All steroids 
of the first group bear a 1-oxo-2-hydroxyethyl side chain (-CO-CH2-OH), whereas those of 
the second group have a 1-oxoethyl (-CO-CH3) or shorter (e.g.  
-CH3) side chain, or no side chain at all (e.g. -OH). This finding indicates that the primary 
alcohol functionality of the oxohydroxyethyl group somehow facilitates the conversion of 
steroids by MroAPO (and maybe it is also the target of oxidation). Unfortunately, the mass 
spectral data of the products are difficult to interpret, so that incorporation of oxygen (m/z 
+16) could be deduced in only a few cases, an (e.g. for Reichstein's substance S, 
pregnenolone, progesterone; see also Table 18 in the results section). Nevertheless the 
mass data indicate another interesting reaction that led to the formation of a progesterone-
like product (m/z 315) from pregnenolone (m/z 317). The reaction could proceed via a 
second hydroxylation of the C3-position yielding a geminal alcohol that eliminates water 
to form a keto group. However, it is unclear whether and if so how the double bound is 
transferred from C5 to C4. In animals and humans these reactions are catalyzed by the 3-β-
hydroxysteroid dehydrogenase/Δ-4-5 isomerase (EC 1.1.1.145), the only enzyme in the 
adrenal pathway of steroid synthesis that is not a member of the P450 superfamily 
(Thomas et al. 2004). Various other human P450s are involved in steroid transformation 
and the synthesis of hormones; among others, they hydroxylate different rings (e.g. 
CYP11B1, CYP17), the side chain (e.g. CYP21) and the C18-methyl group (CYP11B2), 
and as well they are involved in the aromatization of the A ring, thereby converting 
androgens to estrogens (CYP19) (Hall 1986). 
The results of steroid conversion clearly display some limitations and drawbacks of APO 
catalysis. One is that the enzymes have relatively narrow catalytic clefts (albeit the heme-
channel is considerably wider than those of other heme peroxidases), which prevent access 
of markedly bulky substrates to the active site (Piontek et al. 2010). The negative results 
we obtained when treating felbamate (LIX), 17α-ethinylestradiol (XLII), testosterone 
(XLI), Reichstein's substance S (XLIII) and other steroid structures with AaeAPO or 
CraAPO may reflect this limitation. Furthermore, all three tested peroxygenases were 
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unable to mimic some characteristic reactions of human P450s such as felodipine (LIX) 
and coumarin (LVII) oxidation. Why the small and hydrophobic coumarin molecule was 
not attacked remains an enigma. Although MroAPO had no problems with the conversion 
of steroids, it was not able to catalyze the hydroxylation of benzodiazepines, which on the 
other hand were good substrates of AaeAPO and CraAPO. 
In conclusion, fungal APOs may be better suited than most P450s for synthetic 
applications: (i) they utilize a relatively cheap co-substrate, H2O2; (ii) they do not require 
costly co-reactants such as pyridine nucleotides, flavin reductases, or ferredoxins; (iii) they 
are secreted enzymes and thus can be cost-effectively produced (no cell disruption 
required); and (iv) they are stable and soluble due to their high degree of glycosylation 
(Pecyna et al. 2009, Ullrich et al. 2009). 
4.2 Mechanistic studies 
4.2.1 Source of oxygen and stoichiometry. 
 
The results of this work and the previous studies with APOs showed that an oxygen atom 
from hydrogen peroxide is incorporated into the phenolic or alcoholic functionalities 
produced after conversion of alkyl aromatics (Aranda et al. 2009a, Kinne et al. 2009a, 
Kinne et al. 2008, Kluge et al. 2009), and also into  the carbonyls produced after oxidation 
of alcohols or oxidative cleavage of ethers (Kinne et al. 2009b). According to the above 
results, oxygen incorporation from H2O2 should be quantitative when the substrate is 
oxidized. The data on APO-catalyzed oxidation of pharmaceuticals agree with this picture, 
since almost 100% of oxygen present in newly generated phenolic or benzylic-
hydroxylation products - e.g. in the phenolic group of acetaminophen or in the alcohol 
moiety of 4-hydroxytolbutamide - was 18O-labeled when the experiment was conducted 
with H218O2. This result correlated well with the reaction mechanism reported for 
engineered P450 BM3 or P450cam, which can use the so-called “peroxide shunt” pathway, 
in the course of which also one oxygen atom from hydrogen peroxide is incorporated into 
the substrate to yield an oxygenated product without the need of a reductase domain, 
dioxygen or NADPH; (Joo et al. 1999, Otey et al. 2006). Moreover, the stoichiometrical 
experiment with sildenafil showed that one equivalent of N-desmethylsildenafil was 
formed per equivalent of H2O2 supplied. This agrees with the two-electron oxidation 
expected from a peroxygenative mechanism (Section 1.2.7; (Gorsky et al. 1984)). The 
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stoichiometrical experiment with benzodioxoles seems to follow another mechanism and 
that is described in one of the following subchapters (4.2.7). 
4.2.2 Deuterium isotope effect 
Historically, the determination of deuterium isotope effects has been a powerful tool to 
help unravel the intricacies of carbon-hydrogen bond cleavage and define the mechanism 
of specific chemical reactions. The intrinsic primary isotope effect, kH/kD, is the magnitude 
of the isotope effect for a reaction on the rate constant for the bond-breaking step (C–H 
versus C–D) of the reaction and is related to the symmetry of the transition state for that 
step (Nelson and Trager 2003). There are two designs to follow deuterium isotope effects. 
Intermolecular design depends on complex determinations of rate constants, whereas 
intramolecular design is kinetically independent of all steps besides the C-H bond-breaking 
step, and is thereby simpler. In an isotope effect experiment of intramolecular design, a 
substrate that is susceptible to enzymatic attack at either of two symmetrically equivalent 
sites is chosen (Hjelmeland et al. 1977, Nelson and Trager 2003). One site contains 
deuterium and the other retains its normal complement of hydrogen. The enzyme then has 
the choice of attacking a deuterated or an equivalent protio site within the same molecule. 
The observed isotope effect (kH/kD)obs is measured as the ratio of product resulting from 
attack at the protio site versus product resulting from the attack at the deutero site (Kinne 
2010, Nelson and Trager 2003). The intramolecular deuterium isotope effect that was 
observed for phenacetin-d1 oxidation by AaeAPO, is consistent with a P450-like 
mechanism. The determined value of (kH/kD)obs around 3 is close to the values of (kH/kD)obs 
near 2 that have been observed for the P450-catalyzed O-dealkylation of this substrate 
(Garland et al. 1976). A value of 2 is considerably smaller than the intrinsic isotope effect 
near 10 expected for a hydrogen abstraction mechanism, and may indicate that phenacetin 
oxidation by APOs may proceed instead via electron transfers, as proposed earlier for the 
P450-catalyzed reaction (Yun et al. 2000). By contrast, the O-dealkylation of 1,4-
dimethoxybenzene-d3 by AaeAPO probably does proceed via hydrogen abstraction, 
because it was found to exhibit a much higher (kH/kD)obs near 12 (Groves and McClusky 
1978, Kinne et al. 2009b, Yun et al. 2000).  
4.2.3 Kinetics 
The apparent kinetic data determined in this study for the action of AaeAPO on a variety 
of pharmaceuticals suggest that peroxygenases may be a useful alternative to P450s for the 
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regioselective preparation of human drug metabolites (HDMs). Although some P450s are 
known to bind pharmaceutical substrates more strongly than APOs, exhibiting Km values 
between 1 and 70 µM, they generally exhibit relatively low kcat values in the vicinity of 0.2 
s-1 or less (Upthagrove and Nelson 2001, Yun et al. 2000). As a result, the catalytic 
efficiencies [kcat/Km] of AaeAPO for pharmaceutical oxidations - despite relatively high Km 
values - lie in the same range as those of the P450s, as exemplified by our values for 
propranolol hydroxylation (1.32 × 105 M-1 s-1), metoprolol O-dealkylation (4.1 × 104 M-1 s-
1) and phenacetin O-dealkylation (3.3 × 104 M-1 s-1). Moreover, the kcat/Km value we 
obtained for acetanilide (1.5 × 106 M-1 s-1) is much higher than the corresponding value 
found for the P450-catalyzed reaction (Liu et al. 1991).  
4.2.3.1 Bisubstrate kinetics 
In some cases, the kinetic investigation of APO-catalyzed reactions has encountered some 
experimental problems. For example, a previous study showed that, under saturating H2O2 
concentrations, AaeAPO exhibits an interfering catalase activity, which can lead to an 
underestimation of kinetic efficiency (Ullrich et al. 2008). A better option for the 
evaluation of kinetic parameters would be bisubstrate systems using an experimental 
design that varies the concentration of both substrates (Segel 1994). Initial velocity 
patterns are usually obtained by making reciprocal plots for one substrate (variable 
substrate) at different fixed concentrations of one of the others (changing fixed substrate), 
while keeping all other substrates, if there are any, at constant concentration. If the 
mechanism does not include alternate reaction sequences and no substrates react with more 
than one enzyme form, the intercepts always have to be a linear function of the reciprocal 
concentration of the changing fixed substrate. As a result, there are two possible initial 
velocity patterns: parallel lines when no reversible connection exists, or lines intersecting 
to the left of the vertical axis when such a connection does exist (Cleland 1963). Data from 
bisubstrate kinetics under steady state conditions, which were spectrophotometrically 
recorded for the AaeAPO-catalyzed reactions at varying concentrations of 4-
nitrobenzodioxole and H2O2, gave in fact parallel lines for double reciprocal plots of the 
data. This result is consistent with an enzymatic ping-pong mechanism (Bisswanger 2000, 
Cleland 1963, Segel 1994). The mechanism can be explained as follows. The substrate (A) 
binds to the free enzyme (E) to form the enzyme-substrate complex (EA). Substrate (A) 
converts the enzyme to the modified enzyme-product complex (FP). Only after the 
substrate (A) is released in the form of (P) can the second substrate (B) bind to the 
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modified enzyme (F), yielding the enzyme-substrate complex (FB), and then react with the 
modified enzyme, finally regenerating the free enzyme (E) with release of the product (Q) 
(Bisswanger 2000, Kinne 2010, Segel 1994). 
 
Figure 40 Reaction sequence of a "ping-pong bi bi" mechanism. The enzyme constantly bounces 
back and forth between the two states of the enzyme (E) and (F); substrate (A), second substrate 
(co-substrate) (B), product (Q), enzyme-substrate complex (EA), complex of the modified enzyme 
and the second substrate (FB), modified enzyme-product complex (FP), modified enzyme (F) 
 
The kinetic parameters determined in this way for the demethylenation of the model 4-
nitrobenzodioxole by AaeAPO were in the same range as the data obtained for selected 
pharmaceuticals. Thus, the Km for 4-nitrobenzodioxole of 1,190 µM is between the value 
calculated for the N-demethylation of phenacetin (XXI; Km =999) and the hydroxylation of 
acetanilide (II; Km = 1,310 µM). The Km for the demethylenation of methylenedioxy-
methamphetamine (XXXVII) catalyzed by P450s is by two orders of magnitude lower 
(Km=1.7-3 µM) (Tucker et al. 1994). The catalytic efficiency for nitrobenzodioxole O-
demethylenation (kcat /Km = 3.81×105 M-1 s-1), lies in the same range as that for 
naphthalene oxidation (kcat /Km = 5,2 × 105 M-1 s-1; see Chapter 4.2.3 and 3.9.1).  
4.2.4 Assays for human cytochrome P450 activities 
Twelve validated assays for human hepatic cytochrome P450s have been established in the 
last decades. Using this set of assays and substrates, six subfamilies, including nine 
individual P450s can be characterized (Anzenbacher and Anzenbacherová 2001, Walsky 
and Obach 2004, Wrighton and Stevens 1992). All twelve assays were applied here for the 
identification of specific P450-like activities of three fungal peroxygenases (AaeAPO, 
CraAPO and MroAPO; see Table 22, Chapter 3.12). 
In the liver, CYP1A2 metabolizes about 15% of all incoming pharmaceuticals (Gibson and 
Skett 2008). The activity of this enzyme is measured with the phenacetin (XXI) O-
deethylase assay; only MroAPO was unable to perform this reaction. Two additional 
substrates of CYP1A2 and AaeAPO/CraAPO are naproxen (XIX) and 3,4-
aminoantipyrine (XXVI) (Anzenbacher and Anzenbacherová 2001). CYP2A6 contributes 
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about 5% of cytochrome P450-dependent drug metabolism in the liver. One of its 
characteristic catalytic properties, a coumarin 7-hydroxylase activity, is seemingly lacking 
in APOs. Other substrates of CYP2A6 are biogenic amines including tobacco-specific 
nitrosamines with pro-carcinogenic potential (Guengerich and Montellano 2005). 
However, CYP2A6 is generally considered less important in drug metabolism than other 
P450s (Walsky and Obach 2004). CYP2B6 is responsible for only about 1% of hepatic 
metabolism of pharmaceuticals. This enzyme is characterized by its bupropione 
hydroxylase activity. Although AaeAPO and CraAPO converted bupropione to 
hydroxylated products, the absence of an analytical standard did not allow a clear 
conclusion as to whether the same carbon is attacked. Another marker reaction of CYP2B6 
is the N-demethylation of S-mephenytoin, which was performed by the APOs only to a 
low extent. CYP2C8 converts less than 5% of incoming pharmaceuticals in the liver and 
has a generally low catalytic activity towards the known substrates of the CYP2C 
subfamily (Guengerich and Montellano 2005); its characteristic amodiaquine N-
deethylase activity was detected for all APOs as well. CYP2C9 is involved in the 
metabolism of about 20% of pharmaceuticals and drugs, and is one of the major enzymatic 
metabolizers in the liver (Guengerich and Montellano 2005). It is characterized by 
hydroxylating activities towards diclofenac and tolbutamide, both excellent substrates of 
AaeAPO and also convertable by the other APOs (but with lower yields). Additional 
substrates are carbamazepine (III) sildenafil (XXIV) (Warrington et al. 2000) and 
ibuprofen (XIV). S-mephenytoin 4’-hydroxylation is the activity characteristic for 
CYP2C19, which participates in less than 5% of hepatic drug metabolism. APOs 
seemingly share this activity with CYP2C19, and also the ability to efficiently oxidize 
diazepam (VIII), omeprazole (XVII) and propranolol (I). The CYP2E subfamily is present 
in all mammals in the form of the characteristic representative CYP2E1. This enzyme is 
well-known for its involvement in the metabolism of ethanol (Quertemont 2004, Zimatkin 
and Deitrich 1997). Concerning pharmaceutical drugs, it was shown to convert 
acetaminophen, phenacetin (XXI) and chlorzoxazone (LIV), the latter of which is the 
specific assay substrate for CYP2E1 (Anzenbacher and Anzenbacherová 2001). 
Chlorzoxazone (LIV) was found to be a good substrate of AaeAPO and CraAPO but, in 
the absence of an appropriate analytical standard, it was not possible to confirm that the 
same product was formed. The CYP3A subfamily with four human members contributes 
to about 50% of the hepatic metabolism of drugs and pharmaceuticals (Anzenbacher and 
Anzenbacherová 2001, Guengerich and Montellano 2005). The substrate spectrum of these 
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enzymes is very broad and includes, inter alia, various statins, steroids, and codeine 
(XXVIII), but also APO substrates such as sildenafil (XXIV), lidocaine (XXV), 
acetaminophen, carbamazepine (III), dextromethorphan (XX, also converted by 
CYP2D6), diazepam (VIII), omeprazole (XXII), and tamoxifen (XXVII). The typical 
CYP3A substrates felodipine and midazolam (both belonging to the twelve key assay 
substrates) were not at all or only slowly converted by the APOs. Another CYP3A 
substrate, testosterone, was only oxidized by MroAPO. 
The results of this work clearly show that APOs share catalytic activities with all relevant 
human P450s. Since the substrate spectra of P450s overlap with each other, it is not 
possible to select a particular P450 enzyme that shows the most similarities with APOs at 
the reaction level. Some limitations of APO catalysis and differences with human P450s 
were also acertained (coumarin and felodipine were converted by none of the APOs, 
testosterone only to some extent by MroAPO), and may be attributable to issues of 
molecule size or charge, and/or special features of the 3-dimensional structure of the 
substances (see 4.5 for more details). Table 38 summarizes the results of this study. 
Table 38 Summary of the measured activities by P450s and APOs; +(red)- assay metabolite was 
found; (+)(orange)- metabolite with the same ion mass was found, but analitycal standard was 
lacking; *- N-dealkylation; **- hydroxylation 
 
4.2.5 Peroxides and peroxide generation systems 
In the literature, there are many ways described to add or generate peroxides to initiate 
peroxidation/peroxygenation reactions. As a part of this work, three different hydrogen 
peroxide generating systems and three peroxides were tested in the AaeAPO-catalyzed 
conversion of diclofenac to 4'-hydroxydiclofenac. 
One approach that goes back to studies in the 1950s uses the the oxidation of ascorbic acid 
by dioxygen in the presence of Cu(II) perchlorate or L-cysteine, which generates 
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dehydroascorbic acid and hydrogen peroxide (Davies 1984, Khan and Martell 1967, 
Udenfriend et al. 1954). Though the details of H2O2 formation are not fully clear, two 
possible mechanisms may be considered for metal-catalyzed peroxide formation via 
ascorbyl radical intermediates. In the first proposed mechanism a metal-ascorbate complex 
is suggested in a pre-equilibrium step. This is followed by a rate-determining electron 
transfer within the complex from the ascorbate anion to the metal ion. The reduced 
complex dissociates in a fast step to the lower valence metal ion and a semiquinone. 
Afterwards follows reoxidation of the reduced metal ion by O2 to produce superoxide, 
which then generates H2O2 via dismutation. 
22222 OOHHO
fast +⎯→⎯•  
In the second suggested mechanism, at first a metal-ascorbate complex is formed. This is 
followed by an attack of dioxygen on the metal-ascorbate complex with the formation of 
an oxygen complex in a second pre-equilibrium step (Khan and Martell 1967). 
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In the case of the cysteine system, it is thought that the initial oxidation of the thiolate 
group of the amino acid into a thiyl radical initiates peroxide generation (Law et al. 
1983)11. Another peroxide-generating system, which has widely been used in enzymatic 
conversions for decades and was also successfully tested here, is that of glucose/glucose 
oxidase (Hofrichter et al. 1998, Paice et al. 1993, Ullrich et al. 2004). tert-
Butylhydroperoxide and meta-chloroperoxybenzoic acid (mCPBA) were tested as organic 
alternatives replacing hydrogen peroxide in this work. The former peroxide was shown to 
be the best oxidant in sulfur/sulfide and olefin oxidation by chloroperoxidase and 
horseradish peroxidase (Colonna et al. 1990, Hu and Hager 1999). Also mCPBA was used 
as an oxidant in many previous studies, particularly when the oxidations with H2O2 were 
too fast (Kellner et al. 2002, MacKeith et al. 1994). 
Recent studies with hydrogen peroxide have already shown that the dosage and the way of 
adding it can considerably influence the efficiency of a APO-catalyzed reaction (Aranda et 
al. 2009b, Poraj-Kobielska et al. 2011b). The results obtained here demonstrated that 
hydrogen peroxide, mCPBA, and the system glucose/glucose oxidase are the best oxidants 
                                                 
11 Instead glutathione described in this paper, cysteine was used (Scheibner and Hofrichter 1998).  
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in terms of the diclofenac conversion rates (32-45%). A stepwise dosage of the oxidant 
(with a pipette or a syringe pump) further increased product formation (by 3-7%) but was 
not nessesarily required. The worst results were observed for the L-cysteine/ascorbate 
system followed by the Cu(II) chlorate/ascorbate system and the usage of tert-
butylhydroperoxide (conversion rates for diclofenac 6-13%). This experiment showed that 
different peroxides and sources of them can be used in APO-catalyzed reactions; the 
effectiveness depends on the particular peroxide, its dosage and the reaction time. 
4.2.6 Difference binding spectra  
One of the characteristics of P450s is the influence of substrate binding on the appearance 
of the overall spectrum, especially with respect to the positions and intensities of the major 
absorption bands (Lewis 2001, Schenkman et al. 1981). AaeAPO shows difference binding 
spectra that are similar to those of P450s. The pharmaceuticals tested with AaeAPO in this 
respect were: propranolol (II), diclofenac (IV) and dextromethorphan (XX), as well as 
phenol (C6H5-OH) as a reference (Kinne 2010, Lewis 2001). They all gave a binding type I 
spectrum that is also characteristic for the binding exhibited by phenol (Hayhurst et al. 
2001, Schenkman et al. 1981, Topham 1970, Wester et al. 2003). These results suggest 
that the electronic environment of APOs, especially of AaeAPO, is similar to that of 
P450s, although the amino acid residues in the heme channel and near the heme may be 
totally different. 
4.2.7 Phenoxyl radical scavenger 
The high general ("classic") peroxidase activity of APOs can cause problems when the 
desired products are phenols (e.g. after aromatic hydroxylation or O-demethylation of 
methoxyaromatics), and necessitates the inclusion of a radical scavenger such as ascorbate 
in the reactions.The peroxidase activity of APOs causes the formation of phenoxyl radicals 
from phenolic compounds, which leads to undesired coupling reactions. Ascorbic acid is 
present in an aqueous environment in a protonated form (at pH 7) as a monoanionic 
species. The latter (probably as metal ion-ascorbate anion complex, see 1.2.5) can react 
with a phenoxyl radical to give the ascorbyl radical that in turn may disproportionate to 
dehydroascorbic acid and ascorbic acid. In other words, the phenoxyl radical  
(R-C6H5-O•) abstracts one electron from ascorbate followed by hydrogen/proton rebound 
to reform the phenolic compound (R-C6H5-OH). Figure 41 shows the proposed phenoxyl 
radical cycle in the presence of ascorbic acid with propranolol and 5-hydroxypropranolol 
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as APO substrate and phenolic product, respectively (Hofrichter et al. 2010, Kinne et al. 
2009a, Poraj-Kobielska et al. 2011b). 
 
Figure 41 Ascorbic acid as phenoxyl radical scavenger. The radical scavenging cycle is illustrated 
with propranolol as APO substrate. AscH2-ascorbic acid, AscH--monoprotonated (monoionic) 
species of ascorbic acid, Asc2--diionic species, Asc•--ascorbyl radical, Asc- dehydroascorbic acid. 
4.2.8 Stoichiometry and proposed mechanism of demethylenation 
The methylenedioxyphenyl moiety is found widely distributed in essential oils, alkaloids, 
and other physiologically active compounds of natural origin. Compounds containing this 
moiety are extensively utilized in food additives, perfumes, medicinals, topical 
preparations, and insecticides (Fishbein and Falk 1969). The methylenedioxybenzenes 
(1,3-benzodioxoles) contain a blocked catechol system, which is not considered to be 
particularly sensitive to mild hydrolyzing, reducing, or oxidizing reagents (Hennessy 
1965). Proposed metabolic pathways for the oxidation of methylenedioxyphenyl 
compounds by P450s and APOs are summarized in Figure 42. 
Oxidation at the methylene carbon atom (I) causes the generation of a putative 2-hydroxy-
1,3-benzodioxole intermediate (II). The intermediate gives rise to a carbene (IV) by 
dehydration or to an o-hydroxyphenyl formate (V; formic acid ester). The base-catalyzed 
proton abstraction would yield a carbenium ion (III) that could undergo an α-elimination 
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reaction to form also the carbene (Anders et al. 1984). The carbene may either generate 
very stable 1,3-benzodioxol-2-carbene complexes (VI) with the heme of P450s in the 
ferrous state, characterized by a Soret peak at 455 nm (Philpot and Hodgson 1972), or it is 
hydrolyzed to the corresponding formate ester (V) (Murray 2000). Casida and co-workers 
(Casida et al. 1966) have shown that the release of formate-14C upon scission of the 
hydroxy-methylene-14C-dioxyphenyl group would lead to both the formation of 14CO2 , 
and also the introduction of formic acid-14C into the general metabolic pool. The 
metabolism of 1,3-benzodioxoles to catechols (VII), carbon monoxide and formic acid is 
consistent with hydroxylation of the carbene complex (VI) (Correia et al. 2005, 
Simonneaux et al. 2006). During the conversion of 1,3-benzodioxoles with APOs, 
catechols and formic acid were formed in equimolar amounts, i.e. the pathway seemingly 
follows the reaction cascade from (I) via (II) and (V) to (VII) and formic acid. 
The stoichiometrical experiments with AaeAPO and safrole showed that two hydrogen 
peroxide molecules are consumed when one molecule of formic acid is formed (Table 20, 
Chapter 3.7.2). The same ratio (H2O2:formic acid, 2:1) was obtained in stoichiometrical 
experiments with 4-nitrobenzodioxole, in the case of which also the 4-nitrocatechol 
formation was followed by HPLC; the molecular ratio of formic acid:4-nitrocatechol was 
1:1 (Appendix, Table 1). This could mean that the conversion of 1,3-benzodioxoles to 
catechols (VII) and formic acid proceeds in two enzymatic steps. A possible explanation 
can be suggested (but with the proviso that also other reactions are conceivable). APOs 
may catalyze the conversion of 1,3-benzodioxoles in parallel using two pathways. The first 
pathway via the 2-hydroxy-1,3-benzodioxole intermediate (II) may give o-hydroxyphenyl 
formate (V), which is hydrolyzed to a catechol (VII) and formic acid and in the other 
pathway, it is hydroxylated to o-hydroxyphenyl formic acid (X) or the 2,2-dihydroxy-1,3-
benzodioxole intermediate (VIII) (at equilibrium with cyclic phenylene carbonate IX), 
which then break down to a catechol (VII) and carbon dioxide. This would explain the 
double consumption of hydrogen peroxide; however, the formation of carbon dioxide has 
not been proved yet, and the observed molar ratio of formic acid and 4-nitrocatechol of 1:1 
also contradicts this assumption. Considering the latter fact and the presence of ascorbic 
acid in the reaction mixture, another explanation is possible. Part of the peroxide may be 
"uselessly" consumed during the peroxidation of formed catechols whose phenoxyl 
radicals in turn can be re-reduced by ascorbic acid (see also Figure 41). Eventually also the 
catalase-like side activity of APOs that leads to the "unproductive" destruction of H2O2 
may have to be taken into consideration (R. Ullrich, personal communication). 
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Figure 42 Proposed mechanism of benzodioxole demethylenation by P450 and AaeAPO. I-1,3-
benzodioxole; II - 2-hydroxy-1,3-benzodioxole intermediate; III - carbanion; IV - carbene;V - o-
hydroxyphenyl formate; VI - 1,3-benzodioxol-2-carbene complexes; VII - catechol derivative; 
VIII - 2,2-dihydroxy-1,3-benzodioxole intermediate; IX - cyclic phenylene carbonate; X - o-
hydroxyphenyl formic acid. 
 
4.3 NBD assay 
4-Nitrocatechol is a colorimetric, pH-selective indicator compound showing a yellow color 
under acidic conditions and a red color under alkaline conditions in aqueous solutions 
(Cooper and Tulane 1936b). This property has already been in use for a long time, in 
various enzyme assays where 4-nitrocatechol is the diagnostic reaction product (e.g. P450 
monooxygenase-catalyzed oxidation of 4-nitrophenol (Tassaneeyakul et al. 1993a, 
Tassaneeyakul et al. 1993b) or sulfatase-catalysed hydrolysis of 4-nitrocatechol sulfate 
(Baum et al. 1959, Dzialoszyński 1955)). Here, we developed an assay on the basis of 4-
nitrocatechol formation from nitrobenzodioxole (NBD), which is suitable to selectively 
detect peroxygenase activities in complex growth media with high background absorption 
such as soybean-peptone suspensions (Anh et al. 2007, Ullrich et al. 2004). Such growth 
media are typically colored (high background absorption), which may interfere with 
classic peroxygenase assays that follow substrate oxidation in the UV range. 
The exact measurement of peroxygenase activities is an important prerequisite for studying 
them in the lab, for example, during fungal fermentations in bioreactors, heterologous 
expression studies, protein purification and biochemical enzyme characterization as well as 
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during the optimization of enzymatic in vitro reactions. All these approaches require 
simple and rapid enzyme assays, which are selective and based on simple 
spectrophotometric detection. So far, only two spectrophotometric peroxygenase assays 
have been reported: (i) the oxidation of veratryl alcohol (3,4-dimethoxybenzyl alcohol) or 
methyl 3,4-dimethoxybenzyl ether to veratraldehyde (3,4-dimethoxybenzaldehyde) (Kinne 
et al. 2009b, Ullrich et al. 2004), which is followed in the UV range at 310 nm and lacks 
full selectivity, since there is some overlap with lignin peroxidase activity under acidic 
conditions (pH 3-5) (Hofrichter and Ullrich 2010, Schmidt et al. 1989, Tien et al. 1986), 
and (ii) the oxidation of naphthalene to 1-naphthol (Kluge et al. 2007), which proceeds in 
the UV range as well (at 303 nm). The assay established here is a simple method for the 
rapid spectrophotometric detection (in the visible range) of fungal peroxygenase activity in 
vivo and in vitro. The NBD assay can be applied for the spectrophotometric identification 
and quantification of fungal peroxygenase activities, (i) in complex plant-based media 
during fungal growth, (ii) in environmental samples, (iii) for reaction control during 
enzymatic catalysis and (iv) for the detection of peroxygenase-positive fungi in the course 
of high-throughput screenings of wild-type and recombinant strains as well as mutants.  
4.4 Long-term and in-vivo experiments 
The purification of peroxygenases is quite complicated and time-consuming, and would be 
too expensive for most kinds of industrial applications (Gröbe et al. 2012, Ullrich et al. 
2009). For this reason, it is important to find possibilities to apply the enzymes in a more 
economic way, either by using crude preparations or extending their "life-span", for 
example, by immobilization and/or re-use over several cycles (see also chapter 3.5). Initial 
tests in this direction were performed by retaining and re-using the enzyme during 
propranolol hydroxylation in Vivaspins® (special centrifugal concentrators with 
ultrafiltration membranes). Later long-term experiments were carried out in hollow-fiber 
modules holding back the enzyme from the circulating filtrate containing the reactants of 
enzymatic conversion. AaeAPO turned out to be very stable under these conditions and 
was successfully used over a period of two weeks. Over the whole time, the enzyme was 
active and continuously hydroxylated the model substrate propranolol into 5-
hydroxypropranolol (see Figure 35, chapter 3.17.2). The cumulative molar amount of 
product (50.4 µmol) and the amount of applied enzyme (7.9 nmol) show that one 
peroxygenase molecule oxidized about 6,400 substrate molecules in the course of the 
experiment. This is a promising basis for the further improvement of HDM production 
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with fungal peroxygenases. Existing methods use either multi-step organic synthesis 
(Johansson et al. 2007, Oatis et al. 1981), whole-cell biotransformations with cell cultures 
(e.g. human hepatocytes (Acikgöz et al. 2009, Li et al. 1999, Maurel 1996) or microbial 
host cells (e.g. Schizosaccharomyces pombe, Nocardia autotropica or Curvularia lunata; 
(Julsing et al. 2008, Peters et al. 2007) as well as, at least at lab scale, engineered P450 
enzymes (Leemann et al. 1993, Schroer et al. 2010, Weis et al. 2009). 
Another promising field of peroxygenase application could be the removal of 
pharmaceuticals from waste water or other environmental media. The occurrence of water-
soluble and pharmacologically active organic micropollutants in the effluents of 
wastewater treatment plants (WWTPs) has caused much attention over the recent years 
(Lienert et al. 2007). It has been a matter of concern that the existing WWTPs are 
inefficient in removing some of these pollutants and there is an increasing interest to 
develop efficient techniques for achieving their destruction (Clara et al. 2005, Marco-Urrea 
et al. 2009). A number of experiments with the white-rot fungus Trametes versicolor 
showed that waste waters contaminated with several pharmaceuticals such as clofibric 
acid, ibuprofen and carbamazepine could be cleaned to some extent by the fungal 
mycelium. However, in these experiments, adsorption and transformation of 
pharmaceuticals by the fungus were not clearly distinguished, nor were intra- and 
extracellular enzymatic mechanisms (Blánquez et al. 2004). The concentrations tested in 
this study (~10 mg L-1) were also three to five orders of magnitude higher than those 
usually present in effluents of municipal sewage plants (0.1-50-µg L-1 range). Subsequent 
studies dealing with the analgesic ketoprofen at an environmentally relevant concentration 
(40 µg L-1) showed that the substrate was almost completely removed by T. versicolor 
(Marco-Urrea et al. 2010b). Tests with environmentally relevant concentrations of 
propranolol carried out herein demonstrated that AaeAPO is able to remove about 50% of 
the compound at a concentration as low as 1.4 µg L-1. The experiments were done with the 
purified enzyme and respective controls, so that all other paths of substance removal such 
as absorption or involvement of other enzymes than APO could be ruled out. The positive 
result obtained, despite the fact that the Km for propranolol is rather high (1,340 µM), can 
be explained by the reaction cycle of APO and the particular reaction conditions. Thus, the 
continuous dosage of hydrogen peroxide with a syringe pump may have ensured the 
(pre)formation of sufficient amounts of a reactive APO species (compound I; (Wang et al. 
2012). The presence of a certain steady-state concentration of compound I (spontaneous 
decomposition rate 1.4 s-1) combined with a sufficient reaction time (>12 hours) under 
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stirring may enable the oxidation of quite low amounts of the substrate independent on the 
high apparent Km value. 
In vivo experiments with A. aegerita were carried out to follow the fate of two 
pharmaceutical model compounds (propranolol, diclofenac) in fungal cultures and to find 
indications for the involvement of APOs in biodegradation processes under natural 
conditions. The transformation of the anti-inflammatory drug diclofenac had already been 
studied in liquid cultures of Phanerochaete chrysosporium under fed-batch conditions. The 
fungus started to eliminate diclofenac (34 µM) already after two hours (77% removal) and 
after 18 hours, 94% of the compound were converted (Rodarte-Morales et al. 2012). The 
capability of diclofenac degradation by T. versicolor was demonstrated by Marco-Urrea et 
al. (Marco-Urrea et al. 2010a). They observed an almost complete diclofenac removal 
(>94%) within the first hour of fungal treatment in the presence of fungal pellets; the drug 
was added both at relatively high (10 mg L-1) and low, environmentally relevant (45 µg L-
1) concentrations in a defined liquid medium. During this treatment, 4'-hydroxydiclofenac 
and 5-hydroxydiclofenac were detected as metabolites, which disappeared within the next 
24 hours (Cruz-Morató et al. 2012, Marco-Urrea et al. 2010a). Another example of using 
the fungal mycelium as biodegradative agent is the so-called biologically advanced 
oxidation of propranolol by T. versicolor (80% removal within 6 hours of incubation). In 
this case, extracellular oxidizing species (e.g. hydroxyl radicals) were thought to be 
produced through a quinone redox cycling mechanism catalyzed by an intracellular 
quinone reductase and ligninolytic enzymes of Trametes versicolor, after addition of 
lignin-derived 2,6-dimethoxy-1,4-benzoquinone and Fe3+-oxalate (Marco-Urrea et al. 
2010c). 
Diclofenac and propranolol also readily disappeared in liquid cultures of A. aegerita, 
interestingly when a high peroxygenase level (ca. 600 U L-1) was present. The 
experiments, carried out in parallel in two different growth media (one of which stimulated 
peroxygenase production (Ullrich et al. 2004)) indeed indicated an involvement of 
peroxygenase in this process. However, no transformation products were detectable by 
HPLC, probably due to coupling/polymerization reactions, which could not be prevented 
in contrast to in vitro experiments where ascorbic acid served as radical scavenger. 
Furthermore, analyses of control cultures of A. aegerita (soybean medium) showed the 
presence of numerous aromatic ingredients, which disappeared in the course of fungal 
growth. UV-Vis spectra of these substances indicated a polyphenolic nature with 
similarities to flavonoids (Figure 30) (Barková et al. 2011). One-electron oxidation of 
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these compounds would yield phenoxyl radicals, which may force the overall 
polymerization process. The peroxidative activity of AaeAPO, or the activity of laccase 
which is also secreted by A. aegerita (Ullrich et al. 2004), may be responsible for these 
reactions. Interestingly, in both growth media (soybean medium, Czapek-Dox) the color 
changed to violet when diclofenac was added on day six. The same color was observed in 
in vitro studies with APOs in the absence of ascorbic acid (Appendix Figure 2). On the 
basis of UV-Vis and mass spectra as well as literature data from Miyamoto at al. (1997) 
we propose that this compound is the one-electron-oxidation product diclofenac-1',4'-
quinone imine (Figure 43) (Miyamoto et al. 1997, Waldon et al. 2010).  
 
Figure 43 Proposed mechanism of diclofenac-1',4'-quinone imine formation by AaeAPO in vitro 
without ascorbic acid and by by fungal cultures. In Czapek-Dox medium, conversion may be only 
possible by intracellular 450s (no peroxygenase formation; laccase alone is not able to catalyze this 
reaction) (Marco-Urrea et al. 2010a). In soybean medium, this pathway could be realized both by 
intracellular P450s or secreted AaeAPO or a mixed AaeAPO-laccase system (Figure 48; 
(Hofrichter et al. 2010, Ullrich and Hofrichter 2007, Waldon et al. 2010). 
4.5 Homology model structures of APOs.   
In order to better understand the catalytic properties of APOs and differences between 
them, homology modelling was performed. The full-length sequences of the 
peroxygenases from A. aegerita, C. radians and M. rotula have recently been obtained and 
confirm the enzymes’ affiliation to the heme-thiolate proteins. The sequences revealed no 
homology to classic heme peroxidases or cytochrome P450 enzymes, and only little 
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Figure 45 Homology model structures of CraAPO (left), AaeAPO (middle) and MroAPO (right). Homology modelling was performed with I-TASSER 
software (Roy et al. 2010) using the crystal structure of unspecific peroxygenase of A. aegerita as basis [(Piontek et al. 2010), as well as unpublished data, the 
same authors]. The resulting models of CraAPO and MroAPO were superimposed with the AaeAPO structure using the PyMOL program (2010), resulting in 
a root-mean-square deviation (RMS) of 1.133 over 295 aligned residues for CraAPO, and a RMS of 1.381 over 177 aligned residues for MroAPO. Prepared 
by Marek Pecyna and Marzena Poraj-Kobielska (2012).  
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homology (<30%) to fungal chloroperoxidase (CfuCPO) produced by the ascomycete 
Leptoxyphium (Caldariomyces) fumago (Pecyna et al. 2009). A preliminary crystal 
structure (at 2.2 Å) of AaeAPO has already been published (Piontek et al. 2010). Some 
molecular details are still missing but will be published in the near future (K. Piontek, 
personal communication 2012; (Piontek et al. 2012)). Also the crystal structure of 
MroAPO has been solved and reveals considerable differences from AaeAPO (K. Piontek 
2012, personal communication). 
Gene sequences and known crystal structures demonstrate considerable similarities 
between all peroxygenases (including CfuCPO), in particular in the heme region. Thus, the 
proximal cysteine is conserved in a PCP-motif that perfectly exposes the thiolate residue 
towards the heme. Due to the high degree of conservation of the heme binding domain, the 
conformation of the polypeptide chain near the cysteine ligand in AaeAPO, CraAPO, 
MroAPO and CfuCPO is almost identical. It forms an α-helix that is perpendicular to the 
heme stabilized by peptide amide–sulfur hydrogen bonds between the cysteine ligand and 
the surrounding residues (Sundaramoorthy 1995). The homology model in Figure 45 and 
the crystal structure of MroAPO (Piontek at al, 2012, personal communication, so far 
unpublished) show that the enzyme is smaller than AaeAPO and CraAPO, however the 
entrance to the active site of MroAPO is flatter and wider than those of the two other 
enzymes (10 Å vs. 7 Å; Piontek at al, 2012, unpublished results). This fact may explain 
why bulky molecules such as steroids or codeine are oxidized by MroAPO but not by 
AaeAPO and CraAPO. On the basis of the crystal structures of AaeAPO and MroAPO and 
their known substrate spectra, we attempted to model the fits of codeine and 
hydrocortisone into the active site of the enzymes (Figure 45 and Figure 46). The entrance 
and channel of AaeAPO is relatively narrow and the position of some amino acids causes 
an additional obstacle for such large substrate molecules (i.e. it is impossible to fit them 
in).  
 
 
 
 
 
 
Figure 44 3-Dimensional structure of 
propranolol from two different 
perspectives. The model was prepared 
with PyMOL software 2010. 
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For comparison, the structure of propranolol, which is smaller and a good substrate of the 
AaeAPO, was placed into the active site and fit it well (Figure 42, examples of other 
structures are given in the Appendix). The homology model of CraAPO shown in Figure 
45 indicates that the entrance to the heme channel is about the size of that of AaeAPO and 
the active site volume is even larger, but one phenylalanine seems to block the entrance 
(Figure 49). 
The position at the end of the polypeptide chain (C-terminus) indicates that this 
phenylalanine may not be fixed and can move to some extent to open and close the 
entrance of the heme channel, i.e. it may act as a sort of molecular "gatekeeper". This may 
explain the overall lower conversion rates observed for CraAPO compared to AaeAPO, in 
spite of a similar amino acids sequence and configuration (59% sequence identity and 69% 
similarity; for comparison, MraAPO shares only about 30% sequence identity with both 
enzymes) (Pecyna et al. 2009), personal communication). Of course, more precise 
predictions will only be possible when the crystal structures of all three APOs will have 
been published. 
 
Figure 48 Amino acids that possess reactive groups and are found in the active sites of AaeAPO, 
CraAPO and MroAPO. Tyr - tyrosine, Phe - phenylalanine, Glu – glutamic acid, Thr – threonine, 
Ser – serine and Arg - arginine. 
   
Figure 49 shows homology model structures of the active site of the three APOs studied 
here. 
The channels of AaeAPO and CraAPO are rich in aromatic amino acids, mainly 
phenylalanines (Phe) and a tyrosine (Tyr), whereas in MroAPO, almost exclusively 
aliphatic amino acids are found (Ile, Leu, Val, Ala). Phe is a hydrophobic aromatic amino 
acid with a benzyl side chain; Tyr possesses also an aromatic ring that is however less 
hydrophobic than that of Phe due to its phenolic OH-group.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46 Homology models of peroxygenase channels (solvent accessible surface calculation) leading to the active sites of AaeAPO (B) and MroAPO (C) 
fitting codeine. Dimensions (in Ǻ) of the heme channels are shown in (A; AaeAPO) and (F; MroAPO). A 3-Dimensional model of codeine is given in D1, D2 
and D3 from different perspectives. (E) illustrates the active site's architecture of MroAPO with codeine as ball-and-stick model: heme (red), magnesium ion 
(green), codeine substrate (violet), amino acids (gray). 117 
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Figure 47 Homology models of heme channels with active sites fitting hydrocortisone. AaeAPO from the top (A) and from the side (B) with channel length in 
Ǻ and MroAPO from the top (F) and side (E). (C) Electron surface density of hydrocortisone with the length of the structure, and (D) stick model of 
hydrocortisone from two other perspectives (dimensions in Ǻ). 
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Figure 49 Heme channels leading to the active site of AaeAPO, CraAPO and MroAPO, including 
important amino acid residues. Aromatic amino acids (orange): Phe - phenylalanine, Tyr - tyrosine; 
functional amino acids (blue): Glu - glutamic acid, Ser – serine, Arg - arginine, Thr - threonine; 
aliphatic amino acids (grey): Ile - isoleucine, Leu - leucine, Ala - alanine, Gly - glycine, Val - 
valine and Pro - proline. One example of each kind of amino acid is labeled with the respective 
abbreviation (model and figure prepared by M. Pecyna and M. Poraj-Kobielska, 2012). 
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Near the heme and the stabilizing magnesium, three aliphatic amino acids are found: 
glutamic acid (Glu), arginine (Arg) and threonine (Thr; Figure 48)(Ophardt 2003). Glu has 
a carboxylic side chain and can exist as its negatively charged deprotonated carboxylate 
(Pecyna et al. 2009, Piontek et al. 2010, Sundaramoorthy et al. 1995). As an acid-base 
catalyst, it may play a key role in peroxide binding and cleavage, and thereby in the 
formation of AaeAPO compound I (Wang et al. 2012). Arg may act as a charge stabilizer 
in this process as in CPO (Sundaramoorthy 1995) and Thr is probably the proton acceptor. 
In MroAPO, serine (Ser) seemingly replaces Arg. In classical peroxidases, Glu is 
substituted by a histidine (His), whereas in DyP-type peroxidases an aspartic acid (Asp) 
replaces Glu while the charge stabilizer is again an Arg (Sugano et al. 2007). 
4.6 Key findings 
1. All tested fungal unspecific/aromatic peroxygenases (APOs from Agrocybe 
aegerita, Coprinellus radians, Marasmius rotula) catalyzed the 
oxygenation/hydroxylation or N-/O-dealkylation (Figure 50) of diverse 
pharmaceuticals and illicit drugs, in most cases with high regioselectivity. Many of 
the oxidation products were identical to human drug metabolites formed by P450s. 
2. The peroxygenase of M. rotula (MroAPO) was moreover found to catalyze the 
conversion of different steroids with preference for those bearing an oxo-
hydroxyethyl side chain. 
3. The different substrate specificities and selectivities of individual APOs raise the 
possibility to choose the appropriate enzyme according to the needed product 
("catalytic toolbox" for oxyfunctionalizations). 
4. The AaeAPO-catalyzed oxygenation of aromatic pharmaceuticals such as 
propranolol, diclofenac or carbamazepine and the hydroxylation of benzylic 
carbons in compounds such as tolbutamide resulted in the incorporation of an 18O-
atom from H218O2 into the reaction products (phenols, alcohols), which identifies 
these reactions as true peroxygenations. 
5. The stoichiometry of AaeAPO-catalyzed sildenafil oxidation showed that the 
reaction was a two-electron oxidation yielding an N-dealkylated product (N-
desmethylsildenafil) and an aldehyde (formaldehyde). 
6. The deethylenation of phenacetin-d1 by AaeAPO showed an observed 
intramolecular deuterium isotope effect (kH/kD)obs of 3.1, which is close to the 
values that have been observed for the P450-catalyzed O-dealkylation of this 
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substrate. This indicates that phenacetin oxidation by APOs may proceed via an 
electron transfer rather than a hydrogen abstraction mechanism. 
7. The kinetic data and particularly the catalytic turnover numbers (kcat) determined 
for the conversion of various pharmaceuticals by AaeAPO suggest that APOs may 
be at least as efficient as the best P450s and hence represent useful alternatives for 
the regioselective preparation of human drug metabolites (HDMs). 
8. Steady-state bisubstrate kinetics of the AaeAPO-catalyzed demethylenation of 
nitro-1,3-benzodioxole (NBD), which yielded catechol and formic acid, gave 
parallel double reciprocal plots suggestive of a ping-pong mechanism. 
9. The NBD assay established on the basis of this reaction is a simple method for the 
rapid spectrophotometric detection of fungal peroxygenase activities in vivo and in 
vitro. 
10. The testing of twelve validated P450 assays with the three APOs showed that they 
possess a substrate spectrum and an activity range that overlap with those of the 
most important human P450s involved in drug metabolism. 
11. Stoichiometry analysis of AaeAPO-catalyzed safrole oxidation showed that two 
hydrogen peroxide molecules were consumed during the formation of one molecule 
of products (catechol and formic acid). This indicates a divergent mechanism that 
may involve two different pathways and/or unproductive peroxide-consuming side 
reactions. 
12. APOs are able to use, in addition to H2O2, different organic peroxides as co-
oxidant, and they efficiently catalyze oxidation reactions in the presence of 
different peroxide-generating systems. 
13. AaeAPO was capable of oxidizing the pharmaceutical propranolol at a very low, 
environmentally relevant concentration (in the ppb range). 
14. APOs could be used in long-term in-vitro experiments over several days for the 
constant synthesis of the HDM, 5-hydroxypropranolol. 
15. Propranolol and diclofenac disappeared rapidly when added to growing cultures of 
A. aegerita indicating fungal drug degradation also under natural conditions. 
16. Homology models of APOs provide explanations for limitations observed with 
regard to the substrate size and structure. The size of the entrance to the heme 
channel, the amino acids there and the active site volume seem to be key 
parameters determing peroxygenase performance. 
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Figure 50 Mechanistic routes of reactions catalyzed by fungal peroxygenases with pharmaceuticals and drugs. From left to right: demethylenation (ecstasy), 
N-dealkylation (lidocaine), O-dealkylation (naproxen), aliphatic side chain hydroxylation (tolbutamide), aromatic epoxidation/hydroxylation (diclofenac), 
phenol oxidation (morphine); modified according to (Hofrichter et al. 2010) 
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The most important finding of this work is that APOs are capable of oxidizing a large 
variety of pharmaceuticals and other drugs, often yielding typical human drug metabolites. 
This opens the fascinating possibility to produce diverse human drug metabolites in the 
future using a "peroxygenase toolbox", figuratively speaking as an artificial liver in the 
reaction tube. 
4.7 Outlook 
In the meantime, one of the most promising approaches in peroxygenase research, the 
empirical comparison of as many APOs as possible to obtain a broad selection of 
biocatalysts with different substrate specificities, has taken shape. Thus, recent genetic 
investigations have resulted in a phylogenic tree, which impressively shows the widespread 
occurrence of peroxygenases in the whole fungal kingdom (Pecyna et al. 2009). New wild-
type peroxygenases have been found in a number of basidiomycetes, for example, in 
Coprinopsis verticillata (Anh et al. 2007), Agrocybe parasitica and Auricularia auricula-
judae (R. Ullrich 2012, personal communication). Furthermore, the first attempts to 
heterologously produce peroxygenases in suitable hosts (e.g. Aspergillus spp., 
Saccharomyces cerevisiae) have been successful (H. Lund, Novozymes A/S & M. Alcalde, 
CSIC Madrid, 2012; personal communications). The above developments open the 
possibility to extend the APO-based “monooxygenation toolbox” for the production of 
other HDMs and fine chemicals. Also the preparation of HDMs and fine chemicals even at 
industrial scale seems to be reasonable taking into account the positive long-term 
experiments presented here and assuming that the heterologous mass production of 
peroxygenases will be successful in the near future. Environmental studies performed over 
the last years indicate that there is a strong need to remove pharmaceuticals and their 
metabolites from the environment. In this context, peroxygenases could become an 
innovative biocatalytic tool to reduce the risk potential of pharmaceuticals. The properties 
of peroxygenases such as: i) extracellular location, ii) active secretion by the fungi, iii) 
high stability and iv) independence from complex, expensive cofactors, as well as the 
positive results in the removal of low-concentration pharmaceuticals make the application 
of APOs even in the water-treatment sector conceivable. Again, the heterologous large-
scale production of peroxygenases, i.e. their availability in tons per year, will be de rigueur 
to achieve this challenging goal.  
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Figure 51 Phylogenetic tree of peroxygenases (unpublished results, Kellner 2012). 
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6 Appendix 
6.1 Aromatic ring hydroxylation 
 
Appendix Figure 1 HPLC-elution profiles of reaction mixtures showing the formation of products 
after conversion of propranolol (0.5 mM) by the aromatic peroxygenases (2 Units mL-1) of A. 
aegerita (AaeAPO) and C.radians (CraAPO). 
 
Appendix Figure 2 HPLC-elution profiles of reaction mixtures showing the formation of products 
after conversion of diclofenac (0.5 mM) by the aromatic peroxygenase (2 Units mL-1) of A. 
aegerita. The insets show the UV-Vis-spectra of products and the known structures: (I) - 
diclofenac; (II) – 4'-hydroxydiclofenac; (III) – diclofenac-1',4'-quinone imine. 
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6.2 Oxidation of alkyl side chains 
 
Appendix Figure 3 HPLC-elution profiles of reaction mixtures showing the formation of products 
after the conversion of tolbutamide (0.5 mM) by the aromatic peroxygenase (2 U mL-1) of A. 
aegerita (AaeAPO) with and without ascorbic acid. The insets show mass- and UV-Vis-spectra of 
tolbutamide and its products with structures. I – tolbutamide; II – 4-ketotolbutamide; III – 4-
hydroxytolbutamide. 
6.3 O-Dealkylation 
 
Appendix Figure 4 HPLC-elution profiles of reaction mixtures showing the formation of products 
after conversion of naproxen (0.5 mM) by the aromatic peroxygenase (2 U mL-1) of A. aegerita 
(AaeAPO) with ascorbic acid. The insets show the mass spectra of naproxen (II) and O-
desmethylnaproxen (I). 
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6.4 N-dealkylation 
 
Appendix Figure 5 HPLC-elution profiles of reaction mixtures showing the formation of products 
after conversion of sildenafil (0.5 mM) by AaeAPO, MroAPO and a recombinant peroxygenase 
from Novozymes (2 U mL-1). The insets show the mass spectra of sildenafil (I), N-
desmethylsildenafil (II) and proposed other products (III) and (IV). 
6.5 Oxidation of steroids 
 
Appendix Figure 6 HPLC-elution profiles of reaction mixtures showing the formation of products 
after conversion of pregnenolone (0.5 mM) by the aromatic peroxygenase (2 U mL-1) of M. rotula. 
The insets show the mass spectra of two products and known structures: (I)–pregnenolone; (II)–
progesterone; (III), (IV) & (V)–not identified products. 
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6.6 O-Demethylenation 
 
 
 
Appendix Figure 7 HPLC-elution 
profiles of reaction mixtures showing 
the formation of 4-nitrocatechol after 
the oxidation of NBD (0.5 mM) by 
the aromatic peroxygenases (2 Units 
mL-1) of C. verticillata (I), C. radians 
(II) and A. aegerita (III). The 
oxidation of NBD by M. rotula 
peroxygenase and recombinant C. 
cinerea peroxygenase was also tested 
and gave 4-nitrocatechol as major 
metabolite as well (data not shown). 
 
 
 
 
Appendix Figure 8 HPLC-elution profiles of reaction mixtures showing the formation of products 
after conversion of bromobenzodioxole (0.5 mM) by the aromatic peroxygenase (2 U mL-1) of A. 
aegerita. The oxidation of chlorobenzodioxole gave a similar elution profile and corresponding 
products (data not shown). The insets show mass spectra of products and the known structures: (I) 
– bromobenzodioxole; (II) – bromocatechol; (III) – not identified product; (IV) – 
trihydroxybromobenzene (bromopyrrogallol).  
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6.7 Spectrophotometric nitrobenzodioxole assay 
 
 
 
 
Appendix Figure 9 Determination of the 
extinction coefficient of 4-nitrocatechol at 
pH >12. UV-Vis spectra of different 
concentrations of 4-nitocatechol (12.5, 25, 
50, 62.5, 100, 125 µM) dissolved in 
potassium phosphate/NaOH (50 mM/100 
mM) were recorded and the extinction 
coefficient calculated for the maximum at 
514 nm. The inset shows the linear 
relationship between the concentration of 4-
nitrocatechol and the absorbance at 514 nm. 
 
 
 
 
 
6.8 Stoichiometrical analyses 
 
Appendix Table 1 Stoichiometry of nitrobenzodioxole oxidation by A. aegerita 
peroxygenase.1 
 H2O2 added catechol produced catechol/H2O2 
µM  
 23.44 
 46.88 
 70.3 
93.75 
187.5 
  15.1 
 29.21 
39.45 
49.87 
80.50 
0.64 ± 0.01 
0.62 ± 0.03 
0.56 ± 0.04 
0.53 ± 0.01 
0.43 ± 0.03 
 
1The initial nitrobenzodioxole concentration was 0.25 mM. 
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6.9 Experiment with propranolol at an environmentally relevant 
concentrations 
 
Appendix Figure 10 Process flow diagram of the experiment with AaeAPO and an 
environmentally relevant concentration (5 nM) of propranolol (in German). Figure adapted 
from Sylvia Gleissner (Master thesis supervised at the IHI Zittau) 
 
Ausgangslösung 
1800 ml bi-destiliertes H2O 
inclusive 2 ml 5 µM Propranolol 
+ 900 ml Ausgangslösung 
+ 50 ml (inclusive 100 Units  AaeApo) 
+ 50 ml (inclusive 200 µl 30% H2O2 
= 1000 ml mit 5nM Propranolol 
      100 U/l AaeApo und 2 mM H2O2 
1.  Ansatz 
+ 900 ml Ausgangslösung 
+ 100 ml bi-destiliertes H2O        
= 1000 ml mit 5 nM Propranolol 
       
2. Umsatz 
3. Ultrafiltration 
4. pH-Wert Einstellung 
5. Extraktion 
6. Aufkonzentration 
7. Extraktion durch 
Konzentration 
18 h 
Inkubationszeit 
zur Vergleichbarkeit mit der 
Probelösung 
zur Enzymabtrennung 
mit 10 molarer Natronlauge 
auf pH 12 
mit 10 molarer Natronlauge 
auf pH 12 
mit 25 ml Dichlormethan im 
Scheidetrichter 
mit 25 ml Dichlormethan 
im Scheidetrichter 
Dichlormethan mittels Turbo-Vap auf 
1 ml aufkonzentrieren 
Dichlormethan mittels Turbo-Vap 
auf 1 ml aufkonzentrieren 
Dichlormethan mit 2 ml Acetonitril 
mischen und auf 1 ml 
aufkonzentrieren 
Dichlormethan mit 2 ml Acetonitril 
mischen und auf 1 ml 
aufkonzentrieren 
8. Extraktion durch 
Konzentration 
Acetonitril  mit 
2 ml bi-destiliertem H2O mischen und 
auf 1 ml aufkonzentrieren 
Acetonitril  mit 2 ml bi-destiliertem 
H2O mischen und auf 1 ml 
aufkonzentrieren 
9. Analyse HPLC 
„Luna C18“-Säule 
HPLC 
„Luna C18“-Säule 
9. Vergleich 
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Appendix Figure 11 Examplary 3D-structures (stick models) of pharmaceuticals: sildenafil 
(A); diclofenac (B) and dextromethorphan (C). 
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